Influence of Dietary-Induced Obesity on Opiatergic Regulation of Appetite and Blood Pressure in Sheep by Alavi, Fereidon Khan
INFLUENCE OF DIETARY-INDUCED OBESITY ON 
OPIATERGIC REGULATION OF APPETITE 
AND BLOOD PRESSURE 
IN SHEEP 
By 
FEREIDON KHAN ALAVI 
Bachelor of Science in Arts and Sciences 
Oklahoma State University 
Stillwater, Oklahoma 
1981 
Master of Science 
Oklahoma State University 
Stillwater, Oklahoma 
1986 
Submitted to the Faculty of the Graduate College 
of the Oklahoma State University 
in partial fulfillment of the requirements for 
the Degree of 
DOCTOR OF PHILOSOPHY 
December, 1991 

INFLUENCE OF DIETARY-INDUCED OBESITY ON 
OPIATERGIC REGULATION OF APPETITE 
AND BLOOD PRESSURE 
IN SHEEP 
Thesis Approved: 
~ _ _»sis Advisor 
c~ w~~ s.j \7- Ooh 
Dean of the Graduate College 
ii 




My sincere appreciation goes to my advisor Dr. Subbiah Sangiah and to 
Dr. Joseph P. McCann for their guidance and inspirations they generated in me. I 
would like to also thank Drs. George E. Burrows, Cyril R. Clarke and Charles Maxwell 
tor their teachings and participation in my graduate committee. 
Sincere gratitude also goes to the Head of the Department of Physiological 
Sciences, Dr. Charlotte L. Ownby, and to Drs. Everett C. Short, Bruce L. Lessley, 
James E. Breazile, tor their assistance, support and friendly advisement. 
I would like to especially thank Hamid Amouzadeh, Edward Johnson, Terry 
Colberg, Colleen Marshall, Betty Beverage, Diana Moffeit, Dorothy Aalseth, Robin 
Dodge and Iris Wilson for their invaluable friendship, and support throughout these 
years. 
I would like to thank my parents' foresight into my future by supporting me 
emotionally and financially throughout these years in school. 
In addition, I am very thankful to Dr. McCann tor making available to me 
certain unpublished data from his laboratory regarding dietary obese sheep. 
Finally, I acknowledge with deep gratitude, the support and understanding of 
my wife, Marcella B. Szymanski. 
iv 
TABLE OF CONTENTS 
Chapter Page 
I. INTRODUCTION AND LITERATURE REVIEW . . . . . . . . . . . . . . . . . . 1 
Synthesis and secretion of opioids . . . . . . . . . . . . . . . . . . . . . . 1 
Discovery of Opioids . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 
Opioid Synthesis Pathway . . . . . . . . . . . . . . . . . . . . . . . 2 
Site of Opioid Production . . . . . . . . . . . . . . . . . . . . . . . 2 
Opioid Receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 
Opioid Function . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 
Regulation of Feed Intake . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 
Hypothalamus and Feed Intake . . . . . . . . . . . . . . . . . . . 6 
Opioid Peptides and Feed Intake . . . . . . . . . . . . . . . . . . 8 
Non-opioid Chemicals and Feed Intake . . . . . . . . . . . . . 9 
Alpha-adrenergic . . . . . . . . . . . . . . . . . . . . . . . . 9 
Beta-adrenergic . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
Dopaminergic . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
Cholecystokinin . . . . . . . . . . . . . . . . . . . . . . . . . 1 0 
Obesity and Feed Intake . . . . . . . . . . . . . . . . . . . . . . . . 11 
Blood Pressure Regulation . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 
Components of Blood Pressure Regulation . . . . . . . . . . 12 
Adrenergic Regulation of Blood Pressure . . . . . . . . . . . . 14 
a-Adrenoceptors . . . . . . . . . . . . . . . . . . . . . . . . . 15 
B-Adrenoceptors . . . . . . . . . . . . . . . . . . . . . . . . . 16 
Opioid Regulation of Blood Pressure . . . . . . . . . . . . . . . 16 
Hypertension in Health . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 
Risk Factors for Hypertension . . . . . . . . . . . . . . . . . . . . 18 
Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 
Diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 
Hyperinsulinemia . . . . . . . . . . . . . . . . . . . . . . . . 20 
Insulin, SNS Activity and Hypertension . . . . . . . . 21 
Insulin, Sodium Balance and Hypertension . . . . . . 21 
Insulin, Vascular Growth and Hypertension . . . . . 22 
Insulin, Endothelial Function and 
Hypertension . . . . . . . . . . . . . . . . . . . . . . . . . 23 
Objectives and Hypothesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 
v 
Chapter Page 
II. DEVELOPMENT OF OBESE SHEEP MODEL . . . . . . . . . . . . . . . . . . 38 
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 
Animals and Diet . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 
Dietary-Induction of Obesity . . . . . . . . . . . . . . . . . . . . . 41 
Indices of Obesity and Chemical 
Composition of Carcass . . . . . . . . . . . . . . . . . . . . . . . 44 
Results and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 45 
Body Weight and Feed Intakes .......... ·. . . . . . . . . 45 
Indices of Obesity and Carcass 
Composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 7 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 
Ill. EFFECTS OF NALOXONE ON AD LIBITUM INTAKE AND 
PLASMA INSULIN, GLUCOSE, AND FREE FATTY 
ACIDS IN MAINTENANCE-FED SHEEP . . . . . . . . . . . . . . . . . . . . 52 
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 
Discussion 
References 
IV. OPIATERGIC REGULATION OF FEED INTAKE IN 
58 
62 
LEAN AND OBESE SHEEP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 
Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 
Treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 
Chemical Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 
Naloxone Assay . . . . . . . . . . . . . . . . . . . . . . . . . 67 
B-endorphin Assay . . . . . . . . . . . . . . . . . . . . . . . 68 
Calculations and Statistical Analyses . . . . . . . . . . . . . . . 69 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 
Control Feed Intake . . . . . . . . . . . . . . . . . . . . . . . . . . . 71 
Naloxone Treatment Effect . . . . . . . . . . . . . . . . . . . . . . 72 
Plasma Chemicals . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81 
Discussion 
References 
V. CARDIOVASCULAR RESPONSES TO ADRENERGIC 
AGONISTS IN LEAN NORMOTENSIVE AND 
83 
88 




Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 94 
Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 
Animal Preparation and Experimental Protocol . . . . . . . . 95 
Basal Blood Pressure Measurements . . . . . . . . . . . . . . . 95 
Arterial Plasma Catecholamines . . . . . . . . . . . . . . . . . . 97 
Plasma Hormone and Metabolites . . . . . . . . . . . . . . . . . 98 
Statistical Analysis .................. · . . . . . . . . . . 98 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99 
Plasma Chemical Analyses . . . . . . . . . . . . . . . . . . . . . . 99 
Basal Blood Pressure and Heart Rate . . . . . . . . . . . . . . 1 02 
Cardiovascular Responses to Adrenergic 
Agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 03 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 112 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111 
VI. EFFECT OF CLONIDINE ON BLOOD PRESSURE AND 
HEART RATE IN LEAN AND OBESE SHEEP ................ 121 
Introduction .................................... . 
Materials and Methods ............................. . 
Animal Preparation ........................... . 
Experimental Protocol ......................... . 
Calculation and Statistical Analysis ............... . 
Results .................................... . 
Discussion 
References 
VII. HEMODYNAMIC EFFECTS OF CLONIDINE AND 









HYPERTENSIVE OBESE EWES . . . . . . . . . .. . . . . . . . . . . . . . . . . 139 
Introduction .................................... . 
Materials and Methods ............................. . 
Animals Preparation .......................... . 
Experimental Protocol ......................... . 
Statistical Analysis ........................... . 
Results .................................... . 
Discussion 
References 









NALOXONE IN RAMBOUILLET SHEEP ..................... 161 
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 161 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 
Animals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163 
Drug Administration and Sample Collection . . . . . . . . . . 163 




Instrument and Chemicals ................. . 
Sample Extraction and HPLC Analysis ........ . 
Pharmacokinetic Analysis ...................... . 













LIST OF TABLES 
Table Page 
CHAPTER I 
1 . Distribution of Adrenoceptor Subtype and Adrenergic 
Responses of Selected Organs or Tissues . . . . . . . . . . . . . . . . . . . 15 
CHAPTER II 
1 . Nutrient Composition of Diet as Fed . . . . . . . . . . . . . . . . . . . . . . . . . . 43 
2. Average Daily Total Intakes of Dry Matter (OM) and 
Digestible Energy (DE) During the Static Phase 
of Dietary Obesity in Sheep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 
3. Weights of Live Body, Carcass, Internal Organs, and Fat 
Depots and Chemical Composition of Carcass 
During Static Phase Obesity in Sheep . . . . . . . . . . . . . . . . . . . . . . 48 
CHAPTER Ill 
1. Mean (± SE) Cumulative Feed Intake (g) in Lean Sheep (n=5) 
Treated With Naloxone and Fed Ad Libitum . . . . . . . . . . . . . . . . . . 55 
CHAPTER IV 
1. Mean (± SE) Cumulative Feed Intake (g) in Lean (n=5) 
and Obese (n=5) Sheep Treated With Naloxone 




1. Plasma Concentrations of Selected Hormones and 
Metabolites in Lean and Obese Sheep Fasted 16 h . . . . . . . . . . . . 100 
2. Serum lon Concentrations in Lean and Obese Sheep 
Fasted 16 h . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 01 
3. Serum Clinical Chemistry in Lean and Obese Sheep 
Fasted 16 h . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 01 
4. Arterial Plasma Concentration of Norepinephrine and 
Epinephrine in Lean and Obese Sheep Fasted 16 h . . . . . . . . . . . . 1 02 
5. Basal Cardiovascular Variables in Lean and Obese 
Sheep Fasted 16 h . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 03 
6. Absolute Systolic (SBP), Diastolic (DBP), and Mean (MAP) 
Arterial Pressure and Heart Rate (HR) Response to 
Intravenous Norepinephrine (NE) and Phenylephrine 
(PE) in Lean and Obese Sheep . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 05 
7. Effective Adrenergic Agonist Dose in Lean and 
Obese Sheep . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 06 
CHAPTER VI 
1. Blood Pressure Variables and Heart Rate in Sheep 
After iv Administration of 5 j.tg/kg Clonidine . . . . . . . . . . . . . . . . . . 126 
2. Blood Pressure Variables and Heart Rate in Sheep 
After iv Administration of 1 0 j.tg/kg Clonidine . . . . . . . . . . . . . . . . . 127 
3. Maximum Change in MAP and HR After Clonidine 
Injection in Lean and Obese Sheep . . . . . . . . . . . . . . . . . . . . . . . . 128 
CHAPTER VII 
1. Blood Pressure Variables and Heart Rate in Sheep 
After iv Administration of 10 11g/kg Clonidine . . . . . . . . . . . . . . . . . 145 
2. Blood Pressure variables and Heart Rate in Sheep 
After iv· Administration of 3 mg/kg Naloxone . . . . . . . . . . . . . . . . . . 146 
X 
Table Page 
3. Blood Pressure Variables and Heart Rate in Sheep 
Injected iv With Naloxone (8 mg/kg) 5 min 
Before Clonidine (1 0 J.Lg/kg) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 147 
CHAPTER VIII 
1. Pharmacokinetic Parameters (mean ± SD) of Intravenously 
Injected Naloxone (3 mg/kg) in Lean and Obese Sheep . . . . . . . . . 168 
xi 
LIST OF FIGURES 
Figure Page 
CHAPTER I 
1. Diagram Representing the Role of Hypothalamus as the 
Central Neuroendocrine Transducer in Appetite 
Regulation. (From Morley 1980) . . . . . . . . . . . . . . . . . . . . . . . . . . 7 
2. Autonomic Control of Blood Pressure Regulation . . . . . . . . . . . . . . . . . 13 
3. Schematic of Proposed Insulin-Mediated Mechanisms of 
Blood Pressure Regulation. (GI, Gastrointestinal; 
GH, Growth Hormone; ANF, Atrial Natriuretic Factor). 
Adapted From Ferrari and Weidmann 1990. . . . . . . . . . . . . . . . . . 22 
4. This Model Illustrates the Possible Relationship Between 
Obesity and Opiates and Their Interactive Role 
in Feed Intake and Pressure Regulation. The Model 
Is Explained in the Text. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 
CHAPTER II 
1. Schematic Diagram of Development of Dietary Obese Sheep 
Model. The Graph Depicts the Changes in Body Weight 
and Feed Intake in Sheep During Dynamic and Static 
Phases of Obesity. Dynamic Obesity Persists Until 
Nearly Steady-State Body Weight and Feed Consumption 
Occurs at Which Animals Enter Static-Phase Obesity. 
Diagram Provided by Dr. McCann, Oklahoma State 
University . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 
2. Body Weight and Digestible Energy (DE) Intakes in 
Maintenance-Fed Lean Sheep and Obese Sheep During 
the Dynamic and Static Phases of Dietary Obesity. 
The Bottom Panel Represents kcal DE Consumed per kg 
Body Weight in Lean and Obese Sheep. Average Daily 
DE Intake Was Obtained for 7 Day (wk) Intervals 




1. Cumulative Feed Intakes (Mean ± SE) After 10 min, 4 h, and 
24 h of Ad Libitum Intake in Sheep (n=5) Pre-Treated 
With 0, 0.3, 1.0, or 3.0 mg/kg of Naloxone iv. . . . . . . . . . . . . . . . . . 56 
2. Plasma Concentrations (Mean ± SE) of Free Fatty Acids, Glucose 
and Insulin Before (Fasted) and After (Fed) Naloxone 
Treatment in Lean Sheep (n = 5). Arrows Indicate Naloxone 
Injection 5 min Before Start of 24 h of Ad Libitum Feeding. 
The Pooled Standard Error (PSE) for Insulin Concentrations 
Are Shown for Each Treatment Group; Standard Errors (Bar) 
at 16 and 24 h Are Shown Because Mean Concentrations 
Differed the Most at These Times Standard Error Bars 
tor Glucose and FFA Were Numerically Contained Within 
Symbols for Mean Concentration. . . . . . . . . . . . . . . . . . . . . . . . . . 58 
CHAPTER IV 
1. Cumulative Feed Intakes (Mean ± SE) in 16-h Fasted Lean and 
Obese Sheep Allowed Ad Libitum Intake of a Pelleted Hay-
Grain Diet for 32 h. Sheep Were in Steady State and 
Chronically Fed Maintenance of the Hay-Grain Diet to 
Keep Them in Zero-Energy Balance. Sheep Were Presented 
With Fresh Batches (1000 g) of Pellets at Time 0 and at 
Each Time Point Indicated When Intakes Were Determined . . . . . . 71 
2. Cumulative Feed Intakes (Mean ± SE) During 32-h of Ad Libitum 
Intake in Lean Sheep Pretreated With 0, 0.01, 0.1, 1 or 
3 mg/kg of Naloxone. Naloxone Was Injected iv 5 min Before 
Feeding Began. Additional Notes as in Legend to Fig. 1. . . . . . . . . 73 
3. Cumulative Feed Intakes (Mean± SE) During 32-h of Ad Libitum 
Intake in Obese Sheep Pretreated With 0, 0.01, 0.1, 1 and 
3 mg/kg Naloxone iv. Additional Notes as in Legend to Fig. 2 74 
4. Cumulative Feed Intakes (Mean ± SE) During the First 4 h of 
Ad Libitum Intake in Lean and Obese Sheep Pretreated With 
0, 0.01, 0.1, 1 and 3 mg/kg Naloxone iv. For Clarity of 
Presentation, SE Bars Are not Shown but the Pooled SE Values 
Values Were 167, 142, 128, 112 and 90 in Lean Sheep and 131, 
90, 170, 90 and 50 in Obese Sheep Treated With 0.01, 0.1, 1 
or 3 mg/kg Naloxone, Respectively. Additional Notes in 
Legend to Fig. 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75 
xiii 
Figure 
5. Cumulative Feed Intakes as Percent of Control Intakes 
(Mean± SE) in Lean and Obese Sheep Pretreated With 
0.01, 0.1, 1 or 3 mg/kg Naloxone. Cumulative Intakes 
During the First 4 h of Ad Libitum Intake Were 
Expressed as Percent of Corresponding Intake After 
0 mg/kg Naloxone (Control) for Each Sheep and Mean 
Values Calculated at Each Time Point for the Different 
Doses of Naloxone Are Shown. For Clarity of Presentation, 
SE Bars Are not Shown but the Pooled SE Values Were 
12, 16, 13 and 11 in Lean Sheep and 16, 15, 12 and 
12 in Obese Sheep Treated With 0.01, 0.1, 1 or 3 mg/kg 
Naloxone, Respectively. Additional Notes in Legend 
Page 
to Fig. 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76 
6. Feed Intakes as Percent of Control Intake at 20 min, 2 h 
and 4 h of Ad Libitum in Lean and Obese Sheep Injected 
With 0.01, 0.1, 1 and 3 mg/kg Naloxone. Probability 
Values Shown Indicate Significance of Treatment Effects 
of Body Condition (BC), Naloxone Dose (NAL) and Their 
Interaction (lA) Are Derived From Split-Plot Analysis 
of Variance; Means within each Time Period With Similar 
Superscript Letter Are not Different (P>0.05); NS 
Indicates no Significant Effect (P>0.1) . . . . . . . . . . . . . . . . . . . . . . 78 
7. Dose-Response Effect of Naloxone on Acute Feed Intake in 
Lean and Obese Sheep Fed Ad Libitum. Area Under the 
Curve (AUG) for Cumulative Feed Intake in the First 
2 h of Ad Libitum Intake Was Calculated in Each Sheep 
After Each Dose of Naloxone. Within Each Body 
Condition, the 2-h AUG After 0.01, 0.1, 1 and 3 mg/kg 
Naloxone Was Expressed as Percentage of 2-h AUG 
After 0 mg/kg (Control) Naloxone in Each Sheep 
and the Mean (± SE) Values Shown Were Calculated 
for Each Dose. Regression Equations for the Mean 
Data (Lines Shown) Were Y= -33.88(Log Dose) + (-55.07) 
in Lean and Y= -25.04(Log Dose)+ (-31.0) in Obese 
Sheep. Dose of Naloxone Inhibiting Intake by 
25 Percent (D25) Was Calculated From These 
Equations and Was 0.13 mg/kg in Obese Sheep and 
0.57 mg/kg in Lean Sheep as Discussed in Results. 
Additional Notes in Legend to Fig 1 . . . . . . . . . . . . . . . . . . . . . . . . 80 
8. Plasma Concentrations of Naloxone (Mean ± SE) in Lean and 
Obese Sheep Injected With 1 and 3 mg/kg Naloxone iv. 
Concentrations of Naloxone After iv Injection of 0.01 
and 0.1 mg/kg Naloxone Were Below the Sensitivity 




1. Mean Arterial Blood Pressure (MAP) Response to Dose of 
Norepinephrine (Upper Panel) or Phenylephrine (Lower 
Panel). Values Are Mean ± SE. The Pressure Increase 
Above Basal (.t. MAP) Is Plotted as a Function of Each 
Agonist Dose. Best Fit of the Relationship Between 
Lean Increment in MAP and Dose of Agonist Was 
Determined by Noniterative Least Squares Regression 
(See Methods). First Degree Polynomial Was Best 
(P<0.01) Fit of Mean Data Shown Here and all 
Observations (n=25) in Each Group (See Results 
and Table 7). Equations Describing the Relationship 
Shown for NE Were Y= 18.5(X) + 6.8 (r= 0.96) in Lean 
Sheep andY= 17.7(X) + 13.4 (r= 0.89) in Obese Sheep; 
Equations for PE Were Y=46.2(Log X)+ 7.1 (r= 0.84) 
in Lean Sheep and Y=54.3(Log X) + 14.0 (r= 0.88) in 
Obese Sheep. Neither Regression Coefficients (b; Slope) 
nor Intercepts for Each Agonist Differed (P>0.05) 
Between Lean and Obese Sheep as Determined by 
Page 
Regression Analysis of Variance and Student's t Test . . . . . . . . . . . 104 
2. Decrements in Heart Rate (.t.HR) in Lean and Obese Sheep 
(n=5/Group) Injected with Different Doses of 
Norepinephrine (Upper Panel) or Phenylephrine 
Lower Panel). The Maximum Decrement in Heart Rate 
(Beats/min) After Each Agonist Dose Was Used to 
Calculate the Mean (± SE) Values Shown. Probability 
Values Shown for Significances if Treatment Effect 
of Body Condition (BC), Agonist Dose (NE; PE) and 
Their Interaction (lA) Were Derived From 2 x 5 
Split-Plot Analysis of Variance; Means Within Each 
Agonist Type With Similar Lower Case Letter Are not 
Different (P<0.05) as Determined by Duncan's New 
Multiple Range Test. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108 
3. Duration of Pressor Response in Lean and Obese Sheep 
(n=5/Group) Injected With Different Doses of Norepi-
nephrine (Upper Panel) or Phenylephrine (Lower Panel). 
Duration Was Time (min) for the Increased MAP to 
Return to Basal Values After iv Injection of Agonist 
Dose. Probability Values Shown for Significances 
if Treatment Effects of Body Condition (BC), Agonist 
Condition (BC), Agonist Dose (NE; PE) and Their 
Interaction (lA) Were Derived From 2 x 5 Split-Plot 
Analysis of Variance. . ................................. 109 
XV 
Figure 
4. Relationship Between Heart Rate and MAP in Lean and Obese 
Sheep (n=5/Group) Under Basal Conditions and After 
iv Injection of Adrenergic Agonists. Reading Left-to-
Right, Data Points (Mean± SE) Correspond to Basal 
Conditions and then Lowest-to-Highest Dose of Norepi-
nephrine (Upper Panel) or Phenylephrine (Lower Panel). 
Peak Pressure Response and the Attendant Heart Rate 
Page 
for Dose of Adrenergic Agonist Are Shown . . . . . . . . . . . . . . . . . . 110 
5. Baroreflex Sensitivity Ratios (Mean ± SE) in Lean and Obese 
Sheep (n=5/Group) Calculated at Peak Pressor Response 
to Dose of Norepinephrine (Upper Panel) or Phenylephrine 
(Lower Panel). Ratios Calculated as Decrement in Heart 
Rate (Beats/min) Below Basal Divided by Peak Increment 
in MAP (mmHg) Above Basal in Response to Agonist Dose. 
Values for Decrement in Heart Rate Were Those Coincident 
With Peak Pressor Response and Usually This Coincided 
With the Nadir Heart Rate Observed After the iv Injection 
of Adrenergic Agonist. Probability Values Shown for 
Significance of Treatment Effects of Body Condition (BC), 
Agonist Dose (NE; PE) and Their Interaction (lA) Were 
Derived From 2 x 5 Split-Plot Analysis of Variance. . . . . . . . . . . . . 111 
CHAPTER VI 
1. Hemodynamic Effects of 5 and 10 11g/kg Clonidine in 
Lean (n=5) and Obese (n=5) Sheep. Arrows 
Indicate iv Injection of Clonidirie . . . . . . . . . . . . . . . . . . . . . . . . . . 128 
2. MAP Response to 5 and 1 0 11g/kg Clonidine in Lean and Obese 
Sheep. Response Calculated as Area (AUG) Above Basal 
MAP Plus One Standard Deviation of Basal. Probability 
Values From Split-Plot Analysis of Variance for Treatment 
Effects Were Body Condition 0.1; Clonidine Dose 0.005; 
Interaction 0.1. Means With Similar Superscript Letters 
Are not Different (P>0.05) as Determined by 




1. Changes in Absolute Mean Arterial Pressure (MAP) in Lean 
(n=5) and Obese (n=5) Sheep Injected With Clonidine 
(10J..Lg/kg) Alone, Naloxone (3 mg/kg) Alone, or Naloxone 
5 min Before Clonidine (Bottom Panel). Arrows Indicate 
Page 
Time of Injections. Values Are Mean ± SE . . . . . . . . . . . . . . . . . . . 148 
2. Changes in Absolute Heart Rate (HR) in Lean (n=5) and Obese 
(n=5) Sheep Injected With Clonidine (1 0 J..Lg/kg) Alone, 
Naloxone (3 mg/kg) Alone, or Naloxone 5 min Before 
Clonidine (Bottom Panel). Arrows Indicate Time of 
Injections. Values Are Mean ± SE . . . . . . . . . . . . . . . . . . . . . . . . . 149 
3. Maximum Changes in Mean Arterial Pressure (MAP) in Lean 
(n=5) and Obese (n=5) Sheep Injected iv With Clonidine 
(1 0 J..Lg/kg) Alone, Naloxone (3 mg/kg) Alone, or Naloxone 
5 min Before Clonidine. Values Are Mean ± SE and Were 
Calculated Using the Difference Between the Peak MAP 
Developed and the Corresponding Basal Values in Each 
Sheep. The Greatest Change in MAP From Basal Occurred 
in the First 5 min After Time 0 (See Fig 2, 3). 
Probability Values From Split-Plot Analysis of Variance 
for Treatment Effects on MAP Response Were Body 
Condition NS, Treatment 0.005, and Their Interaction 0.1. 
Mean With Similar Lower Case Letters Are Not 
Different (P>0.05) as Determined by Duncan's 
New Multiple Range Test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150 
4. Mean Arterial Pressure (MAP) Response in Lean (n=5) and 
Obese (n=5) Sheep Injected iv With Clonidine (1 0 J..Lg/kg) 
Alone, Naloxone (3mg/kg) Alone, or Naloxone 5 min Before 
Clonidine. Response Calculated as Area Above Basal MAP 
Plus One Standard Deviation of Basal. Probability Values 
From Split-Plot Analysis of Variance for Treatment 
Effects Were Body Condition NS, Drug Treatment 0.1, and 
Their Interaction 0.01. Mean With Similar Lower Case 
Letters Are Not Different (P>0.05) as Determined by 
Duncan's New Multiple Range Test . . . . . . . . . . . . . . . . . . . . . . . . 151 
xvii 
Figure 
5. Maximum Changes in Heart Rate (HR) in Lean (n=5) and 
Obese (n=5) Sheep Injected iv With Clonidine (1 0 Jlg/kg) 
Alone, Naloxone (3 mg/kg) Alone, or Naloxone 5 min 
Before Clonidine. Values Are Mean ± SE and Were 
Calculated Using the Difference Between Greatest 
or Lowest HR Developed and the Corresponding Basal 
Values in Each Sheep. The Greatest Change in HR 
From Basal Occurred in the First 5 min After Time 0 
(See Fig 2). Probability Values From Split-Plot 
Analysis of Variance for Treatment Effects on HR 
Were Body Condition NS, Drug Treatment 0.001, and 
Their Interaction 0.05. Means With Similar Lower 
Case Letters in Each Panel Are not Different (P>0.05) 
Page 
as Determined by Duncan's New Multiple Range Test . . . . . . . . . . 152 
CHAPTER VIII 
1. Disposition of Naloxone (3 mg/kg) in Plasma After Its 
Intravenous Administration to Lean (n=5) and 
Obese (n=5) Ewes. Data Are Mean± SE. 
Components of Equation Describing Curves 
Are Shown in Table 1 .................................. 167 
xviii 
CHAPTER I 
INTRODUCTION AND LITERATURE REVIEW 
Synthesis and Secretion of Opioids 
Discovery of Opioids . 
The name "Opioids" refers to a group of chemicals that produce a morphine-like 
effect. The discovery of specific receptors for opioides in animal tissue by Goldstein 
(1971) and Pert and Snyder (1973) led these authors to suggest that opioid-like 
chemicals were produced by humans and animals. Further evidence for the presence 
of endogenous opioid-like peptides (EOP) came from the discovery that electrical 
stimulation of the brain-stem produces analgesia (Reynolds 1969; Mayer and Liebekind 
197 4; Pasternak 1981 ), and that analgesia could be blocked by administering 
naloxone, a specific opioid antagonist (Pfiffer and Herz 1984, Akil et al 1984). 
The search for identification and purification of EOP lead to the discovery of 
specific brain opioids identified as enkephalins, endorphins, and dynorphins (Hughes 
1975; Li and chung 1976). The name endorphin refers to B-endorphins and related 
peptides (Guillemin, 1978). Recently, "opiopeptins" has been proposed as a generic 
term to cover the three families of endogenous opioid peptides classified as 
enkephalinergic, dynorphinergic or endorphinergic (Morley et al 1982). 
It is now clear that there are at least three genes responsible for producing 
large precursor peptides or prohormones, fragments of which have opioid activity. 
These precursors are proopiomelanocorticotropin (POMC), proenkephalin and 
prodynorphin (Hollt 1983). 
Opioid Synthesis Pathway 
The prohormone, POMC, is a glycoprotein of approximately 285 amino acid 
with sugar residues attached near the N-terminal end of the molecule (Fenger 1990). 
POMC is synthesized by the anterior and intermediate lobes of the pituitary and a 
number of other tissues including hypothalamus, lung, placenta, and gastrointestinal 
tract (Drouin et al 1990; Fenger 1990). POMC is hydrolyzed to a-lipotrophic hormone 
(a-LPH), adrenocorticotropic hormone (ACTH) andy-melanocyte-stimulating hormone 
(y-MSH). a-LPH, a large peptide with 91 amino acid (POMC 42-134) is cleaved toy-
lipotrophin (42-101) and a-endorphin (104-134). The cleavage products may differ 
according to site of synthesis. The 31 amino acid a-endorphin from different species 
varies only by one or two amino acids in the C-terminal region (Bloom 1983). 
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The precursor proenkephalin is hydrolysed to form pentapeptide methionine-
enkephalin (Tyr-Giy-Giy-Phe-Met) and leucine-enkephalin (Tyr-Giy-Giy-Phe-Leu). 
Dynorphin (8 amino acid) and a-nee-endorphin (1 0 amino acid) are derived from 
prodynorphin (Lewis and Stern 1983). These peptides are distributed in brain tissues of 
a wide variety of animal species (Simantov et al 1976). 
Sites of Opioid Production 
Immunohistochemical techniques have been used to identify specific sites of 
opioid synthesis in the brain. The cellular distribution of enkephalins and a-endorphins 
is not the same in different regions of brain. a-Endorphin is found mostly in the 
hypothalamus, midbrain, amygdala, pituitary and brain stem. Although hypothalamus 
may contain high levels of a-endorphin and enkephalins, other areas such as the 
caudate hypothalamus and the globus pallidus contain much more en kephalin than B-
endorphin (Bloom 1978). Immunohistochemical staining of serial sections from rat 
hypothalamus indicates that enkephalins and B-endorphins represent two separate 
neuronal systems (Watson 1978; Baile et al 1986; Ravindra and Grosvenor 1990). 
B-Endorphin is present at higher concentrations in plasma than cerebrospinal 
fluid (CSF) in humans (Atkinson 1987). Some B-endorphin immunoreactivity has been 
detected in the stomach, duodenum, jejunum, pancreas, adrenal gland and follicular 
cells of the ovary (Baile et al 1986; Drouin et al 1990). 
Opioid Receptors 
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The discovery of EOP indicated that perhaps receptors could be categorized as 
either enkephalin or endorphin receptors (Pert and Snyder 1973). It was Martin et al 
(1976) who hypothesized that multiple opioid receptors exist in brain. Subsequently, 
opiate receptors have been classified as mu (!l) receptors which have a high affinity for 
morphine and B-endorphin, delta (8) receptors which have high affinity for enkephalins, 
kappa (K) receptors which have high affinity for dynorphin, and epsilon (e) receptors 
which have highest affinity for B-endorphin (Chang et al 1981; Goldstein et al 1989). In 
human brain, ll· 8 and K type of opiate receptors have been identified (Takemori and 
Portoghese 1985). 
Mapping the location of opiate receptors in human brain showed that ll and k 
types predominated ;3-nd that 8 receptors were rare. The K-receptors are most 
abundant in hypothalamus, amygdala and hippocampus, which are areas involved with 
the neuroendocrine effects of opioids. !l-Receptors also were present in these areas 
and other parts of the brain (Pfeiffer et al 1982). K-receptors in human brain were 
further subdivided into 2 distinct types distinguishable by their low and very high 
affinities for the endogenous opioid peptides B-endorphin and dynorphin, respectively. 
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The K-receptor affinity for B-endorphin is about 300-fold lower than that for dynorphin 
and thus B-endorphin at physiological concentrations may not interact with K-receptors. 
B-endorphin and enkephalins may represent the physiological ligands for !l and 8 
opiate receptors (Miller, 1982). 
Opioid Function 
There is accumulating evidence that opioid peptides represent an unique class 
of regulatory chemicals in the endocrine system and in the central and somatic 
divisions of the nervous system. The fact that three types of opioid chemicals 
(endorphins, enkephalins and dynorphins) are found in the hypothalamus, pituitary and 
the adrenal gland, indicates that opioids play a powerful role in regulating the 
organism's response to physiological and environmental demands, including physical 
and psychological stress (Amir et al 1979; Zalman and Galina 1986). Like 
catecholamines, the opioids may have a basic, multisystem function essential to the 
maintenance of homeostasis and to the survival of the organism. Some of these basic 
functions relate to stress, appetite, and cardiovascular systems. It is often difficult to 
determine whether the effects of the endorphins on complex behaviors are primary or 
whether they are secondary to their ability to modify sensory or autonomic variables. 
Opioid release during stressful conditions has been studied extensively. Stress 
appears to activate the hypothalamus-pituitary-adrenal axis of the peripheral 
sympathetic system, leading to release of endogenous opioid peptides from both the 
anterior pituitary and the adrenal medulla (Guillemin 1977, Holaday 1979). These 
stress-related opioid peptides may serve some analgesic function (Zalman and Galina 
1986). The opioid mu-receptor, and even the delta type, may mediate analgesia when 
stimulated by opioid alkaloids (opium) or opioid peptides (Pasternak 1981 ). In addition, 
mu receptors may mediate local analgesia in peripheral tissues (Akil et al1984). 
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There is extensive literature on the effect of opioids on feeding (Merely and 
Levine 1985). An overwhelming body of evidence favors a role for the endogenous 
opioid peptides in the regulation of ingestive behavior (Morley et al 1983; Gosnell 
1987). More detailed involvement of opioid involvement in feed intake regulation will be 
discussed later in this chapter. 
Opioids influence the cardiovascular system by their interaction with specific 
opioid receptors found in the central and peripheral nervous systems, the vascular tree 
and the heart (Holaday 1985). Exogenous administration of opioid peptides affects 
cardiovascular function by decreasing systemic arterial pressure and heart rate, and by 
suppressing baroreceptor reflex function (Holaday 1985). Furthermore, synthetic opioid 
agonists affect the urinary excretion of water and sodium (Akil et al 1984). 
Opioids produce their biological effect by binding to cell-surface receptors 
(Childers 1991 ). Early studies indicated that opioid receptors (mu, kappa, delta and 
epsilon) were coupled to G-proteins that function as transducers in allowing the opioid 
receptor to inhibit adenylyl cyclase, thereby decreasing intracellular concentrations of 
cAMP (Giugliano et al 1989). However, some of the effects of mu and delta receptors 
may also be mediated by direct receptor interaction with G-proteins coupled to ion 
channels (Childers 1991 ). In a recent report, Giugliano et al (1989) suggested that 
opioids may inhibit insulin release by suppressing cytosolic accumulation of cAMP. 
6 
Regulation of Feed Intake 
The regulation of feed intake and energy balance are influenced by a number of 
factors (Harris 1990). Central regulation of body composition is interfaced with central 
regulation of feed intake. This central control system balances energy input with 
energy output in regulating body weight (Harris 1990). Dysfunction in the central 
regulatory system can result in excessive weight gain or loss (Bray 1991 ). 
Feeding behavior can be influenced by several external factors such as 
environmental conditions, sensory cues and nutrient type in the diet (Morley 1980; 
Kissileff and Van ltallie 1982). The internal regulatory systems, including 
gastrointestinal, hormonal and metabolic factors, also play a role in feeding behavior 
(Kissileff and Van ltallie 1982). The primary site responsible for the integrated control 
of feed intake and energy balance is the central nervous system (CNS), with the 
hypothalamus serving as the primary neuroendocrine transducer in regulation of 
feeding behavior. Peptides found in the CNS have been shown to have a direct effect 
on the control of metabolism, feed intake, and reproductive behaviors. 
Hypothalamus and Feed Intake 
The regulation of feed intake requires the integration of many signals including 
environmental factors and immediate and long term energy needs. Feed intake is 
regulated mainly by the central nervous system. Hypothalamus is an area of the brain 
classically associated with feed intake. It receives input from metabolic, hormonal, 
neurogenic, thermal and cortical factors, which describe the nutritional status of the 
organism (Figure 1 ). Electrical stimulation of the lateral hypothalamic area (LH) initiates 
feeding, but electric or chemical destruction of the LH results in aphagia. Electrical 
stimulation of the ventromedial hypothalamus (VMH) inhibits eating in hungry animals, 
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but ablation of this area produces hyperphagia and obesity. The interaction between 
the two areas is suggested to control feed intake. Other areas added to the list of 
regulatory centers in the central nervous system are the paraventricular nucleus and 
rostral areas such as the nucleus solitarius (Morley 1980; Sullivan and Gruen 1985; 
Harris 1990). 
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Figure 1. Diagram representing the role of hypothalamus as the central neuro-
endocrine transducer in appetite regulation. (From Morley 1980) 
The role of neurotransmitters in initiating feeding was shown by central adminis-
tration of adrenergic, cholinergic, and serotonergic agonists as well as gamma 
aminobutyric acid (GABA) agonists (Blundell 1991 ). In sheep and cattle, feeding has 
been stimulated by ventricular injection of a- and B-adrenergic agonists and 5-
hydroxytryptamine (Simpson 1975; Baile et al 1979). The GABA agonists, when 
injected in the CNS, have stimulated feeding in sheep (Seoane et al 1984). 
Opioid Peptides and Feed Intake 
Accumulating evidence suggests that opioids in the CNS are actively involved 
8 
in the control of feed intake (Baile and Mclaughlin 1987; Levine and Atkinson 1987). 
Central administration of B-endorphin, met-enkephalin or dynorphin increases feed 
intake. Although most opioid peptide work has been done in rats (Morely and Levine 
1891; Lowy 1981 ), some work has been done with humans and sheep. Injection of 
several met-enkephalin analogues and B-endorphin into the central ventricles has 
stimulated feeding in satiated sheep and rats (Grandison and Guidotti 1977; Baile et al 
1981; McKay et al 1981 ). Feeding in sheep was blocked by prior administration of 
naloxone, a pure opioid antagonist (Baile 1981; Alavi et al 1991 ). Intravenous 
administration of naloxone suppressed feed intake (Brown and Holtzman 1971, King et 
al 1979) whilst the quaternary analogue of naloxone, which is incapable of crossing the 
blood brain barrier, had no effect on feed intake (Carr and Simon 1982). Such results 
indicate that opioid regulation of feed intake occurs in the central nervous system .• 
Another determinant of the possible significance of opioid peptides in the 
control of feed intake is the concentration of opioid peptides in various areas of the 
brain of hungry or satiated animals. Measurements of peptides in sheep have shown 
that met-enkephalin concentration in the basomedial hypothalamus increased with 
increasing lengths of fasting from 0 to 2 h (Scallet et al 1985). In separate 
experiments, met-enkephalin concentrations in the VMH, paraventricular nucleus and 
anterior, dorsomedial and posterior hypothalamus were higher in fed than 4-h fasted 
sheep (Scallet et al 1985), whereas concentrations of B-endorphin were lower in the 
LH, and anterior and posterior hypothalamus of fed than in fasted sheep (Baile et al 
1985). The differential response to hunger by opioids indicates that hypothalamic 
concentrations of opioids differ depending on the states of hunger and satiety 
(Margules et al 1978, Kaye et al 1987). 
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Animal experiments support the hypothesis that the endorphin system plays an 
important role in the biological response to stress and constitutes an "endorphin stress 
system" (Rossier et al 1979). B-Endorphin and ACTH are concomitantly released by 
the hypophysis in response to acute stress (Guillemin et al 197, Holtzman 1974, Lowy 
et al 1981, Khawaja et al 1989). Clinical and laboratory studies have shown that 
"stress" may either increase or decrease food consumption depending on type and 
duration of the stress procedure. For example, mild tail pinching produces overeating 
and obesity in rats while immobilization stress may produce anorexia (Morely and 
Levine 1980). It is well known that acute exposure of animals to stressors of various 
kinds, for example heat, cold, immobilization , food deprivation, glucodeprivation or foot 
shock, provoke profound behavioral effects by activating either the sympatho-adrenal 
or the hypothalamo-hypophyseal-adrenal system. 
Non-opioid Chemicals and Feed Intake 
Serotonergic, alpha-adrenergic, beta-adrenergic and dopaminergic pathways 
are some of the well studied monoaminergic systems involved in feed intake regulation 
(Morely 1980; Sullivan and Gruen 1985; Blundell 1991 ). The satiety center in the VMH 
is thought to be under positive serotonergic control in that direct application of a 
serotoninergic agonist to this area causes anorexia (Shor-Posner et al 1986). 
Alpha-adrenergic. An a-adrenergic system is thought to excite feeding by 
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inhibiting the VMH satiety center. Norepinephrine injections into the medial 
hypothalamus produce feeding through a strictly a-adrenergic effect. Long-lasting 
activation of the a-adrenergic receptors with clonidine produces overeating (Mayer and 
McCaleb 1980; Leibowitz and Hor 1982). 
Beta-adrenergic. In contrast the to a-adrenergic system, the B-adrenergic 
system is thought to cause satiety by inhibiting part of the classical feeding center in 
the VLH. Inhibition of feed intake in hungry rats occured when isoproterenol , a B-
adrenergic agonist, was injected into the lateral hypothalamus (Martin 1977). Inhibition 
of feed intake in rats after intraperitoneal injection of salbutamol, a B-adrenergic 
stimulant, was reversed with intracerebroventricular injection of propranalol, a B-
adrenergic blocker (Borsini et al 1982). 
Dopaminergic. Dopamine depletion in the nigrostriatal tract produces anorexia 
while dopamine agonists help restore food ingestion. Administration a of dopamine 
antagonist suppresses feeding elicited either by injection of 2-deoxy-0-glucose or 
fasting (Muller et al 1981 ). 
Cholecystokinin. Cholecystokinin (CCK) initially found in the gastrointestinal 
(GI) tract, later in the brain, is one of several peptides involved in feed intake 
regulation (Baile 1986). In contrast to opioid peptides, CNS administration of CCK 
reduces feeding. Furthermore, it's likely that opioid and CCK-derived peptides may 
interact in regulating feed intake. Injections of physiological co~centrations of CCK into 
the lateral ventricles of sheep decreased their feed intake (Della-fera and Baile 1979). 
Concentrations of CCK in specific hypothalamic areas of hungry and satiated sheep 
have been measured. In the anterior hypothalamus, the CCK concentrations were 
higher in fed than fasted sheep (Scallet et al 1985). 
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Obesity and Feed Intake 
Obesity is characterized by excess adipose tissue. Development of obesity is a 
consequence of caloric intake that exceedes the maintenance energy requirements of 
the body. Increasing prevelance of obesity has directed attention of many researchers 
to study the mechanism by which obesity develops and the patho-physiological 
consequense of such condition. Opiate receptors and endogenous opioids play an 
important role in the central regulation of feed intake under both physiological and 
pathological conditions including obesity (Levine et al 1982; Morley et al 1983; Reid 
1985). 
In 1978, Margules and co-workers demonstrated for the first time elevated 
plasma and pituitary levels of B-endorphin in genetically obese (ob/ob) mice and 
Zucker fatty rats (fa/fa). Margules et al (1978) found genetically obese (ob/ob) mice to 
be ten times more sensitive than their lean littermate controls to the anorectic effect of 
naloxone. In a similar study, Morley et al (1983) demonstrated an elevated pituitary 
concentrations of B-endorphin in genetically obese rats (fa/fa) and mice (ob/ob). It is 
worth mentioning that obese Zucker fatty rats are also hyperinsulinemic and 
hyperglycemic (Margulese et al 1978). Diabetic animals are extremely sensitive to 
naloxone, as demostrated by Levine et al (1982). These investigators found 
spontaneously diabetic mice to be 80 times more sensitive to the feed inhibitory effect 
of naloxone than nondiabetic control and streptozocine-induced diabetic mice to be 
1 000 time more sensitive than their controls. Therefore, it is reasonable to suggest that 
greater sensitivity of obese animals to naloxone may be related to their hyperglycemia 
and glucose-induced increase in the activity of opiatergic recepotors. 
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Blood Pressure Regulation 
Components of Blood Pressure Regulation 
The circulatory, endocrine and nervous systems constitute the major integrating 
systems of the body. The circulatory system transports and distributes essential 
substances, removes by-products of metabolism, and maintains hemostatic balance 
during different physiological states. Blood serves as the vehicle for this homeostatic 
function, which depends on velocity of flow, blood pressure, and vessel diameters. 
Velocity of flow is inversely related to the cross-sectional area of the vessel 
(Laplace law) and directly proportional to the difference between inflow and outflow 
pressure. Thus, changes in the diameter of the vessel (resistance) affect blood 
pressure and flow. Just as in electrical circuitry, vessels added in series to a circulatory 
pathway increase resistance and blood pressure for a given flow (for example in renal, 
splanchnic and hepatic capillaries), whereas addition of blood vessels in parallel 
reduces resistance and blood pressure (f~r example colateral blood vessles in skeletal 
muscle of atheletes). 
Blood flow is regulated by complex regulatory systems. Superimposed on the 
intrinsic local tissue regulation (autoregulation) of blood flow are regulations imposed 
by the hormonal and autonomic nervous systems. The major hormonal regulatory 
system is the renin-angiotensin-aldosterone system. Autonomic regulation of blood 
pressure is in the realm of the sympathetic nervous system (SNS), which controls the 
blood pressure through sympathetic nerve fibers distributed over small arteries and 
arterioles. The vasomotor center in the brain stem (medulla) transmits impulses 
through the sympathetic fibers to regulate vascular smooth muscle tone. The upper 
and lower parts of the vasomotor center in the medulla serve as pressor and depressor 
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centers, respectively. The opposing actions of two parts regulate the vascular tone and 
thereby the vascular resistance (Figure 2). 








Figure 2. Autonomic control of blood pressure regulation 
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Blood pressure is a function of cardiac output and total vascular resistance. Any 
condition that increases either cardiac output or total peripheral resistance will cause 
an increase in mean arterial blood pressure. An increase in vascular resistance rather 
than cardiac output, is thought to be the principal factor contributing to essential 
hypertension in humans (Folkow et al 1958; Dustan et al 1981; Korner et al 1989; 
Shepherd 1990). 
Adrenergic Regulation of Blood Pressure 
Norepinephrine (NE) and epinephrine (EPI) are catecholamines involved in 
adrenergic regulation of blood pressure. Adrenal medulla is the major site of EPI 
production. Sympathetic nerve endings produce NE, which is the neurotransmitter at 
most sympathetic postganglionic nerve endings and at some synapses in the central 
nervous system. EPI secreted by the adrenal medulla functions as a neuroendocrine 
chemical. Both NE and EPI exert their effects by activating adrenoceptors located on 
the cell surface of target cells (Table 1 ). 
Two major classes of adrenoceptors exist and these are termed alpha (a) and 
beta (B) adrenoceptors (Raper 1987). Distribution of adrenoceptors varies from organ 
to organ (Table 1 ). The balance between the a- and B-adrenoceptor and their subtypes 
known as a1, a 2, B1 , and B2 determines the characteristic cardiovacular responses to 
NE and EPI release. 
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TABLE 1 
DISTRIBUTION OF ADRENOCEPTOR SUBTYPE AND ADRENERGIC RESPONSES 
OF SELECTED ORGANS OR TISSUES 
Organ/Tissue Receptor Effect 
Heart B1 i force of contraction i heart rate 
Blood vessels a1, ~. B2 <X1, a2 = vasoconstriction B2= vasodilation 
Kidney a1, B1 a1= t renin release B1= i renin release 
Pancreas a1, ~. B2 <X1, a2 = t secretion B2= i secretion 
Fat cells a2, B1 <X2= t lipolysis, B1= i lipolysis 
Liver a1, B2 Glycogenolysis and gluconeogenesis 
Symp. Terminals a2, B2 <X2= t NE release, B2= i NE release 
Bronchioles B2 Dialation 
1 Adapted from Maki et al 1990. 
a-Adrenoceptor. The two subtypes of a-adrenoceptors are a1 and a2. Both 
types are located on the postsynaptic plasma membrane of target cells. The a2-
adrenoceptors also are located in the presynaptic membrane, where they function in 
the regulation of neurotransmitter release. Release of NE by exocytosis into the 
myoneuronal junction occurs when a nerve impulse is propagated along the 
postganglionic adrenergic neuron to the varicosities of the axon terminal. NE then 
activates a-adrenoceptors on the peripheral vascular smooth muscle causing 
vasoconstriction (Timmermans and Van Zwieten 1980; Bylund 1988). ~-Adrenoceptors 
at the presynaptic sites mediate feedback inhibition of NE release (Brummelen 1987). 
The characteristic order of potency for agonists at both ~ and a2-adrenoceptors is 
epinephrine > norepinephrine > dopamine > isoproterenol. 
a1-Adrenoceptors produce their effect via phopholipase hydrolysis of 
phosphotidyl biphosphate and attendant intracellular increase in calcium and protein 
kinase C. ~-Adrenoceptors produce their effect by inhibiting adenyl cyclase, thereby 
decreasing production of intracellular cAMP from ATP (Maki et al 1990). 
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Plasma NE is almost entirely derived from sympathetic nerve terminals, and as 
such reflects sympathetic nerve activity (Cryer 1980). Previous studies in normotensive 
human subjects showed that changes in plasma NE levels mirrored the changes in 
blood pressure during barroreflex activation by vasoactive drugs (Grossman et al 
1982). 
B-adrenoceptors. The B-adrenoceptors are divided into two subtypes, 
generally referred to' as B,- and B2-adrenoceptors. The B, -adrenoceptor is considered 
unique to the heart, kidney and intestine, with B2-adrenoceptors present in other 
tissues and heart (Brodde 1984). The characteristic order of potency for agonists at 
both B, and B2-adrenoceptors is isoproterenol > epinephrine > norepinephrine > 
dopamine (Kalant and Roschlau 1989). Stimulation of the peripheral B2-adrenoceptor 
causes vasodilation, whereas stimulation of a-adrenergic receptors in blood vessels 
causes vasocons-triction. Most, if not all, of the actions of catecholamines at B-
adrenoceptor sites are mediated by the stimulation of the plasma membrane-bound 
adenyl cyclase enzyme, which stimulates the formation of intracelluar cAMP from ATP 
(Maki et al 1990). 
Opioid Regulation of Blood Pressure 
Neuroendocrine contributions to the CNS regulation of blood pressure and heart 
rate are well established (Ganong et al 1979). Endogenous opioids are among the 
neuropeptides identified in this regulatory role (Rubin 1984). Opiatergic peptides have 
been demonstrated in important cardiovascular control centers of the brain (Holaday 
1983). Stimulation of central opiatergic receptors results in change in cardiovascular 
function. For example Haddard et al (1986) and Naranjo et al (1985) observed a 
decrease in blood pressure following central administration of B-endorphin. 
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Central administration of opioids such as B-endorphin or enkephalin causes a 
significant decrease in blood pressure in normotensive animals( Schatz et al 1980; 
Kunos et al 1981 Cuthbert et al 1989), whereas the opiate antagonist naloxone 
increases blood pressure in hypovolemic-shock-associated hypotension in non-human 
primates (Mcintosh 1986). Proopiomelanocorticotrophin derived peptides are 
distributed throughout the brain and brain stem; opioid-containing axonal projections 
originate in the hypothalamus and extend to various brainstem areas, including the 
locus cerulus, nucleus tractus solitarius and area postrema. It is in these areas that 
opiate receptors exist and opiate containing neurons synapse with a-adrenergic 
neurons, suggesting a functional relationship between the two systems (Zamir et al 
1984). Randich and co-workers (1991) found that intrathecal (spinal) administration of 
naloxone antagonized the vagal-mediated bradycardia produced by morphine. 
There is experimental evidence to support the hypothesis that opioid peptides 
may function as neurotransmitters or as modulators in various peripheral effector 
organs innervated by sympathetic and parasympathetic neurons. Lang et al (1983) and 
Xiang et al (1984) reported that a considerable amount of enkephalins are stored in the 
heart, possibly in sympathetic nerve endings. Koyanagawa et al (1989) suggest that 
opioid receptors may mediate vagal bradycardia in dogs. Recently, Rogers and 
Henderson (1990) demonstrated that activation of presynaptic mu- and delta-opioid 
receptors depressed acetylcholine release in the hypogastric ganglion, thus indicating 
that opioids and opioid receptors may regulate neurotransmitter release in 
parasympathetic and sympathetic systems by a presynaptic mechanism. 
Evidence for the interaction between opiatergic and sympathetic nervous 
systems in the regulation of blood pressure was demonstraed by Kunos et al (1981 ), 
who showed that the hypotensive effect of clonidine, an ~-adrenergic agonist, was 
reversed by naloxone. Further, Laskey et al (1989) showed that the effects of B-
agonists on blood pressure were mediated via an opioid pathway. 
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Opioid receptors and peptides have been found in high concentration in the 
nucleus tractus solitarius (NTS) in the rat, cat and monkey brain, with the greatest 
concentration of each occurring in the area of NTS that receives afferent input from 
heart (Lesli 1985). It is therefore possible that stimulation of these afferents causes the 
release of an opioid peptide in the NTS, which in turn leads to reduced sympathetic 
outflow to renal and other vascular beds (Weinstock et al 1989). 
Hypertension in Health 
According to guidelines set by The World Health Organization (WHO), 
hypertension is defined as systolic pressure greater than 160 mmHg and diastolic 
pressure greater than 90 mmHg, although most US authors consider 140/90 mmHg as 
an adequate criterion (Trevisan et al 1988; Stoner and Parker 1991 ). The etiology of 
hypertension is complex and not always well understood. In situations where the 
etiology is known, such as in renal hypertension, the hypertension can be effectively 
treated . However, hypertension of unknown cause (essential hypertension) is difficult 
to treat (Folkow 1982). 
The prevalence of hypertension is sufficiently high in western societies to 
warrant considering it as a serious public health problem. Epidemiological data reveal 
that premature cardiovascular morbidity and mortality are directly related to the level of 
diastolic and systolic blood pressure (Kannel, 197 4, 1979; Hansen et al 1990). 
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Hypertension can produce two primary damaging effects on the cardiovascular system: 
( 1) increased work load on the heart and (2) damage to blood vessles caused by 
excessive pressure {Messerli 1990; Morgan and Baker 1991 ). 
Risk Factors for Hypertension 
Certain risk factors increase the probability of developing hypertension. An 
individual with one or a combination of specific risk factors has a greater probability of 
becoming hypertensive than an individual without such risk factors. The most common 
risk factors for hypertension are obesity, diabetes, excess sodium ingestion and excess 
alcohol ingestion (Van ltallie 1986; Horan and Lenfant 1990; Reaven 1990; Mahler 
1990; McKeigue et al 1991 ). 
Obesity. An association between obesity and hypertension has been 
demonstrated clearly in several epidemiological studies (Stamler 1978; Van ltallie 
1985; Dryer et al 1990; Falkner et al 1990; Xavier Pi-Sunyer 1990, Horswill and Zipf 
1991 ). Conclusions from these studies are supported by experiments demonstrating 
hypertension in obese dogs (Rocchini et al 1989) and Zucker fatty rats (Kurtz et al 
1989). Patients are considered obese when their body weight exceeds by 25 % their 
ideal body weight which is calculated according to the actuarial tables of the 
Metropolitan Life Insurance Company (Stamler et al 1978). 
Although a high proportion of obese individuals develop hypertension, not all 
obese individuals are hypertensive. In a study of 1 million people, Stamler and co-
workers (1978) reported that the prevalence rate for hypertension was 50% greater in 
overweight than normal weight people. The prevalence of hypertension increases with 
increasing age and body weight (Stamler 1978; Leitschuh et al 1991 ). The incidence of 
hypertension was higher in obese blacks as compared with obese caucasians. 
Regardless of race, obese males have a higher prevalence of hypertension than 
female individuals (Stamler 1978, Ramirez et al 1991 ). Several adaptations in the 
cardiovascular system occur during the development of obesity that may lead to 
development of hypertension. For example, as a consequence of the expanding 
adipose tissue a greater demand is placed on the heart and blood supply, and this is 
associated with elevated cardiac output and eventually, left ventricular hypertrophy. 
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Diabetes. Distribution of adipose tissue may have a significant effect on the 
association observed between obesity, diabetes and hypertension (Krieger and 
Landsberg 1988; Evers et al 1989; Lundgren et al 1989; Mahler 1990; Despres et al 
1991 ). Upper body (abdominal) obesity, assessed by increased waist-to-hip ratio, may 
contribute significantly more to high blood pressure and diabetes than lower body 
(gluteal) obesity (Bray 1990; Gerber et al 1990; Skarfors et al 1991 ). Studies show that 
hypertension also is strongly associated with diabetes in obese and nonobese 
individuals (Young and Landsberg 1982; Memeh 1990; Xavier Pi-Sunyer 1990, 
Muscelli et al 1990; Gans and Donker 1991 ). Diabetes and hyperinsulinemia play a 
significant role in the pathogenesis of hypertension and coronary heart disease 
(Ronnemaa et al 1991; Reaven 1990). This relationship between diabetes and 
hypertension has been demonstrated recently in humans (Ronnemaa et al 1991 ), and 
in spontaneously hypertensive rats (Hulman et al 1991 ). The interactions between 
diabetes and obesity and hypertension are not completely understood, but 
hyperinsulinemia and insulin resistance may serve as causative links (Swislocki 1990). 
Hyperinsulinemia. Some of the suggested mechanisms (Fig. 3) linking 
hyperinsulinemia to hypertension include: (1) insulin's stimulatory effect on SNS activity 
(Rowe et al 1981 ); (2) insulin's stimulation of sodium absorption in the kidney 
(DeFronzo 1981; Skott et al 1989); (3) insulin stimulation of locally active growth 
factors in the vascular wall (Baret al 1988); and (4) insulin stimulation of endothelial-
derived vasoactive hormones (Ferrari and Weidmann 1990; Ferrannini and Natali 
1991 ). 
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Insulin, SNS activity and Hypertension. Insulin may affect hypertension by 
increasing sympathetic nervous system activity (SNS). Intravenous infusion of insulin 
increased plasma catecholamine concentrations in normal individuals independently of 
changes in glucose concentrations (Rowe et al 1981 ). Siani et al (1989) showed that iv 
administration of insulin increased heart rate and that this was reversible by 
propranolol, a B-adn:inergic blocker. Whether these results were caused directly by 
insulin or indirectly by insulin effect on glucose is still not clear, since some studies 
have shown that dietary glucose influences the sympathetic activity in rats (Kaufman et 
al 1991 ). 
Insulin, Sodium Balance and Hypertension. Insulin increases sodium 
reabsorption in kidney distal tubules (DeFronzo et al 1981; Skott et al 1989; Gesek et 
al 1991 ). The increase in sodium reabsorption leads to water retention and, 
consequently, increases in blood volume and pressure. Insulin may also enhance 
sodium reabsorption indirectly by its effect on renal sympathetic activity (Gans and 
Donker 1991 ). Brands and co-workers (1991) showed that sustained iv infusion of 
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Figure 3. Schematic of proposed insulin-mediated mechanisms of blood pressure 
regulation. (GI, gastrointestinal; GH, growth hormone; ANF, atrial 
natriuretic factor). Adapted from Ferrari and Weidmann 1990. 
Insulin, Vascular Growth and Hypertension. Abnormal cellular calcium 
homeostasis may link insulin resistance and high blood pressure in non-insulin 
dependent diabetic individuals (Levy at al 1989; Resnick et al 1991 ). These authors 
found that plasma co~centrations of Ca2+ and Mg2+ were positively and negatively 
correlte with incidence of diabetes in humans, repectively. It has been suggested that 
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insulin may contribute to vascular hypertrophy leading to increased vascular tone, and 
subsequent increase in blood pressure (Raij 1991 ). Insulin inhibition of plasma 
membrane Ca++/Mg++_ATPase activity, increases intracellular calcium concentrations 
(Pershadsingh and McDonald 1979), which could potentially modulate cardiovascular 
function (Ferrari and Weidmann 1990). 
Insulin, Endothelial Function and Hypertension. Vascular endothelium 
represents an extraordinary complex network of cells with multiple metabolic and 
immunological properties. These cells are continuously bathed by chemicals in blood. 
The presence of insulin receptors in endothelial cells (Frank and Partridge 1981) 
indicates that these cells respond to insulin regulation of glucose and amino acid 
transport and glucose metabolism (Baret al 1988). Endothelial cells produce a number 
of factors that cause relaxation (nitric oxide, prostacyclin) and contraction (endothelin) 
of vascular smooth muscle (Miller 1991 ). Endothelial cells synthesize clotting factors 
and this can be. affected by insulin. In both type I and type II diabetes, the levels of 
prostacyclin are depressed but may improve with normalization of hyperglycemia 
suggesting that high plasma glucose may compromise endothelial cell function (Stolar 
1988). Therefore, one may suggest that a dysregulation of endothelial cell's function 
may lead to alterations in the regulation of the blood hemodynamics in the blood 
vessels of obese diabetic and nondiabetic individuals. 
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Objectives and Hypothesis 
Opioids have an important role in regulation of feeding behavior and 
cardiovascular function (Morely 1982, Holaday 1983). Dysfunction in opioid biology has 
been associated with development of obesity in obese Zucker rats and also with 
development of hypertension in animals (Guillemin et al 1977, Holaday 1983). 
The schematic in Fig. 4 displays a working model that illustrates the relationship 
between opiates and obesity and their interactive effect on blood pressure regulation. 
The model indicates that enhanced activity in the opiatergic system is essential for the 
overeating that leads to dietary obesity. Opiatergic regulation of intake during the 
induction or dynamic phase of obesity will differ from that during the maintenance or 
static phase of obesity because the obese state per se modifies opiatergic regulation 
of appetite. Obesity is closely linked with the development of hypertension. 
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Figure 4. This model illustrates the possible relationship between obesity 
and opiates and their interactive role in feed intake and 
pressure regulation. The model is explained in the text. 
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The model further shows that abnormal cardiovascular function in obese 
individuals is partly the result of an obesity-induced defect in the opiatergic regulation 
of blood pressure and cardiovascular function. The model does not distinguish if the 
defects in opiatergic regulation of appetite and blood pressure are one-and-the-same 
or whether the defective site(s) of opiate dysfunction is exclusively central or is located 
at central and peripheral sites. The model subserves the thesis that static obesity 
changes opiatergic regulation of appetite and blood pressure. Experiments were 
designed to address this thesis and to further determine the cellular mechanisms 
explaining opiate involvement in obesity-associated hypertension. 
Objectives in experiment 1 were to determine the dose-response curve for 
naloxone inhibition of feed intake in sheep and to establish doses that were without 
side effects. 
Experiment 2 was designed to test the hypothesis that obesity alters the 
opiatergic regulation of feed intake. The inhibitory effect of naloxone on feed intake 
was evaluated in lean sheep and sheep in the static phase of obesity. Sheep became 
obese by overeating for 40 - 50 wk (see Chapter 2). 
Experiments 3, 4 and 5 tested the hypothesis that obesity in sheep is asso-
ciated with hypertension and that cardiovascular responses to opioid blockade differ in 
lean and obese sheep. Cardiovascular responses to clonidine were determined in the 
presence and absence of naloxone to examine the interactive effects of opioids and 
adrenergic receptors on cardiovascular function in lean compared with obese sheep. 
Finally, the effect of obesity on the pharmacokinetics of iv injected naloxone 
was investigated. Results obtained in lean and obese sheep treated with naloxone can 
be readily compared only if body condition has no effect on plasma levels or 
degradation of the injected naloxone. 
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CHAPTER II 
DEVELOPMENT OF OBESE SHEEP MODEL 
Introduction 
Obesity, diabetes and hypertension are clinical diseases with high prevalence in 
western society. Epidemiological statistics reveal that diabetes and obesity are major 
predisposing factors for premature cardiovascular morbidity. It has been estimated that 
approximately 26% of the US population (age 20-74 yr) currently are considered 
obese (Van ltallie 1985). 
Obesity is an important risk factor for development of hypertension. Indeed, in 
the United States, national data for 1979-1980 suggest that 44% of the hypertensive 
population are obese, whereas only 16% of the normotensive population are obese. 
Conversely, 53% of all obese subjects are hypertensive, but only 22% of non-obese 
individuals are hypertensive (Horan and Lenfant 1990). There seems to be a clear 
association between obesity and high blood pressure. 
Understanding and treating human diseases has depended to a great extent on 
the use of animal research models. Obese animals may represent models of human 
obesity in certain respects but not others. Studies in animal models may be aimed at 
elucidating etiological factors in obesity or the metabolic abnormalities and clinical 
diseases associated with obesity. Animals may be used to study neurotransmitters 
involved in the regulation of food intake, pharmacokinetic properties of therapeutic 
drugs in obese patients, and finally the pathophysiology of obesity-associated 
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hypertension and diabetes (Fuller and Yen 1987; Bohr and Dominiczak 1991 ). 
Obesity can have different origins and etiologies in animals just as in humans. 
In animals, obesity can be genetic in origin or induced by chemical, surgical or dietary 
means (Bray 1979). Genetically obese animal models, e.g. ob/ob mouse and fa/fa fatty 
rats, might be good models for genetic obesity but not for nongenetic obesity in 
humans (Bray 1977; Fuller and Yen 1987). 
Excessive caloric intake produces obesity in humans and animals. Animals can 
be induced to overeat either by force feeding, enhancing the palatability of food, 
manipulations such as hypothalamic lesions, or by tail-pressure stress to enhance 
feeding (Bray 1979; Penicaud et al 1989). Special effort is necessary to produce 
dietary-induced obesity in rodents. Rats become dietary obese by consuming a diet 
comprised of cheese, ham, salami, bread, and crackers; the so-called "cafeteria diet" 
(Sclafani and Springer 1976; Rolls et al 1980; Bubag et al 1990). The lack of 
homogeneity of diet introduces difficulty in estimating the type of nutrients and amount 
of calories that are ingested in dietary-obese rats as compared with control rats fed 
standard rat chow. Alternative procedures involve the feeding of high glucose, high 
fructose or high fat diets to induce dietary obesity in rats while control animals are fed 
standard rat chow (Levin et al1983; Kaufman et al1991). 
Genetic and nongenetic obese animal models have been used to study the 
patho-physiology of hypertension in humans. The most studied animal models are 
genetically hypertensive such as the Dahl salt sensitive rat (OS) and the Japanese 
spontaneously hypertensive rat (SHR). Dahl and co-workers established a genetic stain 
of rats that became hypertensive when fed a high salt diet and a second salt-resistant 
strain (SR) that did not develop hypertension (Dahl 1962). The SHR rats were 
originally developed by Okamoto and Aoki (1963) by selectively breeding of the Wistar 
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Kyoto (WKY) rats for higher blood pressure. The SHR rats have many similarities to 
human essential hypertension and currently SHR rats are the most widely used animal 
model of essential hypertension. SHR rats have enhanced our understanding of some 
of the mechanisms associated with hypertension, but unfortunately this genetic animal 
model does not show the risk factors appropriate for obesity-associated hypertension. 
An animal model of renal hypertension, originally described by Goldblatt and 
associates in 1937, is produced by clamping one or both renal arteries (Goldblatt et al 
1937). Variation of Goldblatt's original technique has been used by other investigators 
(Hall et al 1990; Xie et al 1990; I mig and Anderson 1991 ), to advance significantly our 
understanding of renal hypertension. 
Dietary obese hypertensive dogs were first described by Wood and Cash 
(1939). Recently, Rocchini and associates reported that high fat feeding produces 
obesity and hypertension in dogs (Rocchini et al 1987). The obesity was produced by 
supplementing the regular diet of dogs with 2 lb of freshly cooked beef fat per·day. 
After 5 wk on this diet, mean arterial pressure and heart rate were increased 24 and 
21 %, respectively, in high-fat supplemented dogs compared with control animals fed 
only regular diet (Rocchini et al 1987). 
Development of hypertension in genetically obese rats has been inconsistent. 
Kurtz et al (1989) reported an increase of approximately 20 mmHg in the mean arterial 
blood pressure of Zucker fatty rat compared with lean Zucker rats. However, others 
have failed to see any significant difference in the blood pressure of lean or obese 
Zucker rats (Ernsberger and Nelson 1988; Kasiske et al 1991 ). Furthermore, 
development of hypertension in the Zucker rat may be genetic in origin, and distinct 
from the obese state because caloric restriction did not attenuate the hypertension 
(Kurtz et al 1989). 
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In some models of dietary-induced obesity, rats and dogs are fed excess fat in 
their normal ration to develop obesity-associated hypertension (Levin et al 1983; 
Rocchini et al 1987; Bunag et al 1990). In these studies, obese animals are compared 
to lean ones which are fed normal diet without the excess amount of fat, and thus 
comparisons may not be appropriate since animals belong to different dietary 
treatments. We have developed an obese sheep model (Fig. 1) by dietary means, in 
which the composition of the diet is the same for both lean and obese sheep. This 
sheep model of obesity develops some of the risk factors associated with diabetes and 
hypertension in humans, such as hyperinsulinemia, hyperglycemia, and insulin 
resistance (McCann and Bergman 1988; McCann et al 1991 ). In this chapter we will 
present results pertaining to the development of dietary obesity in Rambouillet ewes 
that were used in this thesis. 
Materials and Methods 
Animals and Diet 
Lean adult Rambouillet ewes aged 3-4 years were purchased from USDA-ARS, 
Forage and Livestock Research Laboratoy, Fort Reno, OK. The diet fed throughout the 
experiment was a pelleted hay-grain mixture (Stillwater Ag and Mill, Stillwater, OK) with 
a small amount of prairie hay to provide long-stem roughage for maintenance of rumen 
motility. Fresh water was always available to each sheep. Chemical composition of the 
pelleted feed and hay was relatively constant throughout the experiment (Table 1 ). 
Dietary-Induction of Obesity 
Ewes were assigned randomly to the lean (n=5) and obese (n=5) groups and 
housed individually in pens (1.1 x1.8 m) bedded with sawdust in a room with constant. 
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Figure 1. Schematic diagram of development of dietary obese sheep model. 
The graph depicts the changes in body weight and feed intake in sheep during 
dynamic and static phases of obesity. Dynamic obesity persists until nearly 
steady-state body weight and feed consumption occurs at which time animals 
enter static-phase obesity. Diagram provided by Or. McCann, Oklahoma State 
University. 
TABLE 1 
NUTRIENT COMPOSITION OF DIET AS FED1 
Nutrient 
Dry Matter (OM) 
Total Digestible Nutrient (TON) 
Total Protein 
Crude Fat 
















Values as g/kg 
934.6 ± 2.0 942.0 ± 6.2 
671.4 ± 12.3 523.2 ± 7.9 
152.4 ± 4.7 47.3 ± 3.3 
27.9 ± 0.4 12.8 ± 0.9 
545.9 ± 9.1 480.1 ± 17.2 
149.1 ± 12.6 373.8 ± 18.0 
98.3 ± 3.4 58.9 ± 3.5 
13.2±0.3 3.2 ± 0.3 
5.2 ± 0.3 0.89 ± 0.20 
9.1 ± 0.4 1.03 ± 0.16 
15.8 ± 0.3 5.23 ± 1.59 
3.0 ± 0.2 0.23 ± 0.02 
1.6 ± 0.2 1.07 ± 0.29 
Values as mg/kg 
60.5 ± 6.5 48.7 ± 8.8 
5.82 ± 0.79 1.44 ± 0.36 
1.49 ± 0.08 0.212 ± 0.054 
67.4 ± 15.5 5.96 ± 1.80 
994.6 ± 45.6 43.6 ± 6.6 
2.5 ± 0.22 0.50 ± 0.11 
1 Values are means (± SE) of means of 5 analyses done at 
intervals of approximately 4 months on 5 different batches of pellets 
and hay. Analyses performed by Triple "S" Labs, Loveland, CO, USA. 
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light, temperature (20 ± 1 oC) and music (radio). Sheep were acclimated to environment, 
jugular venipuncture and personel for 4 wk before experimental data were coolected.were 
collected. At this time, all sheep were fed maintenance levels of the pelleted feed (12.8 
g/kg) and hay (1 g/kg). The target body weight associated with lean body condition was 
calculated using wither heights and a weight-to-wither height ratio of 0.65 kg/em (McCann 
and Bergman 1988, McCann et al 1991 ). Target body weights were used in calculating 
maintenance intakes in all sheep during the acclimation period and in lean sheep throught 
the experiment. 
Amount of pellets fed to obese sheep increased from maintenance to 1 .5 kg per 
sheep per day in week (wk) 1, to 2.0 kg in wk 2 and to 2.5 kg per sheep per day in wk 
3 of the experiment. Feed refusal was determined daily and amounts fed adjusted to 
provide weigh backs of approximately 1 0% of the amount fed. Pellets were fed in two 
equal amounts at 0900 and 1630 h. Hay (1 g/kg) was fed daily at 0900 h throughout the 
experiment. 
Indices of Obesity and Chemical Composition of Carcass 
Sheep were necropsied over a 4 month period at wk 11 0 to 130 of the 
experiment. A lean and obese sheep were necropsied as a pair after an overnight fast. 
All sheep were in equilibrium body weight at necropsy. 
Sheep were electrically stunned, exsanguinated and eviscerated. The omental, 
perirenal and pericardia! fat depots were removed and weighed to the nearest 1 g. 
Weights of heart, kidney and liver also were recorded. The carcass was split longitudinally 
into right and left halves and chilled overnight at 4 oC. The half-carcass was ground 
seven times through a 9 mm plate before subsampling for proximate analysis. Proximate 
composition was done by standard AOAC method (Association of Official Analytical 
Chemists 1970). Protein was determined by the macro-Kjehldal method. Lipid content was 
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determined using Soxhlet extraction procedure with anhydrous petroleum ether. Moisture 
content was the difference in weight of tissue before and after freezecdrying of 
subsamples (500 g) of comminuted carcass. 
Results and Discussion 
Body Weight and Feed Intakes 
Body weights in the obese group increased in a curvilinear fashion until attaining 
a plateau value by wk 40 approximately (Fig. 2). Overeating for 40 wk increased body 
weight from 45 ± 3 kg to 85 ± 3 kg in obese sheep. Intakes of pellets and hay in obese 
sheep peaked at 1840 ± 1 05 g x sheep·1 x day-1 at wk 3-5 and declined gradually 
thereafter until plateauing at nearly constant levels of 915 ± 32 g x sheep-1 x day-1 at wk 
30-60 of ad libitum feeding. Intakes of digestible energy mirrored feed intakes (Fig. 2), and . 
clearly were decreasing from peak values (5490 ± 315 Kcal DE.sheep -1 • day-1 ) at wk 3 
while body weights continued to increase in obese sheep. Body weights and intakes in 
lean sheep were nearly constant throughout the experiment (Fig. 2). 
Obese sheep were in static-phase obesity afterwk 40 based on stable body weight 
and relatively constant consumption that was sufficient for maintenance of steady-state 
body weight and presumably steady-state body composition. Obese sheep were fed 
a specified maintenance intake starting wk 72 of the experiment. During static phase 
obesity (wk 40-120), average intakes of dry matter and digestible energy per kg body 
weight were practically equivalent in lean sheep fed maintenance and obese sheep fed 
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Figure 2. Body weight and digestible energy (DE) intakes in maintenance-fed lean sheep 
and obese sheep during the dynamic and static phases of dietary obesity. 
The bottom panel represents kcal DE consumed per kg body weight in lean 
and obese sheep. Average daily DE intake was obtained for 7 day (wk) 
intervals throughout the experiment. 
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Indices of Obesity and Carcass Composition 
Body weights in obese sheep (79 ± 3 kg) were about twice those in lean sheep 
(46 ± 2 kg) at necropsy (Table 3). Weights of the omental, perirenal fat and pericardia! 
fatdepots were markedly greater (P<0.01) in obese than lean sheep. Weights of some 
of the vital organs, (e.g., heart, liver and kidneys) were greater (P<0.01) in obese than 
lean sheep. The percentage of lipid was greater (P<0.01) and the percentage of 
protein less (P<0.01) in the heavier (P<0.01) carcass of obese compared with lean 
sheep. 
TABLE 2 
AVERAGE DAILY TOTAL INTAKES OF DRY MATTER (OM) AND DIGESTIBLE 
ENERGY (DE) DURING THE STATIC PHASE OF DIETARY 
OBESITY IN SHEEP1 
Lean (5} Obese (5} 
Item WK 50-120 WK 50-66 WK 70-120 
Dry Matter g/kg1.0 12.5 ± 0.2 11.3 ± 0.3 10.3 ± 0.2 
(DM) g/kg0.75 32.5 ± 0.6 34.5 ± 1.0 30.7 ± 0.5 
Digestible Energy Kcal/kg1·0 38.7 ± 0.8 35.5 ± 0.9 32.0 ± 0.5 
(DE) Kcal/kg075 101.1 ± 2.9 107.8 ± 3.3 95.3 ± 1.4 
1 Obese sheep were fed ad libitum but consuming maintenance during week (WK) 
50-66 and were fed a specified maintenance during WK 72-120. Daily intakes of OM and 
DE were averaged for each sheep during each period and the average value used to 
calculate the mean ± SE values shown. DE intakes were calculated on the basis that 1 
g of total digestible nutrient (TON) provides 4.45 Kcal DE. 
Item 
TABLE 3 
WEIGHTS OF LIVE BODY, CARCASS, INTERNAL ORGANS, AND FAT 
DEPOTS AND CHEMICAL COMPOSITION OF CARCASS DURING 
STATIC PHASE OBESITY IN SHEEP 
Lean (5) Obese (5}1 
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Body and organ weights ___ _ 
Body weight (kg) 
Carcass weight (kg) 
Omental fat {kg) 
Perirenal fat {kg) 
Pericardia! fat {g) 
Heart {g) 
Liver {g) 
Right kidney {g) 





46 ± 2 79 ± 3 
20 ± 0.5 40 ± 1 
0.94 ± 0.14 4.42 ± 0.2 
0.48 ± 0.09 2.17 ± 0.23 
91 ± 12 274 ± 26 
248 ± 17 287 ± 16 
530 ± 20 714 ± 49 
58± 2 76 ± 6 
54±2 82 ± 7 
Carcass Percent Composition 
23±2 
14.9 ± 1.2 
58± 1.0 
4.2 ± 0.4 
46 ± 1 
10.7 ± 0.5 
24 ± 0.7 
3.1 ± 0.2 
1 Except for heart weights, values for lean and obese sheep within an item differ 
{P<0.05) 
Dietary obese sheep portray some of the risk factors associated with obesity in 
humans such as hyperinsulinemia, hyperglycemia, insulin resistance. Our 
understanding of the etiology and pathophysiology of obesity relies heavily on the 
availability of suitable animal models. Genetically obese rodents are well suited to 
study pathophysiology of obesity with genetic origin. Dietary obese rodents are difficult 
49 
to produce. One of the limitations of genetically obese or dietary obese rodents is their 
small body size which precludes repetitive sampling. Obese sheep provide an ideal 
model of non-genetic origin for studies including diabetes, insulin resistance and blood 
pressure. Sheep are equivalent in size to humans, are docile, do not molest the 
experimenter, and are readily instrumented for short term or chronic physiological and 
pharmacological studies. As with any model, sheep have their limitations. Sheep are 
herbivorous ruminants whereas humans are omnivorous and nonruminants. However, 
sheep are established animal models for humans in areas of neurophysiology, 
cardiovascular physiology and reproductive biology. 
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CHAPTER Ill 
EFFECTS OF NALOXONE ON AD LIBITUM INTAKE 
AND PLASMA INSULIN, GLUCOSE, AND FREE 
FATTY ACIDS IN MAINTENANCE-FED SHEEP 
Introduction 
Changes in plasma levels of insulin, glucose and free fatty acids (FFA) are 
thought to play a role in systemic regulation of feed intake in animals (Bray 1986; 
Friedman et al 1986; Morley 1987). Endogenous opiates and their receptors also play _ 
important roles in the regulation of feed intake in physiological and pathological 
conditions (Morley et al 1983; Vim and Lowy 1984; Reid 1985). Opiate antagonists 
such as naloxone and naltrexone decrease feed intake in fasted or fed animals and 
humans (Morley 1987; Baile and Mclaughlin 1987). In addition to their effects on 
appetite, endorphins also are capable of affecting the plasma concentrations of insulin, 
FFA and glucose directly via peripheral opiate receptors and( or) indirectly via opiate 
receptors in the central nervous system (Morley 1987; Appel et al 1987; Rudman and 
Kutner 1986; Curry et al 1987). Naloxone, therefore, may suppress feed intake by 
direct effects within the CNS alone or in combination with naloxone-induced changes in 
the concentrations of plasma chemicals such as insulin, glucose and FFA that serve as 
peripheral signals in appetite regulation. Conversely, plasma glucose itself may 
influence appetite by regulating the activity of central opiate receptors in rats (Morley 
and Levine 1982). 
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Endorphinergic regulation of appetite may differ among species and between 
animals of the same species that are in differing physiological states. For example, 
doses of naloxone that decreased feed intake in satiated chickens were ineffective in 
12-h fasted chickens (Sangiah et al 1988). In these and other similar studies in 
domestic animals (Baile et al 1981 ), the endorphinergic link between feed intake and 
changes in plasma insulin, glucose and FFA were not examined. Therefore, the 
objectives of this study were to determine (1) dose-dependent inhibitory effects of 
naloxone on ad libitum intake in lean sheep fasted overnight, and (2) whether effects of 
naloxone on feed intake were dissociated from concomitant effects of naloxone on 
plasma concentrations of insulin, glucose and FFA. 
Materials and Methods 
Dorset ewes (n = 5), 3 to 4 years of age and weighing 36 ± 2 kg, were housed 
individually in a room with constant light and temperature (23-25 ·c). Except on 
experimental days, sheep were fed a maintenance intake (540 g) of a pelleted hay-
grain feed (14% CP; 12% fibre, 63% TON; 93% OM) in two equal amounts at 0900 h 
and 1700 h and 90 g of hay at 0900 h. All feed routinely was consumed within 30 min 
of feeding. Previous work showed that sheep fed this ration were in zero-energy 
balance (McCann and Bergman 1988; McCann et al 1990) as indicated in this study by 
steady-state body weights over prolonged time intervals of at least several months 
before and during data collection. The weight-to-height ratio in these Dorset ewes 
indicated a lean body condition that has been associated with a stripped carcass lipid 
content of about 23% and a live body lipid content of 16% to 20% (McCann and 
Bergman 1988; McCann et al 1990). 
Five of twenty four sequences possible for treatments of 0 (saline), 0.3, 1.0 and 
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3.0 mg/kg naloxone were assigned to sheep in a generalized block design with sheep 
considered as blocks. At least 7 d elapsed between successive treatments. Naloxone 
hydrochloride (DuPont, Wilmington, Delaware) was prepared fresh in sterile saline (5 
ml) as needed on each experimental day, and was injected iv by jugular vein catheter 
5 min before 16-h fasted sheep were allowed ad libitum intake of pellets for the 
ensuing 24 h. A sham trial consisting of blood sampling and 24 h of ad libitum feeding 
was done in all sheep to acclimate them to experimental procedures. Feed intakes 
were determined and blood samples obtained at 10, 20, 40 and 60 min and 2, 4, 8, 12, 
16 and 24 h of ad libitum feeding; additional blood samples were taken 30, 20 and 5 
min before ad libitum feeding. Blood samples were collected via jugular catheter that 
was inserted at least 12 h before sample collections. Plasma samples were stored(-
22 C) after centrifugation (4 C) of whole blood tor 20 min at 1000 x g. Glucose and 
FFA concentrations in plasma were determined using enzymatic colorimetric assays 
(McCann et al 1990; McCann et al 1986). Plasma concentrations of insulin were 
determined in duplicate by a validated solid-phase radioimmunoassay (McCann et al 
1986). 
Treatment effects of animal, naloxone dose, sample time and their interactions 
were tested by repeated measures analysis of variance using the General Linear 
Model (GLM) procedure in SAS (Freund 1986). An analysis of covariance model of 
SAS for split-unit and repeated measures (Meredith et al 1988) was done to adjust 
plasma concentrations of insulin, glucose and FFA for differences in feed intakes 
among treatment groups; feed intake was considered as the covariate changing with 
the subunit levels (time). Data are presented as mean ± SE. 
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Results 
Saline-treated sheep, that previously had been meal fed a maintenance intake, 
consumed 1.79 kg of a high-energy diet during 24 h of ad libitum feeding (Table 1 ). 
Approximately 50% and 80% of their total 24-h intake was consumed in the first 60 
min and 4 h of ad libitum intake, respectively. Relative to control intakes in saline-
treated sheep, naloxone at doses of 0.3 and 1.0 mg/kg initially had no significant effect 
on intakes in the first 60 min of ad libitum intake, but both doses decreased (P < 0.01) 
the cumulative 2-h and 4-h intakes by approximately 35% (Table 1 ; Fig. 1). In contrast, 
the highest dose of naloxone (3 mg/kg) had immediate (1 0-min) and protracted (4 h) 
TABLE 1 
MEAN (± SE) CUMULATIVE FEED INTAKE (g) IN LEAN SHEEP (n=5) 
TREATED WITH NALOXONE AND FED AD LIBITUM A 
Dose of Naloxone (mg/kg) 
Time Saline 0.3 1.0 3.0 
10 min 630 ± 29b 649 ± 39b 690 ± 31 b 344 ± 79c 
20 min 885 ± 82b 718 ± 64b 718 ± 40b 392 ± 115c 
40 min 908 ± 84b 730 ± 58b 718 ± 40b 392 ± 114c 
60 min 947 ± 104b 765 ± 64b 720 ± 40bc 475 ± 114c 
2 h 1,216 ± 149b 822 ± 69c 769 ± 61c 482 ± 117d 
4 h 1,397 ± 216b 987 ± 104c 836 ± 74c 560 ± 111d 
8 h 1,515 ± 220b 1,225 ± 123c 1,066 ± 114cd 849±171d 
12 h 1,615 ± 194b 1,501 ± 95bc 1,329 ± 129cd 1,151 ± 157d 
16 h 1,699 ± 166b 1,684 ± 69b 1,489 ± 155b 1, 443 ± 152b 
24 h 1,788 ± 137b 1,826 ± 56b 1,638 ± 154b 1,890 ± 85b 
asheep were allowed 24-h ad libitum intake after a 16-h fast. 
bcdMeans within a time period with similar superscripts are not different (P > 0.05). 
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FEED INTAKE IN NALOXONE-TREATED SHEEP 
2000 
10 MINUTE 4 HOUR a 
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Figure 1. Cumulative feed intakes (mean± SE) after 10 min, 4h, and 24 h of ad 
libitum intake in sheep (n=5) pretreated with 0, 0.3, 1.0, or 3.0 mg/kg of 
naloxone iv. 
inhibitory effects on feed intake. Doses of naloxone used had no observable effects 
onthe gross motor behaviour or well-being of the sheep. Preliminary experiments by us 
in 2 sheep showed that 10 mg/kg naloxone clearly affected motor behaviour adversely. 
Compared with saline-treated sheep, 0.3 and 1.0 mg/kg naloxone decreased 
(P<0.01) cumulative intakes during the first 8 to 12 h of ad libitum intake, whereas 3 
mg/kg naloxone decreased (P< 0.01) cumulative intake during the first 12 to 16 h of 
ad libitum intake. Although 16-h cumulative intakes in naloxone-treated sheep 
generally were less than those in saline-treated sheep, the mean rate of intake 
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between 4 and 16 h in sheep treated with 0.3 mg/kg (2.9 g/min), 1.0 mg/kg (2.7 g/min) 
or 3.0 mg/kg (3.7 g/min) of naloxone exceeded (P < 0.05) that during saline treatment 
(1.2 g/min). These results suggest that pretreatment with naloxone effectively 
suppressed intake only in the first 2 to 4 h of ad libitum intake; thereafter the effects of 
naloxone waned and a rebound response was observed as evidenced by greater 
consumption rate in naloxone-treated than in control sheep. Consequently, total 
intakes at 24 h were similar in all groups of sheep (see Table 1 and Fig. 1 ). 
Plasma concentrations of insulin (38 ± 7 vs 95 ± 22 fmol/ml) and glucose (2.7 ± 
0.2 vs 3.6 ± 0.2 J.tmol/ml) first increased (P < 0.01) above fasting levels at 40 min and 
4 h, respectively, of ad libitum intake in saline-treated sheep (Fig. 2). 
Plasma FFA levels decreased (P < 0.01) from 291 ± 48 nmol/ml to a sustained low 
level of 92 ± 14 nmol/ml after 60 min of ad libitum intake in saline-treated sheep. 
Concentrations of insulin, glucose and FFA in plasma of ad libitum-fed sheep 
pretreated with three doses of naloxone were statistically similar to those in control 
sheep despite the fact that feed intakes were affected by naloxone. To determine 
naloxone effects per se on plasma variables, the plasma concentrations of insulin, 
glucose and FFA were adjusted statistically for naloxone-induced differences in feed 
intake (18, 19). This analysis showed significant covariate relationship between plasma 
variables and feed intake across sheep in all treatment groups. The adjusted 
treatment means for glucose and FFA remained unaffected by naloxone treatment, but 
the highest dose of naloxone tended (P=0.09) to increase plasma insulin concen-
trations independent of feed intake. Collectively, results suggest that the inhibitory 
effects of naloxone on appetite in sheep likely were independent of peripheral 
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Figure 2. Plasma concentrations (mean ± SE) of free fatty acids, glucose and insulin 
before (fasted) and after (fed) naloxone treatment in lean sheep (n=5). 
Arrows indicate naloxone injection 5 min before start of 24 h of ad libitum 
feeding. The pooled standard error (PSE) for insulin concentrations are 
shown for each treatment group; standard errors (bar) at 16 and 24 h are 
shown because mean concentrations differed the most at these times. 
Standard error bars for glucose and FFA were numerically contained 
within symbols for mean concentration. 
Discussion 
This study demonstrated dose-dependent inhibitory effects of naloxone on ad 
libitum intake in 16-h fasted lean sheep that routinely had been meal fed a 
maintenance intake. However, only the highest dose of naloxone (3 mg/kg) had 
59 
immediate inhibitory effects on feed intake. Lower doses of naloxone did not reduce 
intake significantly until sheep had consumed feed in the initial h of ad libitum intake. 
The behavioral response of feed intake to low doses of naloxone in this study 
apparently was modified with time as animals ate. One interpretation is that the strong 
endorphinergic drive for hunger in our sheep could be antagonized immediately only by 
high dose naloxone, and that low dose naloxone became effective with time because 
endorphinergic drive for eating diminished as the animals consumed feed. This 
postulate is strengthened by comparing our results with those of Baile et al (Baile et al 
1981) who determined dose-dependent effects of naloxone in 4-h fasted sheep that 
previously were maintained on ad libitum intake. Baile et al (1981) reported that as 
little as 0.03 mg/kg naloxone suppressed 2-h intake in their sheep, whereas much 
higher doses of 0.3 and 1.0 mg/kg naloxone were ineffective in our study. Fasting an 
overfed animal for 4 h (Baile et al 1981) should result in less hunger drive than fasting 
maintenance-fed animals for 16 h, as was done in our study. The degree of negative 
energy balance, therefore, would seem to be directly related to the endorphinergic 
drive for hunger in sheep, as illustrated by responses to naloxone in this study and that 
of Baile et al ( 1981 ). A further consideration is that our sheep purposefully were lean, 
whilst those of Baile et al ( 1981) should have been fatter, relatively, because their 
sheep chronically were overfed. Data in lean and obese Rambouillet ewes suggest 
that body condition per se alters opiate regulation of appetite in sheep (Chapter IV). 
Additionally, it should be noted that the supraphysiological dose of 3 mg/kg of 
naloxone was incapable of completely suppressing intake in these sheep. In broiler 
chicks, doses of naloxone as high as 10 mg/kg had no effect whatsoever on intake in 
12-h fasted birds (Sangiah et al 1988). That intake was not suppressed completely by 
high dose naloxone in fasted sheep or chicks suggests that opiate and nonopiate 
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systems (e.g., monaminergic and gaba-receptors) in the CNS are involved to different 
degrees in initiating feeding in hunger-driven sheep and chicks. Girard and co-workers 
(1985; 1986) reported that initiation of feeding in sheep may involve neurons in the 
medial hypothalamus that are responsive to gamma-aminobutyric acid. 
This study also sought to determine if the inhibitory effects of naloxone on feed 
intake were mediated in part by changes in the plasma levels of insulin, glucose, or 
FFA. Increases in the concentrations of insulin or glucose are purportedly feedback 
signals for satiety, whereas increases in plasma FFA may have a role in hunger drive 
(Rezek 1976; Morley 1987). Our results showed that dose-dependent effects of 
naloxone on appetite in sheep were manifested without concomitant naloxone-induced 
changes in plasma insulin, glucose, or FFA. However, the highest dose of naloxone 
tended to increase plasma insulin levels, independent of changes in feed intake, 
towards the latter half of ad libitum intake. This supports other studies in rats where 
naloxone treatment significantly increased the plasma insulin level (Fontela et al 1986; 
Knudtzon 1986). A direct effect of naloxone on pancreatic B-cell function in sheep 
should be considered because B-cells of rodents respond to opiate stimulation in vitro 
(Rudman and Kunter 1986; Curry et al 1987). 
The biological half-life of naloxone in rats approximates 40 min (Tepperman et 
al 1983). It is assumed that the ability of naloxone to effectively block opiate action in 
sheep in this study waned within 2 to 4 h of iv injection of naloxone consistant with the 
naloxone short half life of 43 min sheep (Chapter VIII). We suggest that the recovery 
in feed intake in our naloxone-treated sheep after 4 h of ad libitum intake likely 
reflected loss of naloxone bioactivity because of its metabolism and elimination. 
Morley (1987) has addressed the teleological practicality of opiates suppressing 
reproductive function while stimulating feeding drive in hungry animals. It is well 
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established that naloxone treatment increases LH secretion in postpartum cows that 
are in negative energy balance and lactating (Whisnant et al 1986). Results of this 
study and those of Baile et al (1981) would suggest that the greater the degree of 
negative energy balance then the greater the opiate drive for hunger that directly or 
indirectly could curtail reproductive function in domestic ruminants. Indeed, a dose of 
naloxone that increased plasma LH in beef cows at d 42 postpartum was ineffective at 
d 14 or 28 postpartum when negative energy balance may have been more severe 
(Whisnant et al 1986a). Central opiate systems may be part of an intricate neural 
regulatory mechanism that links nutritional state and reproduction in domestic 
ruminants (McCann and Hansel 1986), and such a system would be influenced by the 
suckling calf (Whisnant et al 1986b). 
We conclude that the ability of naloxone to suppress appetite in sheep is 
negatively associated with duration of fasting or severity of negative energy balance, 
and that the appetite inhibitory effects of naloxone in sheep do not involve peripheral 
changes in plasma insulin, glucose, or FFA. 
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CHAPTER IV 
OPIATERGIC REGULATION OF FEED INTAKE 
IN LEAN AND OBESE SHEEP 
Introduction 
Considerable evidence supports the involvement of the opiatergic system in 
regulation of appetite in mammalian and nonmammalian species (Sanger 1981; Morley 
et al1983; Reid 1985; Sangiah et al 1988; Alavi et al 1991). Although opiatergic 
control of appetite requires opioid receptors located centrally in the brain and 
peripherally in the intestine, centrally located receptors in the hypothalamus and 
surrounding area are believed to play the dominant role in appetite regulation (Morley 
· et al 1983; Atkinson 1987). Stimulation of opiate receptors in the central nervous 
system (CNS) is associated with hunger drive and eating. Opiate antagonists such as 
naloxone reduce intake in hungry animals, whereas opiate agonists can increase 
intake in satiated animals (Gosnell 1987; Baile et al 1981, 1987; Alavi et al 1991 ). 
Dysfunction in opiatergic regulation of appetite may be involved in the 
development and maintenance of the obese state in humans (Baranowska et al 1987; 
Giugliano et al 1987) and animals (Margules et al 1978; Shimomura et al 1982). 
Concentrations of B-endorphin were higher in pituitary and plasma of genetically obese 
than lean mice or rats during the development of the obese state (Margules et al 1978; 
Givens et al 1980). Plasma levels of B-endorphin generally are greater in humans with 
established obesity than in humans of lean body condition (Ritter et al 1991 ). Further 
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support for opiatergic dysfunction in obesity comes from results consistently showing 
greater appetite inhibitory effects of naloxone in obese humans (Atkinson 1987) and 
genetically obese rodents (Margules et al 1978) than in their lean controls. However, 
the exact roles played by central and peripheral opioid receptors in appetite regulation 
during dynamic obesity and static phase obesity are not clear (Morley et al 1983; Vim 
and Lowy 1984) 
Dysfunction in opioid regulation of appetite could be an initiating factor in the 
development of obesity in genetically obese rodents or it could be a prerequisite for 
allowing hyperphagia during the dynamic or induction phase of obesity. Most, if not all, 
studies comparing opioid regulation of appetite between genetically lean and obese 
rodents have examined opiatergic control of appetite in obese animals during the 
dynamic phase of obesity. In contrast, similar studies in humans compare responses to 
naloxone between lean individuals and individuals in the static or established phase of 
obesity. Unlike dynamic phase obesity, hyperphagia is not evident during the steady 
state conditions of static phase obesity if hyperphagia means that animals consume 
more than their maintenance requirements (McCann and Bergman 1988). 
McCann et al (1991) has developed an animal model of dietary obesity in 
sheep. Dietary obese sheep are hyperinsulinemic, hyperglycemic and insulin resistant 
(McCann and Bergman 1988; McCann et al 1991 ). Sheep consume 3 to 6 times 
maintenance during dynamic obesity but consume only maintenance upon attainment 
of static phase obesity (McCann et al 1991 ). The impact of the obese state per se on 
opiatergic regulation of appetite in sheep therefore can be examined readily because 
diet type, level of intake, and energy balance are equivalent in both lean sheep and 
sheep in the static phase of obesity (McCann et al 1991 ). The objectives in this study , 
therefore, were to determine if intake differed between lean and obese sheep allowed 
free access to a common diet, and whether obesity affected opiatergic regulation of 
appetite in sheep. 
Materials and Methods 
Animals 
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Rambouillet ewes aged 3 to 4 years were purchased from USDA-ARS, Forage 
and Livestock Research Laboratory, Fort Reno, Oklahoma. Detailed description of 
development of obesity is discussed in Chapter II. Briefly, sheep were fed a pelleted 
hay-grain diet maintain them in lean body condition (lean, n=5) or were fed the same 
diet ad libitum to induce dietary obesity (obese, n=5). Obese sheep were considered to 
be in static phase of obesity after 50 wk of overfeeding as indicated by nearly constant 
body weight and feed intake. 
Lean (46 ± 2 kg) and obese (79 ± 3 kg) sheep were fed the pelleted hay-grain 
mixture (12.5 g/kg) in two equal amounts at 0900 and 1500 h; small amounts of hay (1 
g/kg) were fed daily at 0900 h to maintain rumen tone. Uneaten feed was removed at 
1700 h. This ration maintained zero-energy balance in lean and obese sheep. 
Chemical composition of the pellets and hay was presented in Chapter II (see Table 
1 ). Sheep were housed and fed individually in a room with constant light and 
temperature (21-23 C). 
Treatments 
Lean and obese sheep were paired and assigned randomly by latin square to 5 
treatments of 0 (saline), 0.01, 0.1, 1 and 3 mg/kg naloxone. Naloxone hydrochloride 
generously provided by DuPont Pharmaceutical (Wilminigton, Delaware, USA) was 
prepared fresh in sterile saline and filtered through a disposable 0.2 J.L nylon filter 
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before injection on each experimental day. Saline (1 0 ml) and naloxone solutions (1 0 
ml) were injected via a cannulated jugular vein 5 min before 16-h fasted sheep were 
allowed ad libitum intake of pellets for the ensuing 32 h. Cannula were flushed quickly 
with 2 ml of saline after each dose of naloxone. At least 7 d elapsed between 
successive treatments. Blood samples were collected and feed intakes were 
determined at 20, 40 and 60 min and 2, 4, 8, 12, 16, 24 and 32 h of ad libitum feeding. 
The amount of feed consumed was measured by replacing the uneaten feed with a 
fresh batch of pellets (1 000 g) at each time interval. Blood samples (5 ml) were 
collected into glass tubes containing 50 f..ll mixture of benzamidine (200 mg/ml) and 
heparin (5000 U/ml) that were held in an ice-water bath. Chilled blood samples were 
centrifuged (4 C) for 10 min at 1000 x g and plasma stored (-30 C) for determination of 
plasma naloxone. Additional blood samples (5 ml) were collected into chilled glass 
tubes containing EDTA (7.2 mg) at 60, 30 and 1 min before each naloxone injection 
and the recovered plasma used for quantification of B-endorphin concentrations. A 
sham trial was conducted to familiarize animals to all experimental procedures 
including ad libitum feeding for 32 h. 
Chemical Analysis 
Naloxone Assay. Plasma concentrations of naloxone immediately before and at 
25, 45 and 65 min after the 4 highest doses of naloxone were quantified by Waters 
HPLC system equipped with a reverse-phase radial pak C18 column cartridge (Waters, 
Milford, MA, USA). Preliminary experiments indicated that a mobile phase (pH 4.5) 
comprising 0.1 M ammonium dihydrogen phosphate, 0.9 mM octasulfonic acid, 5.4 mM 
disodium EDT A, and 4.5 % n-propanol at a flow rate of 0. 7 ml/min provided optimal 
conditions with respect to the separation of naloxone, naltrexone (internal standard) 
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and benzamidine added to blood tubes to prevent proteolytic degradation of peptide 
hormones. The intraassay and interassay coefficients of variation were 4.1 and 3.5%, 
respectively. 
B-Endorphin Assay. Plasma concentrations of immunoreactive B-endorphin 
were measured by radioimmunoassay (lncStar, Stillwater, MN). Sepharose particles in 
suspension were added (0.5 ml) to columns provided by the manufacturer. The 
supernatant in the column was forced through using a rubber bulb, and then the 
bottom of the column was tightly capped. Columns received 1 ml of either human B-
endorphin (17-272 pg/ml), ovine B-endorphin standard (25-200 pg/ml), sheep plasma 
samples, or control sheep plasma for determination of non specific binding in RIA. The 
columns were then capped and rotated end over end for 4 h (± 15 min) at 2-8 C before 
plasma was allowed to drain through the column. Any remaining fluid in the column 
was forced out gently with the rubber bulb. The remaining sepharose particles in the 
column were washed with 3 X 1 ml aliquots of saline (0.9% NaCI) until all the particles 
settled at the bottom of the column. Saline was forced to drain as before. To elute the 
sepharose bound B-endorphin, two sequential additions of 250 J.LI of 0.025 N HCI were 
added and allowed to sit for 1 min and then the HCI was forced through the column 
and collected into a clean glass test tube. The extract collected was mixed and placed 
on crushed ice for immediate radioimmunoassay. 
All samples were assayed in duplicate according to manufacturer's instructions. 
Briefly, 200 J.LI of extract were transferred to duplicate 12 X 75 mm glass tubes held in 
crushed ice. Neutralizing buffer (100 J.LI) was added to all tubes before 100 J.LI of rabbit 
anti-B-endorphin serum were added to all tubes except total count (TC) and 
nonspecific binding tubes. Tubes were gently mixed and incubated for 16-24 h at 2-8 
C, before 100 J.ll C 25 1] B-endorphin were added. Vials were mixed gently and incubated 
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for 16-24 h at 2-8 C. Goat anti-rabbit serum (0.5 ml) was added, vials were mixed and 
then incubated for 15-25 min at 2-8 C before centrifugation (20 C) at 1 000 x g for 20 
min. The supernatant was discarded and tubes allowed to drain for at least 2 min. The 
excess supernatant around the edge of the tubes was blotted before turning tubes 
upright. Using a Micromedic MEplus gamma-scintillation counter (Horsham, PA, USA), 
the activity of the precipitate of each tube was counted for 5 min to achieve statistical 
accuracy and results were calculated automatically from linear standard curves 
generated as log-logit plots by weighted least-squares regression. 
The B-endorphin RIA was validated for use in ovine samples as follows. Serial 
dilutions of plasma or serum from lean (n = 2) or obese (n= 2) sheep inhibited binding 
of C25I]B-endorphin to antibody in a manner that paralleled inhibition by either human B-
endorphin (lncStar, Stillwater, MN) or ovine B-endorphin (Peninsula Laboratories, 
Belmont, CA). The RIA had reasonable accuracy for measuring B-endorphin in sheep 
plasma because mean (± SE) recovery of ovine B-endorphin was 82.5 ± 8.0% and 
95.9 ± 19.9% when sheep plasma samples (n=4) were spiked with 50 and 200 pg/ml 
of ovine B-endorphin, respectively. lntraassay and interassay coefficients of variation 
were 6.6% and 13.5%, respectively. Reported values of immunoreactive B-endorphin 
have not been corrected for recovery losses. 
Calculations and Statistical Analyses 
Differences in cumulative feed intake between lean and obese sheep in the first 
32 h after 0 mg/kg naloxone were tested by univariate correlated t test for repeated 
measurements (Gill 1979). Effects of dose, time and their interaction on cumulative 
feed intake at each level of body condition were tested using repeated measures 
analysis of variance in the general linear model procedure of SAS (Freund et al 1986); 
Fisher's protected (P<0.05) LSD test was used for multiple comparisons among means 
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at a given sample time in each body condition. Effects of body condition, naloxone 
dose and their interaction on feed intake were examined using cumulative intakes after 
naloxone injections calculated as percentage of the corresponding control intake in 
each sheep. Percent cumulative feed intakes at +20 min, +2 h and +4 h of ad libitum 
feeding then were each analyzed by 2 x 4 split-plot analysis of variance; multiple 
comparisons among means were done using Duncan's new multiple range test if a 
significant F-value (P<0.1) was found. 
Dose-response curves for naloxone effects on intake were constructed as 
follows. Area under the curve (AUG) for cumulative intakes in the first 2 h after each 
dose of naloxone were calculated by trapezoid method. For each sheep, the AUG after 
0.01, 0.1, 1 and 3 mg/kg naloxone were calculated as percent of AUG after the control 
dose (0 mg/kg) of naloxone to provide data on relative feed intakes in naloxone-treated 
lean and obese sheep. Best fit of the relationship between relative feed intake and 
naloxone dose was determined using least squares polynomial regression analysis of 
observations (n=20) in each body condition group (SAS, Cary, NC, USA). Comparisons 
of regression residual sum-of-squares and coefficient of determination determined that 
a first degree polynomial best described the dose-response effect of naloxone on 
intake in lean and obese sheep. Dose of naloxone suppressing relative intake by 25% 
(D25} was calculated using an equation derived from first degree (linear) polynomial 
regression analysis of mean data in each body condition group. Significance of 
difference in the mean D25 dose between lean and obese sheep was determined by 
comparing the 95% confidence interval range for the mean 0 25 dose in lean sheep with 
the mean 0 25 dose in obese sheep. Level of significance was 0.05. Values are 
presented as mean ± SE. 
Results 
Control Feed Intake. 
Intakes after 0 mg/kg naloxone were greater (P< 0.05) in lean than obese 
sheep through the first 8 h of ad libitum feeding (Fig 1 ). In the first 20 min of ad 
libitum feeding, saline-treated lean and obese sheep had consumed 42% and 26%, 






















FEED INTAKE IN SHEEP FED AD LIBITUM 
LEAN BW= 46±2 kg 
OBESE BW= 79±3 kg 
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Figure 1. Cumulative feed intakes (mean± se) in 16-h fasted lean and obese 
sheep allowed ad libitum intake of a pelleted hay-grain diet for 32 h. 
Sheep were in steady state and chronically fed maintenance of the hay-
grain diet to keep them in zero-energy balance. Sheep were presented 
with fresh batches (1 000 g) of pellets at time 0 and at each time point 
indicated when intakes were determined. 
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After 2 h of ad libitum feeding, lean sheep had consumed approximately twice as much 
as obese sheep, whether measured as absolute intake (1343 vs 645 g) or as percent 
of 32-h total intakes (61 vs 35 %). Cumulative intakes became equivalent statistically in 
both groups at + 12 h, and thereafter, of ad libitum intake. Differences in shape of the 
control intake curves (see Fig. 1) may reflect differences in the chemical regulation of 
early (+20 min to + 16 h), but not late, consummatory behavior in lean and obese 
sheep fed under the conditions of this experiment. 
Naloxone Treatment Effect 
Dose-dependent and time-dependent inhibitory effects of naloxone on intake 
were observed in lean and obese sheep (Fig. 2, 3 and Table 1). Cumulative intakes 
were most affected by naloxone in the first 2 to 4 h of ad libitum feeding in both groups 
of sheep and these results are highlighted in Fig 4. 
To allow comparison of the effects of naloxone in lean versus obese sheep, 
cumulative intakes during the first 4 h of ad libitum intake were recalculated as percent 
of corresponding control intakes in each sheep. The lowest dose of naloxone (0.01 
mg/kg) increased cumulative intake nonsignificantly by 15 to 20 % in lean sheep in the 
first 4 h of ad libitum feeding (Fig. 5). This dose also increased cumulative intake 
nonsignificantly by 20 % in obese sheep only at + 1 h of ad libitum intake. Of the ten 
sheep used in this experiment , four lean and two obese sheep displayed a stimulatory 
response to low dose naloxone in that their 2-h cumulative intake was 37 ± 9 % 
greater (P<0.01) after 0.01 mg/kg naloxone than after 0 mg/kg naloxone. 
Maximum suppression of intakes occurred during the first 2 h after injection of 
naloxone (0.1, 1 and 3 mg/kg). Injection of 0.1 mg/kg naloxone had no effect on intake 
in lean sheep but the 2-h intakes in obese sheep were suppressed (P<0.05) 30 ±13% 
by this dose. Naloxone doses of 1 and 3 mg/kg suppressed (P<O.O) 2-h intakes in lean 
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sheep by approximately 29% and 50%, respectively. In contrast, intakes in obese 
sheep at +2 h were suppressed (P<0.025) 48% and 71% by 1 and 3 mg/kg naloxone, 
respectively. Interactive effects of body condition and naloxone on feed intake were 
determined using cumulative intakes calculated as percent of corresponding control 
intake at +20 min, +2 h and +4 h of ad libitum feeding. Intakes at these times were 
affected by body condition (+20 min only) and naloxone dose but not by their 
interaction (Fig. 6). 
FEED INTAKE IN NALOXONE-TREATED SHEEP 
Figure 2. Cumulative feed intakes (mean ± SE) during 32-h of ad libitum intake in lean 
sheep pretreated with 0, 0.01, 0.1, 1 or 3 mg/kg of naloxone. Naloxone 
was injected iv 5 min before feeding began. Additional notes as in legend 
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Figure 3. Cumulative feed intakes (mean ± SE) during 32-h of ad libitum intake in 
obese sheep pretreated with 0, 0.01, 0.1, 1 and 3 mg/kg naloxone iv. 
Additional notes as in legend to Fig. 2. 
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Figure 4. Cumulative feed intakes (mean ± SE) during the first 4 h of ad libitum intake 
in lean and obese sheep pretreated with 0, 0.01, 0.1, 1 and 3 mg/kg 
naloxone iv. For clarity of presentation, SE bars are not shown but the pooled SE 
values were 167, 142, 128, 112 and 90 in lean sheep and 131, 90, 170, 90 and 50 in 
obese sheep treated with 0.01, 0.1, 1 or 3 mg/kg naloxone, respectively. Additional notes 
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Figure 5. Cumulative feed intakes as percent of control intakes (mean ± SE} in lean 
and obese sheep pretreated with 0.01, 0.1, 1 or 3 mg/kg naloxone. 
Cumulative intakes during the first 4 h of ad libitum intake were expressed 
as percent of corresponding intake after 0 mg/kg naloxone (control} for 
each sheep and mean values calculated at each time point for the 
different doses of naloxone are shown. For clarity of presentation, SE 
bars are not shown but the pooled SE values were 12, 16, 13 and 11 in 
lean sheep and 16, 15, 12 and 12 in obese sheep treated with 0.01, 0.1, 
1 or 3 mg/kg naloxone, respectively. Additional notes in legend to Fig. 2. 
TABLE 1 
MEAN (± SE) CUMULATIVE FEED INTAKE (g) IN LEAN (n=5) AND OBESE (n=5) SHEEP 
TREATED WITH NALOXONE AND FED AD LIBITUM 







Condition 0.33 0.66 1 2 4 8 12 16 24 32 
Lean 931 ± 66"b 1054± 1630. 1156±165" 1343 ± 2060. 1468 ± 239"'1o 1586 ± 2400. 1650 ± 222 1697 ± 220 1812 ± 200 2195 ± 205 
Obese 483 ± 109~ 527 ± 130 0. 538 ± 127o.b 645 ± 143" 748 ± 149"' 953 ± 200"'b 1182 ± 194 1357 ± 208 1427 ± 188 1831 ± 186 
Lean 1000 ± 86" 1191 ± 170(.\ 1297 ± 165"' 1530 ± 1510. 1611 ± 1400. 1665 ± 142" 1730 ± 154 1749 ± 162 1781 ± 146 2172 ± 227 
Obese 513 ± 800. 563 ± 900. 613 ± 101"' 630 ± 102"' 727 ± 120"- 880 ± 270" 1183 ± 224 1319 ± 245 1450 ± 285 1873 ± 397 
Lean 981±1140. 1010± 1210.0 1067± 115"'b 1156± 153"b 1217± 138"b 1376±78"' 1467 ± 68 1520±84 1578 ± 80 1806 ± 154 
Obese 382± 130a.b 398± 145o.b 398± 145(\bC 509± 2240. 723 ± 207 C\ 1090 ± 273(). 1284 ± 280 1440 ± 295 1607 ± 263 1966 ± 256 
Lean 625 ± 127a.b 654 ± 108 bC 707 ± 97 be 859 ± 92bc 1240 ± 136 b 1609 ± 214 0.. 1792 ± 262 1855 ± 306 2057 ± 318 2554 ± 367 
Obese 224 ±55 o.b 269 ± 76"b 277± 93bC 318 ± 101CI.C 429 ± 138°b 700 ± 168G\b 849 ± 144 1021 ± 154 1224 ± 175 1615 ± 198 
Lean 587 ± 104b 588 ± 103c 600 ± 96c 615±90C 736 ±sse 1113 ± 33"' 1337 ± 60 1580 ± 138 1842 ± 147 2389 ± 172 
Obese 69 ± 35 b 87 ± 43 b 112±47c 165 ± 52c 227 ± 75 b 410 ± 125 b 601 ± 190 890 ± 257 1085 ± 279 1508 ± 376 
1 Sheep fasted 16 h were injected iv with saline or naloxone 5 min before they were allowed ad libitum feeding 
for 32 h. Means with the same superscript letters are not different (P<0.05) for comparison at each time interval within 
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Figure 6. Feed intakes as percent of control intake at 20 min, 2 h and 4 h of ad libitum 
in lean and obese sheep injected with 0.01, 0.1, 1 and 3 mg/kg naloxone. 
Probability values shown indicate significance of treatment effects of body 
condition (BC), naloxone dose (NAL) and their interaction (lA) are derived 
from split-plot analysis of variance; means within each time period with 
similar superscript letter are not different (P>0.05); NS indicates no 
significant effect (P>0.1 ). 
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The dose-response curve for naloxone's effect on intake was shifted leftward in 
obese compared with lean sheep (Fig. 7). The significant (P<0.05) best fit regression 
line in lean sheep was Y = -25.04(1og dose) + (-31.04) (r= 0.990) and that in obese 
sheep was Y = -33.87(1og dose)+ (-55.1) (r= 0.980). Regression analysis of variance 
showed that the linear regression fits were affected by body condition (P<0.02) and 
naloxone dose (P<0.001 ), but not by their interaction. Regression coefficients (slopes; 
b) of each equation were equivalent but the position of the lines differed (P<0.02) in 
lean and obese sheep. Dose of naloxone suppressing intake by 25% (025) was 
calculated from these equations and was significantly less in obese (0.129 mg/kg ) 
than lean (0.574 mg/kg) sheep; endpoints for a 95 percent confidence interval for 0 25 
dose of naloxone were 0.0654 and 0.257 mg/kg and 0.218 and 1.51 mg/kg in obese 
and lean sheep, respectively. Results show that obese sheep were about 4 times more 
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Figure 7. Dose-response effect of naloxone on acute feed intake in lean and 
obese sheep fed ad libitum. Area under the curve (AUC) for cumulative 
feed intake in the first 2 h of ad libitum intake was calculated in each 
sheep after each dose of naloxone. Within each body condition, the 2-h 
AUC after 0.01, 0.1, 1 and 3 mg/kg naloxone was expressed as 
percentage of 2-h AUC after 0 mg/kg (control) naloxone in each sheep 
and the mean (± SE) values shown were calculated for each dose. 
Regression equations for the mean data (lines shown) were 
Y= -33.88(1og dose) + (-55.07) in lean andY= -25.04(1og dose) + (-31.0) 
in obese sheep. Dose of naloxone inhibiting intake by 25 percent (025) 
was calculated from these equations and was 0.13 mg/kg in obese sheep 
and 0.57 mg/kg in lean sheep as discussed in results. Additional notes in 
legend to Fig 1 . 
81 
Plasma Chemicals 
The quantitatively greater inhibitory effects of naloxone in obese than lean 
sheep were associated with similar plasma concentrations of naloxone in both groups 
after either 1 or 3 mg/kg naloxone (Fig. 7). Levels of naloxone in plasma after injection 
of 0.1 and 0.01 mg/kg naloxone were below the sensitivity (1 0 ng/ml) of the assay 
system. 
Concentrations of B-endorphin in plasma obtained from 16-h fasted sheep were 
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Plasma concentrations of naloxone (mean ± SE) in lean and 
obese sheep injected with 1 and 3 mg/kg naloxone iv. 
Concentrations of naloxone after iv injection of 0.01 and 
0.1 mg/kg naloxone were below the sensitivity (1 0 ng/ml) 




We have developed a nongenetic animal model of obesity in which the obesity 
is caused by excessive voluntary consumption of a normal diet fed at maintenance to 
lean control sheep. Our results show clearly that early consummatory behavior differs 
in lean and obese sheep. Hunger drive was greater in lean than obese sheep in the 
first 8 h of ad libitum feeding. The initial rapid consumption rate in lean sheep slowed 
to a nearly constant rate of consumption which was comparable with that in obese 
sheep. Cumulative intake consistently was less in obese than lean sheep despite an 
approximate doubling of body mass in obese compared with lean sheep. 
The stronger appetite-inhibitory effect of naloxone in obese than lean sheep 
suggests that opiatergic regulation of appetite differs between lean and obese sheep in 
the static phase of obesity. Response to the appetite-inhibitory effect of naloxone also -
was greater in genetically obese rats (fa/fa) and mice (ob/ob) than in lean ones 
(Margules et al 1978). The 0 25 dose of naloxone was approximately three times lower 
in obese (ob/ob) mice (approximately 0.39 vs 1.12 mg/kg) and obese (fa/fa) rats 
(approximately 0.17 vs 0.57 mg/kg) than in lean controls when intakes were measured 
1 to 2 h after feeding began in naloxone-treated animals (Margules et al 1978). Feed-
inhibitory response to naloxone also was greater in genetically obese Zucker rats than 
in lean ones (Mclaughlin and Baile 1984 a, b). Greater responsiveness to the feed-
inhibitory effects of naloxone also has been reported in obese compared with lean 
humans (Atkinson 1987). In contrast, sensitivity to naloxone appears similar in control 
rats and rats with nongenetic forms of obesity due to ventromedial hypothalamic 
lesions, ovariectomy or drug administration (Gun ion and Peters 1981). Reasons for the 
increased sensitivity to naloxone in dietary obese sheep, obese humans and 
genetically obese rodents are unknown but may involve down-regulation of central 
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opioid receptors, and(or) effects of hyperglycemia on opioid receptor activity (Morley et 
al 1983). 
There is a good positive relationship between increased plasma 13-endorphin 
levels and overeating in normal and genetically obese rats (Margules et al 1978; Davis 
et al 1982). Plasma levels of 13-endorphin are higher in obese than lean humans, 
particularly when comparisons are restricted to female subjects (Ritter et al 1991 ). 
Margules et al ( 1978) reported higher plasma and pituitary, but unchanged 
hypothalamic, concentrations of 13-endorphin in obese mice (ob/ob) and Zucker rats 
(fa/fa) than in lean controls during the dynamic phase of obesity in these young 
animals aged 2 to 5 months. Others have reported markedly elevated 13-endorphin and 
met-enkephalin concentrations in the pituitary and hypothalamus of genetically obese 
(ob/ob) than lean mice aged 4 to 5 months (Khawaja et al 1989). Concentration of 
kappa and delta binding sites were greater and that of mu binding sites less in 
membranes isolated from brain of obese (ob/ob) than lean mice (Khawaja et al 1989). 
However, it remains controversial whether increased pituitary synthesis and release of 
opioids play an important role in the central control of appetite during development of 
the obese state (Morley et al 1982; Vim and Lowy 1984). Results of several studies 
support the claim that plasma 13-endorphin enters the CSF but not the interstitial fluid of 
brain (Banks and Kastin 1990). Pituitary-derived increases in the plasma 
concentrations of 13-endorphin do not always result in parallel increase in CSF levels of 
13-endorphin in sheep, which are results suggesting that hypothalamic opioid receptors 
may respond only to centrally produced opioids in sheep (Smith et al 1986). 
It is still not clear whether brain opioid peptides increase in hungry animals to 
initiate feeding, and thus would be involved with hunger drive, or whether opioid 
peptides increase after feeding commences so as to act as a positive reinforcement 
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and increase the "joy" of eating (Morley et al 1982; Kirkham and Blundell 1984; Carr 
and Simon 1984; Stein et al 1990). In our sheep model, obese sheep were continually 
exposed to feed during the dynamic phase of obesity and consequently were unlikely 
to experience significant increases in hunger drive despite a change in feed intake 
amounts as sheep progressed from the dynamic to static phase obesity. Nevertheless, 
increased opioid activity during dynamic phase obesity could have resulted in down-
regulation of central opioid receptors, thus explaining the greater sensitivity to naloxone 
in obese than lean sheep during static phase obesity. Greater response to antagonist 
is an expected response in systems that have undergone receptor down-regulation. 
Although plasma concentrations of immunoreactive a-endorphin were similar in 
16-h fasted lean and obese sheep in this study, it is possible that central opioid 
receptor activity and plasma a-endorphin concentrations differed between lean and 
obese sheep during dynamic obesity and in the fed state during static phase obesity. 
Although there is no clear relationship between plasma levels of a-endorphin and 
activity of central opioid control of appetite in animals (Morley et al 1982; Vim and 
Lowy 1984), plasma a-endorphin levels routinely are used as a crude index of opioid 
biology in animals. 
Plasma glucose concentration can affect opioid receptor activity and animal 
response to naloxone treatment. Levine et al (1982) reported that genetically obese 
diabetic mice (db/db) and streptozotocin-induced diabetic mice were 80 to 1000 times 
more sensitive, respectively, than control animals to naloxone's inhibitory effect on feed 
intake. On the other hand, streptozotocin-induced diabetes decreased the effectiveness 
of some opioid agonists in stimulating feed intake in rats (Gosnell et al 1989) and 
reduced the contractile response of guinea-pig ileum to stimulation by the opioid 
agonist, morphine (Shook et al 1986). Further, glucose added to incubation media 
reportedly increased the amount and affinity of binding of naloxone to membranes 
isolated from rat brain (Morley et al 1981 ). Morley et al (1983) postulated that 
increasing concentrations of glucose alter conformation and binding properties of an 
opioid receptor such that this receptor in the presence of glucose preferentially binds 
naloxone with high affinity while failing to bind opioid agonists. 
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Because obese mice and rats are hyperglycemic, the greater effectiveness of 
naloxone in obese than lean rodents may be related to the increase in plasma glucose 
levels. Dietary obese sheep are hyperglycemic and hyperinsulinemic and the 
approximate increases in plasma glucose of 5 to 10 mg/dl and plasma insulin of 
approximately 10 to 30 J.LU/ml in obese sheep are very similar to the increases in 
plasma insulin and glucose observed in obese compared with lean humans. The 
increase in plasma glucose in genetically obese compared with lean rodents usually 
exceeds 1 0 mg/dl. It is possible that modest hyperglycemia in dietary obese sheep and 
obese humans sufficiently affects opioid receptor activity, as postulated by Morley et al 
(1983), resulting in greater inhibitory effects of naloxone in obese than lean subjects. 
An interesting finding in this study was the response of four lean and two obese 
sheep to the lowest dose of naloxone (0.01 mg/kg) which stimulated their feed intake 
by approximately 37%. Relative to saline-treated controls, low doses of naloxone of 
0.06 mg/kg (Lowy et al 1980) and 0.01 to 0.1 mg/kg (Brown and Holtzman 1979) 
increased food intake in rats by 20 to 35%. The ability of low dose naloxone to 
increase intake in rats may depend on duration of fasting before treatment and whether 
naloxone is administered during the light or dark cycle (Brown and Holtzman 1979). 
One possible explanation for stimulation of intake by low dose naloxone could be that 
of different affinities of naloxone for the opioid receptors involved in appetite regulation. 
Naloxone at very low concentration may bind preferentially to high affinity and few 
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opioid receptors that stimulate appetite, whereas higher concentration of naloxone bind 
to many opioid receptors coupled to appetite inhibitory pathways. In a recent study, 
Kelly et al (1990) demonstrated that autoregulation of B-endorphin release by 
hypothalamic arcuate neurons may be controlled by presynaptic opioid receptors, a 
mechanism similar to the autoregulation of adrenergic neurons by a 2-adrenoceptors. In 
support of the finding of Kelly et al (1991 ), Rogers and Henderson (1990) previously 
had reported that activation of presynaptic mu and delta receptors by opioid agonists 
resulted in reduction of transmitter release from the same preganglionic nerve 
terminals. Possibly, naloxone at low concentration could block presynaptic opioid 
receptors leading to increased release of B-endorphin and stimulation of feed intake, 
whereas high concentrations of naloxone could block both presynaptic and 
postsynaptic opioid receptors thereby resulting in naloxone suppression of feed intake. 
In conclusion, early feeding behavior differs substantially in lean and dietary 
obese sheep. Sensitivity to the appetite-inhibitory effects of naloxone was at least four 
times greater in dietary obese than lean sheep, and this change in sensitivity was 
associated with comparable levels of B-endorphin and naloxone in the plasma of lean 
and obese sheep. 
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CHAPTER V 
CARDIOVASCULAR RESPONSES TO ADRENERGIC 
AGONISTS IN LEAN NORMOTENSIVE AND 
OBESE HYPERTENSIVE SHEEP 
Introduction 
Hypertension or high blood pressure is a serious public health problem in 
western societies. Risk factors commonly associated with the development of 
hypertension are obesity, glucose intolerance, and dyslipidemia (Van ltallie 1986; 
Cambien et al 1987; Ferrari and Weidmann 1990; Reaven 1990; Crandall and 
DiGirolamo 1990). Origin and nature of irregularities in glucose and lipid metabolism 
associated with hypertension are still unknown (Ferrannini and Natali 1991; Ferrari and 
Weidmann 1990). Obesity-associated hypertension is very prevalent in the United 
States where obesity exists in 44% of the hypertensive population as compared with 
an incidence of obesity of only 16% in the normotensive population. Conversely, 53% 
of obese subjects are hypertensive as compared with an incidence of hypertension of 
22% in nonobese subjects (Hoarn and Lenfant 1990). There seems to be a fairly clear 
association between sedentary lifestyle, overweight and high blood pressure (Stamler 
et al 1978; Van ltallie 1985). 
Obesity frequently coexists with hyperinsulinemia, hyperglycemia and 
hypertension in humans and other animal models (Cambien et al 1987; Krieger and 
Landsberg 1988). Defects in glucose and insulin metabolism may play a role in both 
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the etiology and clinical course of hypertension because abnormalities of glucose and 
insulin metabolism occur more frequently in hypertensive patients than in normotensive 
ones (Krieger and Landsberg 1988; Haffer et al 1989; Falkner et al 1990). Patients 
with high blood pressure have been shown to be relatively glucose intolerant 
(Ferrannini et al 1987). In addition, spontaneously hypertensive rats tend to be 
hyperinsulinemic and insulin resistant when compared to normotensive Wistar-Kyoto 
rats (Hulman 1991 ). 
Elevated plasma levels of very low-density lipoproteins (VLDL) and decreased 
levels of high-density lipoproteins (HDL-cholesterol) are common abnormalities of 
lipoprotein metabolism in hypertensive humans (Williams et al 1990; Frohlich and 
Pritchard 1989; Bjorntorp 1990; Despres et al 1990). The plasma H DL-cholesterol 
concentration is inversely related to the plasma insulin level in obese subjects 
(McKeigue et al 1991; Ronnemaa et al 1991 ). Hyperinsulinemia together with 
decreased plasma levels of HDL-cholesterol are frequent findings in obese 
hypertensive compared with obese normotensive subjects (Cambien et al 1987; 
McKeigue et al 1991 ). 
The other risk factor associated with hypertension is excess sodium ingestion 
(Beard 1990). It appears that approximately one fourth of normotensive subjects and 
one half of hypertensive patients are characterized as sodium sensitive in that excess 
dietary sodium increases their blood pressure. The relationship between excess dietary 
sodium and blood pressure is complicated. It seems that obesity associated-
hyperinsulinemia may significantly interact with sodium metabolism in the development 
of hypertension in humans (Rocchini 1990; Horan and Lenfant 1990; Folkow 1990). 
Blood pressure is a function of cardiac output (CO) and total peripheral 
resistance (TPR). Established human hypertension is associated with increased TPR 
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and normal rates of CO (Folkow et al 1958; Lund-Johansen 1983). Several 
mechanisms may explain the increased TPR. Increased vascular wall diameter in 
hypertensive humans correlated positively with increased vascular response to 
adrenergic agonist stimulation (Aalkjaer et al 1987). Sympathetic outflow from the 
central nervous system (CNS) modulates activity of the resistance vessels and thus 
systemic blood pressure. Hyperinsulinemia in obesity may affect sympathetic nervous 
system (SNS) activity and its regulation of resistance vessels, and thus hyper-
insulinemia could increase TPR (Krieger et al 1988). 
Attempts have been made to develop animal models to further understanding of 
the mechanisms responsible for hypertension in obesity. Spontaneously hypertensive 
rats (SHR) have been used extensively in hypertension research, but unfortunately this 
genetically developed model is not obese and lacks other risk factors associated with 
essential hypertension in humans (Wexler 1981 ). Although genetically obese rats are 
hyperinsulinemic, development of hypertension in these animals has not been a 
consistent finding. Kurtz et al (1989) reported that obese Zucker rats become 
hypertensive, whereas others found no significant difference in blood pressure between 
lean and obese Zucker rats (Levin et al 1984; Contreras and Williams 1989). 
Dietary obese hypertensive models were first demonstrated by Wood and Cash 
(1939). Recently, Rocchini and associates (1987) produced hypertension in dogs fed a 
high fat diet as compared with control dogs fed a different diet devoid of high fat. 
Differences in diet, levels of energy balance, and the probability that high-fat feeding 
incites renal damage (Grone et al 1989; Kasiske et al 1991) confounds any 
conclusions that hypertension in dogs fed a high diet is strictly obesity associated. 
Furthermore, high-fat feeding prevented development of hypertension in spontaneously 
hypertensive rats (Wexler 1981 ). Feeding rats a high fructose diet results in 
hyperinsulinemia and hypertension (Hwang et al 1987). Such results also are 
confounded by differences in diet, energy balance and unknown effects due to 
abnormally high intakes of fructose. 
We have developed a dietary obese sheep model that is hyperinsulinemic, 
hyperglycemic, and insulin resistant (McCann et al 1991 ). This animal model also 
portrays most of the above mentioned risk factors associated with essential 
hypertension in humans. Our objectives were therefore to determine if dietary obese 
sheep are hypertensive, whether obesity affects cardiovascular responses to the 
adrenergic agonists norepinephrine and phenylephrine, and whether sympathetic 
activity, indirectly assessed by arterial plasma catecholamines, differs in lean and 
obese sheep. 
Materials and Methods 
Animals 
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Lean and obese Rambouillet ewes (n=5/group} aged 3-4 years were housed 
individually in a room with constant light and temperature (21 ± 1 C). Sheep were fed a 
pelleted hay-grain mixture (12.5 g/kg) and hay (1 g/kg) to provide approximately 38 Kcal 
DE/kg, an amount sufficient to maintain sheep in zero-energy balance. Nutrient 
composition of the diet and detailed results on events during the induction and 
maintenance phase of dietary obesity are reported elsewhere (Chapter 2). Briefly, lean 
adult sheep were fed a maintenance intake of pelleted hay-grain diet to keep them in 
lean body condition, or were fed the same diet ad libitum to induce obesity. Sheep 
were in static phase obesity after 50 wk of ad libitum intake at which time body weight, 
feed intakes and body composition were in relatively steady state. At wk 70 of ad 
libitum feeding, obese sheep were a maintenance intake of pellets in two equal 
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amounts at 0900 and 1700 h, with small amounts of hay ( 1 g/kg) fed at 0900 h. 
Animal Preparation and Experimental Protocol 
Surgery was conducted with aseptic technique for survival surgery. Anesthesia 
was induced with pentobarbital sodium (Nembutal®, Abbott, IL; 50 mg/kg) and 
maintained with mixture of 1-2% halothane (Fiuthane®, Ayerst Lab, NY) and oxygen. 
The gas mixture was delivered to the sheep through an endotracheal tube using a 
surgical anesthesia machine (Ohio Chemical & Surgical Equipment, Madison, WI). 
Catheters with diameters of 12.7 mm (ID) were implanted in the caudal aorta 
and the caudal vena cava through the femoral artery and vein, respectively. The distal 
end of the catheters were exteriorized from the right hind leg and brought to the mid 
back of the animal. The catheters were connected to Tuohy-Borst adapters (Perfektum, 
New Hyde Park, NY, USA) and wrapped in surgical adhesive tape which was glued to 
the animal. Sheep were treated with penicillin (300,000 U/kg) daily for 5 days after 
surgery. Catheters were flushed thrice weekly with sterile heparinized saline (1 0 U/ml) 
and filled with 1 .5 ml of heparin ( 1 000 U/ml). At least 2 wk elapsed between surgery 
and experiments in any sheep. Inspection at necropsy confirmed that both catheter tips 
were positioned about 3 to 4 em cranial to the ileac bifurcations. 
Basal Blood Pressure Measurements. One lean and one obese sheep 
constituted a replicate and replicates were assigned randomly by latin square design to 
sequence of norepinephrine (0.25, 0.5, 1.0, 2.0, and 4.0 J.Lg/kg) and phenylephrine (1, 
3, 7, 10 and 30 J.Lg/kg) dose. The doses of norepinephrine (NE; Sigma, St. Louis, MO) 
and phenylephrine (PE; Sigma, St. Louis, MO) were paired by dosage and coded for 
assignment as experimental days within a replicate. All experiments were done 
between 0900 and 1200 h in 16-h fasted sheep with at least 4 d between PE and N E 
96 
experiment. 
NE and PE were given as a bolus injection via the vena cava catheter to 
conscious standing sheep. Order of administration of the paired doses of NE and PE in 
each experiment day was alternated across replicates. Cardiovascular variables 
returned to basal values for at least 20 min before the second adrenergic agonist was 
given on any experimental day. The venous catheter was flushed immediately with 2 
ml saline after each agonist injection. Doses of NE and PE used were established in 
preliminary experiments with lean and obese sheep. 
Blood pressure transducers and physiograph were calibrated using a water 
column with 1 .36 em H20 height equal to 1 mmHg (West 1985); the physiograph pen 
deflection set at 5 em for 1 00 mmHg. Relationship between water pressure developed 
and physiograph pressure measured was determined by least square linear regression 
for each transducer assigned for use in lean or obese sheep. The regression equation 
in lean sheep was Y= 0.8305(X) + 0.471 (r=0.999) and that in obese sheep was 
Y=0.8342(X} + 0.2449 (r=0.999}, where Y equals physiograph (transducer} pressure 
and X equals absolute water pressure converted to mmHg. All blood pressure readings 
consequently were divided by the correction factor of 0.831 (lean sheep) or 0.834 
(obese sheep) to obtain absolute pressure. The aortic catheter was connected to a 
calibrated pressure transducer (Narco Bio-System, International Biomedics, Houston 
USA} which was located at the level of the heart. Changes in blood pressure were 
recorded continuously by 4-channel physiograph (Narcotrace Model 40 MKIV, Narco 
Bio-Systems). Heart rates were determined simultaneously using a Narco 
biotachometer model 7302 (Narco Bio-Systems) coupled to the pressure transducer. 
On each experimental day, recordings of blood pressure and heart rate were made for 
45 min before agonist injection. Three observations on blood pressure and heart rate 
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were done during this stabilization period at approximately 15 min intervals for each 
sheep. These basal recordings were done once a wk for 5 wk to provide a mean basal 
pressure and heart rate measurement in each sheep which was comprised of 5 
separate observations of three values each. Mean arterial pressure (MAP) was 
calculated 2/3 diastolic plus 1/3 of systolic pressure (West 1985) 
Arterial Plasma Catecholamines. Arterial blood (5 ml) was collected into 
heparinized syringes during the stabilization period on three separate experimental 
days. Blood was immediately transferred to a prechilled (4 C) glass tube containing 
100 Ill of mixture of EGTA (ethyleneglycol-bis-[B-aminoethylether] N,N,N',N'-tetraacetic 
acid; 90 mg/ml) and GSH (reduced glutathione; 75 mg/ml). The chilled blood was 
centrifuged at 1 000 x g for 1 0 min at 4 C and the recovered plasma stored at -20 C for 
later HPLC analysis. NE and epinephrine (EPI) were determined by HPLC and 
electrochemical detection system comprised of Waters Model 510 pump, C 18 reverse 
phase column (3.9 X 150 mm) with 5).! particles, and Model 460 electrochemical 
detector (Waters, Division of Millipore, Milford, MA, USA). The concentrations of NE 
and EPI were determined by the method described by Water's catecholamine analysis 
kit (Waters, Milford, MA USA). Briefly, to 1.5 ml of plasma, 50 ).!1 of internal standard 
(3,4-dihydroxybenzylamine; 10 pg/).!1) and 10 mg of aluminum oxide were added. The 
mixture was alkalinized with 400 Ill of 2 M Tris buffer (pH 8.7), and shaken for 15 min. 
The solution was centrifuged for 1 min at 1 000 x g. The supernatant was eluted and 
the precipitated alumina washed and the supernatent discarded 3 successive times 
with 1 ml of 0.0165 M Tris buffer (pH 8.1). The alumina-bound catecholamines were 
desorbed from the alumina by 100 Ill of a mixture (1 0 ml) containing 100 ).!I of glacial 
acetic acid, 50 ).!I sodium disulfite (1 0%, w/v), 50 Ill EDTA (5%, w/v) and 9.8 ml of 
distilled water. The suspension was centrifuged and 50 111 of the supernatant containing 
the catecholamines was gently separated from the precipitated alumina and injected 
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for analysis. The mobile phase contained 5% methanol, 0.1 M anhydrous sodium 
acetate, 0.1 M citric acid anhydrous, 0.5 mM 1-octane sulfonic acid and 0.15 mM 
EDT A. The flow rate was 1.0 ml/min. The voltage of the glassy carbon electrode was 
maintained at +0.60 mV against the Ag/AgCI reference electrode throughout the 
experiment. 
Plasma Hormone and Metabolites. Arterial blood (5 ml) was collected into 
heparinized syringes during the 45 min stabilization period in wk 1 and 5 of the 
experiments. Blood was immediately dispensed into glass tubes containing 50 Jll 
solution of heparin (5,000 U/ml) and benzamidine (200 mg/ml) that were held in an ice-
water bath (4 C). Plasma was recovered by centrifugation (1 000 x g, 15 min, 4 C) and 
stored frozen (-22 C). Plasma concentrations of insulin and glucagon were quantified 
by validated radioimmuno-assay (McCann et al 1991; Blackett et al 1991 ), and those of_ 
glucose, free fatty acid (FFA), total cholesterol, HDL-cholesterol and total triglyceride 
were quantified by enzymatic assay (McCann et al 1991 ). A single serum sample was 
obtained from each sheep at wk 5 of the experiment and used to quantify serum 
electrolyte concentrations of Na+, K+, cr. Ca2+, Mg2+ and P04-, and serum clinical 
chemistry levels of creatine, creatine phosphate kinase (CPK), albumin, alkaline 
phosphatase (ALP), lactate dehydrogenase (LDH), gamma glutamyl transferase 
(SGGT), and blood urea nitrogen (BUN); analyses were done by automated enzymatic 
procedures (Cobas Mira, Roach Diagnostic System , Nutley, NJ, USA) in the 
Department of Clinical Pathology, College of Veterinary Medicine , Oklahoma State 
University. 
Statistical Analysis 
Differences in plasma and serum variables, basal blood pressures and heart 
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rates between lean and obese sheep were evaluated by Students unpaired two-tailed t 
test (Steel and Torrie 1980). Main and interactive effects of body condition and agonist 
dose on maximum increments in MAP and maximum decrement in heart rate observed 
after each agonist dose were determined using 2 x 5 split-plot analysis of variance; 
multiple comparisons among means were done using Duncan's new multiple range test 
if a significant f-value (P<0.1) was found (Steel and Torrie 1980). Dose-response 
curves of blood pressure response to adrenergic agonist were constructed as follows. 
The maximum increment in MAP after each dose of agonist was determined for all 
sheep. Best fit of the relationship between blood pressure increase and agonist dose 
was determined using noniterative least squares polynomial regression analysis (Fig P; 
Biosoft, Ferguson, MO) of observations (n=25) in each body condition group. 
Comparison of residual sum-of-squares and coefficient of determinations determined 
that a first polynomial adequately described the data as compared with higher degree 
polynomial, exponential, logarithmic, or power fits. Best fit of group data dictated fit 
used in individual sheep to determine dose of agonist increasing MAP by 25 (D25} or 
50 (050} mmHg; differences in mean agonist dose for 0 25 and 0 50 between lean and 
obese sheep were evaluated by Student's two-tailed t test (Steel and Torrie 1980). 
Results 
Plasma Chemical Analyses 
Compared with lean sheep, obese sheep had higher (P< 0.05) plasma 
concentrations of insulin, glucagon and glucose but lower (P< 0.05) concentrations of 
HDL-cholesterol (Table 1 ). Plasma levels of total cholesterol and triglyceride were 
unaffected by obesity, but levels of total cholesterol tended to be higher (P<0.1) in lean 
than obese sheep. 
TABLE 1 
PLASMA CONCENTRATIONS OF SELECTED HORMONES 
AND METABOLITES IN LEAN AND OBESE 
SHEEP FASTED 16 h 
Item Lean (5) Obese (5) 
Insulin ( J.LU/ml) 7 ± 1 19 ± 2* 
Glucose (mg/dl) 47 ± 1 53± 2* 
Glucagon (pg/ml) 68 ± 7 113 ± 8* 
HDL Cholesterol (mg/dl) 52± 4 31 ± 3* 
Total Cholesterol (mg/dl) 74 ±4 60 ± 5 
Triglycerides (mg/dl) 13 ± 1 15 ± 3 
* Lean and obese differ (P < 0.05). 
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Serum ion concentrations were not remarkable and equivalent concentrations 
were measured in serum of lean and obese sheep (Table 2). The serum magnesium 
concentration, however, apparently was increased (P <0.05) in obese compared with 
lean sheep. Serum levels of clinically relevant chemicals were similar in lean and 
obese sheep (Table 3). 
Arterial plasma catecholamine levels were unaffected by obesity in sheep 
(Table 4). Large variation was observed in the data even though the average of three 
observations was used to calculate the final value in each sheep. 
TABLE 2 
SERUM ION CONCENTRATIONS IN LEAN AND OBESE 
SHEEP FASTED 16 h 
Item Lean (5) Obese (5) 
Sodium (meq/1) 139.8 ± 0.5 140.8 ± 0.9 
Potassium (meq/1) 4.5 ± 0.1 4.4 ± 0.2 
Chloride (meq/1) 105.0 ± 5.3 105.6 ± 4.3 
Calcium (mg/dl) 8.1 ± 0.4 8.5 ± 0.4 
Magnesium (mg/dl) 2.0 ± 0.04 2.5 ± 0.15* 
Phosphorus (mg/dl) 7.1 ± 0.8 7.3 ± 0.6 
* Lean and obese differ (P < 0.05) 
TABLE 3 
SERUM CLINICAL CHEMISTRY IN LEAN AND OBESE 
SHEEP FASTED 16 h 
Item Lean (5) Obese (5) 
BUN (mg/dl) 15.8 ± 1.5 14.8±1.7 
Creatine (mg/dl) 0.9 ± 0.1 1.0 ± 0.1 
Albumin (mg/dl) 2.7 ± 0.2 3.0 ± 0.1 
Total Protein (mg/dl) 6.7 ± 0.2 7.2 ± 0.3 
Alkaline Phosphatase (U/L) 99.2 ± 14.5 64.2 ± 15.4 
LDH (U/L) 198.0±19.4 203.6 ± 27.7 
CPK (U/L) 48.0 ± 12.7 38.8 ± 8.2 
SGGT (U/L) 68.4 ± 5.1 72.4 ± 2.5 
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TABLE 4 
ARTERIAL PLASMA CONCENTRATION OF NOREPINEPHRINE 
AND EPINEPHRINE IN LEAN AND OBESE 




Basal Blood Pressure and Heart Rate 
Lean (5) 
167 ± 34 
110 ± 27 
Obese (5) 
106 ± 27 
48 ± 7 
Systolic, diastolic and mean arterial blood pressure were approximately 25% 
greater (P< 0.01) in obese than lean sheep (Table 5). The obesity-associated 
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hypertension coexisted with a marked 50 percent increase in the heart rate of obese 
compared with lean sheep. Blood pressure variability in obese sheep appeared similar 
to that in lean sheep because the mean (± SE) coefficient of variation in blood 
pressure was similar in lean (7.0 ± 0.3%) and obese (6.4 ± 0.2%) sheep. 
TABLE 5 
BASAL CARDIOVASCULAR VARIABLES IN LEAN AND 
OBESE SHEEP FASTED 16 h 
Item 
Systolic Blood Pressure, mmHg 
Diastolic Blood Pressure, mmHg 
Mean Arterial Blood Pressure, mmHg 
Heart Rate, beats/min 
• Lean and obese differ (P < 0.01 ). 
LEAN (5) 
96.6 ± 2.9 
65.2 ± 2.2 
75.7 ± 2.2 
49.6 ± 1.4 
OBESE (5) 
121.6 ± 3.0* 
81.1 ± 2.7• 
94.6 ± 2.8'1\' 
74.8 ± 5.61J 
Cardiovascular Responses to Adrenergic Agonists 
Overall mean arterial pressure before NE or PE injections was similar (P> 
0.05) in lean sheep (77.0 ± 2.3 vs 78.0 ± 2.8 mmHg) as also was the case in obese 
sheep (95.8 ± 3.2 vs 95.7 ± 2.2 mmHg). 
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NE and PE increased (P<0.01) MAP in a dose-dependent manner in lean and 
obese sheep (Fig. 1 ). Body condition did not affect peak blood pressure response to 
NE or PE dose, although mean response in obese sheep always exceeded that in lean 
sheep. Peak blood pressure response and nadir heart rates after each dose of agonist 
are summerized in Table 6. 
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1.0 3.0 10.0 30.0 
Phenylephrine, 119/kg 
Figure 1. Mean arterial blood pressure (MAP) response to 
dose of norepinephrine (upper panel) or phenylephrine 
(lower panel). Values are mean ± SE. The pressure increase 
above basal (A MAP) is plotted as a function of each agonist dose. 
Best fit of the relationship between mean increment in MAP and 
dose of agonist was determined by noniterative least squares 
regression (see Methods). First degree polynomial was best (P<0.01) 
fit of mean data shown here and all observations (n=25) in each 
group (see results and Table 7). Equations describing the 
relationship shown for NE were Y= 18.5(X) + 6.8 (r= 0.96) in lean 
sheep and Y = 17. 7(X) + 13.4 (r= 0.89) in obese sheep; equations for 
PE were Y=46.2(1ogX) + 7.1 (r= 0.84) in lean sheep and 
Y=54.3(1ogX) + 14.0 (r= 0.88) in obese sheep. Neither regression 
coefficients (b; slope) nor intercepts for each agonist differed 
(P>0.05) between lean and obese sheep as determined by 
regression analysis of variance and Student's t test. 
104 
TABLE 6 
ABSOLUTE SYSTOLIC (SBP), DIASTOLIC (DBP) AND MEAN (MAP) ARTERIAL PRESSURE AND HEART RATE (HR) 
RESPONSE TO INTRAVENOUS NOREPINEPHRINE (NE) AND PHENYLEPHRINE (PE) 
IN LEAN AND OBESE SHEEP 1 
SBP {mmHg) DBP (mmHg) MAP (mmHg} HR (beats/min} 
NE Lean Obese Lean Obese Lean Obese Lean Obese 
(J.tg/kg) 
Control 99.2 ± 3.5 122.9 ± 4.1 65.7 ± 2.4 82.3 ± 3.4 77.0 ± 2.3 95.8 ± 3.2 51.7 ± 2.9 77.2 ± 6.0 
0.25 109.3 ± 3.0 143.3 ± 2.8 73.8 ± 4.0 93.7±1.7 71.0±3.1 110.2 ± 2.0 41.6 ± 2.4 56.8 ± 3.6 
0.5 118.5 ± 3.2 148.1 ± 5.9 81.4 ± 4.0 100.0 ± 2.8 79.2 ± 3.2 116.0 ± 3.7 38.6 ± 2.7 59.8 ± 1.9 
1.0 129.3 ± 3.7 175.5 ± 5.3 87.7 ± 4.3 112.2 ± 3.0 86.9 ± 3.5 133.3 ± 3.7 39.6 ± 3.2 55.8 ± 3.0 
2.0 158.4 ± 8.2 192.3 ± 8.1 106.9 ± 4.8 123.1 ± 4.6 109.5 ± 5.3 146.2 ± 5.7 37.2 ± 3.4 49.2 ± 1.2 
4.0 199.2 ± 9.2 234.6 ± 11 135.8 ± 6.2 149.5±10 142.3 ± 6.2 177.9 ± 10 36.8 ± 3.5 48.0 ± 2.3 
PE (J.tg/kg) 
Control 100.1 ± 3.8 123.2 ± 2.6 66.9 ± 2.6 81.9±2.1 78.0 ± 2.8 95.7 ± 2.2 46.9 ± 1.5 70.8 ± 5.1 
1.0 114.1 ± 4.8 144.7 ± 4.6 77.6 ± 4.3 96.6 ± 3.0 89.8 ± 4.9 112.6 ± 3.9 40.4 ± 1.7 58.0 ± 4.0 
3.0 129.1 ± 6.1 170.7 ± 6.6 91.5 ± 5.5 113.9 ± 6.4 104.0 ± 6.0 132.8 ± 7.1 33.6 ± 1.5 47.2 ± 3.5 
7.0 152.6 ± 10 194.7 ± 6.2 101.6±7.1 129.8 ± 6.1 118.6 ± 8.9 151.4±6.7 34.0 ± 2.3 46.4 ± 5.5 
10.0 166.5±12 211.5 ± 6.2 111.7±7.1 143.3 ± 7.1 130.0 ± 9.5 166.0 ± 7.4 30.8 ± 0.7 40.8 ± 4.5 
30.0 194.9 ± 15 246.5 ± 7.4 140.1 ± 10 167.1 ± 14 158.4 ± 13 193.6 ± 12 27.8 ± 1.8 37.3 ± 5.8 
1 Peak blood pressure and nadir heart rates were measured in each sheep 0 to 3 min after each agonist injection and 





Noniterative least squares regression indicated that a first degree polynomial 
was the best fit of relationship between peak increment in MAP and dose of NE and 
log dose of PE in lean and obese sheep. Regression equations for observations in 
lean (n=25) sheep after NE and PE were Y= 18.5(X) + 6.8 (r= 0.96) and Y= 46.2(1og 
X)+ 7.1 (r= 0.84), and those for observations (n=25) in obese sheep were Y= 17.7(X) 
+ 13.4 (r= 0.89) and Y= 54.3(1og X) + 14.0 (r= 0.88), respectively. Equations derived 
from linear regression of data in individual sheep were used to estimate dose of NE 
and PE that increased their MAP by 25 (D25} or 50 (D50} mmHg. The mean D25 and D50 
doses of NE and PE were similar (P>0.05) in lean and obese sheep, although D25 for 
NE was lower (P<0.08) in obese than lean sheep (Table 7). The D25 dose of NE and 
PEon average was 34% and 42% lower, respectively, in obese than lean sheep. 
TABLE 7 
EFFECTIVE ADRENERGIC AGONIST DOSE IN LEAN AND OBESE SHEEP 
Dose, J.tg/kg Probability Values 
Agonist Type BC D25 D5o BC Dose lA 
Norepinephrine Lean 0.97 ± 0.11 2.37 ± 0.15 0.1 0.05 NS 
Obese 0.64 ± 0.11 2.47 ± 0.56 
Phenylephrine Lean 2.95 ± 0.6 4.84 ± 5.6 0.1 0.05 NS 
Obese 1.71 ± 0.281 5.49 ± 1.25 
Agonist dose for D25 and D50 were determined in each sheep using equations 
derived from linear regression analysis (see text) and mean (± SE) values shown were 
calculated for lean (n=5) and obese (n=5) sheep. Probability values for significance of 
treatment effects from split plot analysis of variance; treatments were body condition 
(BC), dose of agonist (Dose) and their interaction (lA). Means within each agonist type 
with similar superscript letter are not different (P>0.05) as determined by Duncan's new 
multiple-range test. 
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Regardless of dose, heart rate (HR) was decreased (P<0.01) approximately 
27% in lean sheep treated with NE (Fig. 2). In contrast, heart rate in obese sheep was 
decreased (P<0.01) approximately 25% by 0.25, 0.5 and 1 mg/kg NE and 
approximately 37% by 2 and 4 mg/kg NE. Overall decrease in heart rate was affected 
(P<0.05) by body condition with greater decrement in obese than lean sheep. 
Body condition markedly affected (P<0.01) the heart rate response to PE (Fig. 
2). The decrease in heart rate (beats/min) was greater (P<0.05) in obese than lean 
sheep after 1 (6.5 vs 12.8), 3 (13.3 vs 23.6), 7 (13.7 vs 24.4), 10 (16.1 vs 30) and 30 
( 19.1 vs 33.5) J..l.g/kg PE. Duration of blood pressure response increased with 
increasing dose of NE or PE equally in lean and obese sheep (Fig. 3). Equivalent 
duration of response suggests similar blood levels of the injected NE and PE in lean 
and obese sheep. 
Baroreceptor reflex function was assessed by plotting absolute HR as function 
of absolute MAP after NE or PE treatment (Fig. 4). Although the regulation of 
baroreceptor control as function of increasing blood pressure appears similar in both 
groups of sheep, it is clear that for any given blood pressure the heart rate was greater 
in obese than lean sheep. The shift in the position of the curve indicates that the set 
point about which this regulation operates is different in lean and obese sheep. That 
regulation of the baroreceptor reflex was similar in lean and obese sheep was attested 
to by calculating similar baroreceptor sensitivity ratios in lean and obese sheep (Fig. 
5). 
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Figure 2. Decrements in heart rate {.e..HR) in lean and obese sheep 
(n=5/group) injected with different doses of norepinephrine 
(upper panel) or phenylephrine (lower panel). The maximum 
decrement in heart rate (beats/min) after each agonist dose was used to 
calculate the mean (± SE) values shown. Probability values shown for 
significances if treatment effects of body condition (BC), agonist dose 
(NE; PE) and their interaction (lA) were derived from 2 x 5 split-plot 
analysis of variance; means within each agonist type with similar lower 
case letter are not different (P<0.05) as determined by Duncan's new 
multiple range test. 
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DURATION OF BLOOD PRESSURE RESPONSE 
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Figure 3. Duration of pressor response in lean and obese sheep 
(n=5/group) injected with different doses of norepinephrine 
(upper panel) or phenylephrine (lower panel). Duration was 
time (min) for the increased MAP to return to basal values after iv 
injection of agonist dose. Probability values shown for significances if 
treatment effects of body condition (BC), agonist dose (NE; PE) and 
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Figure 4. Relationship between heart rate and MAP in lean and obese 
sheep (n=5/group) under basal conditions and after iv 
injection of adrenergic agonists. Reading left-to-right, data points 
(mean ± SE) correspond to basal conditions and then lowest-to-highest 
dose of norepinephrine (upper panel) or phenylephrine (lower panel). 
Peak pressure response and the attendant heart rate for dose of 
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Figure 5. Baroreflex sensitivity ratios (mean ± SE) in lean and obese 
sheep (n=5/group) calculated at peak pressor response to 
dose of norepinephrine (upper panel) or phenylephrine 
(lower panel). Ratios calculated as decrement in heart rate 
(beats/min) below basal divided by peak increment in MAP (mmHg) 
above basal in response to agonist dose. Values for decrement in heart 
rate were those coincident with peak pressor response and usually this 
coincided with the nadir heart rate observed after the iv injection of 
adrenergic agonist. Probability values shown for significance of 
treatment effects of body condition (BC), agonist dose (NE; PE) and 





Many epidemiological studies have demonstrated a strong relationship between 
obesity and essential hypertension (Stamler 1978; Van ltallie 1985; Krieger et al 1988). 
The pathophysiological mechanisms involved in obesity-associated hypertension are 
unknown, but suggested mechanisms include insulin's effects on vascular structure 
and reactivity and insulin's effects on sympathetic nervous system activity (Krieger and 
Landsberg 1988; Swislocki 1990; Ferrari and Weidmann 1990). 
We have established the dietary obese sheep as an alternative animal model 
applicable to obese humans with or without type II diabetes mellitus (McCann and 
Bergman 1988; McGann et al 1991 ). We report here that dietary obese sheep also are 
hypertensive. MAP and HR were 25% and 50% greater, respectively, in obese than 
lean sheep under basal, defined conditions. Dietary means have been used to induce 
obesity-associated hypertension in dogs (Rocchini 1989; Wehberg et al 1990) and rats 
(Kaufmann et al 1991) fed a high fat diet and in rats fed a high fructose diet (Hwang et 
al 1987); MAP was increased approximately 13 to 22% in these models of obesity-
associated hypertension. 
Ernberger and Nelson (1988) reported obesity-associated hypertension in rats 
made dietary obese by recurrent bouts of fasting/refeeding but not in rats made obese 
by chronic ad libitum feeding. Results in obese sheep, however, clearly show that 
hypertension was associated with obesity per se and not obesity interacting with diet 
type, level of intake, or non-steady state conditions of the dynamic phase of obesity. 
Our sheep became obese over 40 to 50 wk by consuming ad libitum the same normal 
diet fed at maintenance to lean control sheep. Blood pressure recordings were done in 
our study when lean and obese animals were fed equivalent levels of a common diet 
such that each was in zero-energy balance. Further, we purposefully measured basal 
cardiovascular variables over 5 wk when cardiovascular variables and animal 
metabolism were in pseudo-steady state conditions and this is seldom the case in 
other animal models of obesity-associated hypertension. 
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Obesity induced by feeding a diet different from that fed to control animals may 
have ontoward effects other than those associated with the obese state. For example, 
high fat feeding has produced renal damage in rodents (Grone et al 1989; Kasiske et 
al 1991 ). Moreover, surgical manipulation of the animal (e.g., catheterization) requires 
suitable recovery time before reliable measurement of cardiovascular variables can be 
made. Simple catheterization of leg blood vessels in sheep required at least 7 d 
recovery before the surgery-induced increase in MAP abated and MAP returned to 
basal values; this effect was more pronounced in obese than lean sheep. 
Obesity-associated hypertension in sheep coexisted with hyperinsulinemia, 
hyperglycemia and decreased plasma concentrations of HDL-cholesterol, which are 
results consistent with obesity-associated hypertension in humans. However, unlike 
humans, plasma triglyceride concentration was similar in lean and obese sheep. These 
results suggest that hypertriglyceridemia is not a prerequisite finding in obese 
mammals that are hypertensive. Plasma levels of Ca2+, Na+ and K+ were similar in lean 
and obese sheep indicating that the obesity-associated hypertension likely was 
unrelated to abnormal metabolism of sodium, potassium or calcium. 
It has been argued that the hyperinsulinemia of obesity increases sympathetic 
nervous system activity leading to increased vascular constriction and hypertension 
(Krieger and Landsberg 1988). Fasting hyperinsulinemia was evident in obese sheep 
since approximately wk 2 to 7 of ad libitum feeding (J. P. McCann, unpublished data), 
but plasma catecholamines at wk 100 to 120 of obesity in this study were similar in 
lean and obese sheep. In fact, arterial plasma catecholamines tend to be greater in 
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lean than obese sheep. O'Hare et al (1989) also reported that obese men had greater 
plasma insulin, glucose and MAP than lean controls and that plasma NE 
concentrations did not differ. The SHR rat and some hypertensive humans reportedly 
have elevated plasma venous levels of catecholamines relative to values in 
normotensive controls (VIachkis and Alexander 1981; Tuck 1986; Ludwig et al 1991 ). 
Dogs fed a high fat diet for 6 wk developed hypertension, but the elevated levels of 
plasma catecholamines noted at wk 1 remained steady throughout the next 5 wk of 
high-fat diet feeding (Rocchini et al 1989). Other workers, however, reported a 
decrease in plasma catecholamine levels in dietary-obese compared with lean rats 
(Levin et al 1983). It appears that hyperinsulinemia and hypertension can coexist in 
obesity without concomitant significant elevation in the plasma catecholamine levels. 
Hyperinsulinemia definitely plays some role in the development and sustenance 
of hypertension, coronary heart disease and atherosclerosis in obese and nonobese 
humans with or without diabetes (Swislocki 1990; Gwinup and Elias 1991; Reaven 
1990; Ronnemaa et al 1991 ). The exact mechanism linking hyperinsulinemia to 
cardiovascular disease are unknown. Experimental efforts to induce hypertension in 
animals infused with insulin have been largely unsuccessful. Five-told elevation in 
plasma insulin in euglycemic dogs tor 7 d did not affect MAP (Hall et al 1990) and 
high-sucrose feeding together with 5-d iv infusion of insulin in rats barely increased 
MAP above values in chow-ted control rats (Brands et al 1991 ). High fructose (Hwang 
et al 1987) feeding alone has produced obesity, hyperinsulinemia, insulin resistance 
and a modest rise in systolic blood pressure. 
Increased TPR is believed responsible for the increased blood pressure in 
obesity-associated hypertension (Folkow 1982). Enhanced vascular reactivity to 
adrenergic stimulation will increase vascular resistance and this could explain the 
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increased blood pressure in obese subjects (Landsberg and Kreiger 1989). Blood 
pressure increases in response to NE or PE injections were similar in lean and obese 
sheep in this study, although dose of NE increasing MAP by 25 mmHg was greater 
(P<0.08) somewhat in obese than lean sheep. However, increases in MAP after iv 
injections of PE were significantly greater in obese, high-fat fed dogs than in lean dogs 
fed a low-fat diet (Wehberg et al 1990). Pressure response to iv infusion of PE was 
greater marginally in obese rats chronically fed high fat than in lean rats fed regular 
chow (Bunag et al 1990). The relative contribution of high-fat feeding and the obese 
state to adrenergic agonist-induced increase in blood pressure in such syudies are not 
clear. Hypertensive dogs and rats made obese by high-fat feeding become 
normotensive if fed a normal levels of fat intake (Rocchini et al 1987; Kaufman et al 
1991 ). Results comparing pressor response to alpha-adrenergic agonists in lean 
versus obese humans apparently are not available, but dose of NE increasing blood 
pressure by 20 mmHg was less in nonobese humans with essential hypertension than 
in normotensive humans (Weidmann 1989). 
Several studies suggest that baroreflex function may be altered in hypertensive 
animals and humans (Aars 1968; Dustan 1983; Corner 1989; Xie et al 1991 ). Alteration 
in baroreflex control of heart rate can involve resetting of the threshold pressure for 
inhibition of heart rate and(or) change in sensitivity of the baroreflex pressure-activity 
curve (Korner 1989). Baroreflex sensitivity was normal but baroreflex response was 
reset to function at higher pressure levels in rats (Jones and Floras 1980) and rabbits 
I 
(Guo et al 1983; Xie et al 1991) with renal hypertension and in nonobese humans with 
essential hypertension (Bristow et al 1969; Eckberg 1979). That the curve relating 
change in heart rate to change in MAP was shifted rightward in obese compared with 
lean sheep in this study, suggests that baroreflex control of heart rate was impaired in 
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the dietary obese sheep and that this impairment was characterized by resetting of the 
reflex without change in sensitivity of the reflex. Similar results on baroreflex control of 
heart rate were found in dogs that developed hypertension and obesity after 6 wk of 
high-fat feeding (Wehberg et al 1990) and in Wistar rats chronically fed high fat to 
develop obesity and border-line hypertension (Bunag et al 1990). 
In summary, we report a new model of obesity-associated hypertension in 
sheep in which the obesity is induced by overconsumption of a normal diet. 
Hypertension in our dietary obese sheep model coexists with hyperinsulinemia, 
hyperglycemia, insulin resistance, hyperglucagonemia and lower plasma levels of HDL-
cholesterol. Moderately greater hypertensive responses to adrenergic agonists in 
obese than lean sheep suggest the obesity-associated hypertension may be related to 
enhanced reactivity of adrenoceptor mechanisms in vascular smooth muscle of the 
obese sheep; this interpretation is valid only if the hypertensive response was caused 
directly via agonist-induced constriction of vascular smooth muscle and not indirectly 
by adrenergic agonist modification of central sympathetic outflow to resistance vessels. 
Chronic hyperinsulinemia in obese sheep may enhance vascular reactivity to 
vasoconstrictive agents and it also may play a role in resetting of the baroreflex 
control of heart rate, possibly by inducing structural changes in thickness and collagen 
content of vascular smooth muscle. 
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CHAPTER VI 
EFFECT OF CLONIDINE ON BLOOD PRESSURE AND 
HEART RATE IN LEAN AND OBESE SHEEP 
Introduction 
a-Adrenergic receptors mediate vasoconstriction and elevation of blood 
pressure. Modulation of synaptic norepinephrine release by presynaptic adrenergic 
receptors and the subclassification of a-adrenoceptors into 01- and a 2- subtypes have 
been well documented (Kobinger 1978). Postsynaptic a,-adrenoceptors located in the 
plasma membrane of vascular smooth muscle are the a-adrenoceptor type most 
responsible for vasoconstriction and blood pressure elevation (Timmermans and Van 
Zwieten 1980; Van Brummelen et al 1984). Adrenergic ~-adrenoceptors are widely 
distributed in the body and are usually pre-synaptic, but they appear to be also located 
postjunctionally on vascular smooth muscle cells where they mediate vasoconstriction 
(Docherty and McGrath 1980; Timmermans and Van Zwieten 1980; Van Brummelen et 
al 1984; Goldberg and Robertson 1984). Activation of presynaptic a 2-adrenoceptors 
results in a decrease in release of endogenous transmitter (Schmitt 1967; Kobinger 
1978). 
Many drugs used in therapy of hypertension decrease blood pressure either by 
reducing the sympathetic drive to the cardiovascular system or by blocking the 
transduction of this signal to the effector organ. Clonidine hydrochloride is a 
hypotensive drug with agonistic properties for ~-adrenoceptors (Bentley and Li 1968; 
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Langer et al 1980). Because of its pKa of 8.05, about 85% of administered clonidine 
exists in the protonated form in extracellular fluid (pH 7.36). Further, the lipid-solubility 
of clonidine enables it to cross the blood brain barrier and reach the pressure 
regulatory centers in the brain (Kobinger 1978). 
Clonidine activation of ~-adrenoceptors in the cardiovascular control center in 
the brain reduces sympathetic outflow to heart and vasculature and enhances 
parasympathetic tone to the heart, processes that promote lowering of blood pressure 
and heart rate (Schmitt et al 1967; Kobinger and Walland 1971; Pettinger 1980). 
Clonidine-induced decrease in heart rate and blood pressure is accompanied by 
decreased sympathetic activity as measured by electrical activity in peripheral 
sympathetic nerves of animals and by decreased plasma levels of catecholamines in 
animals and humans (Isaac 1980; Pettinger 1980). 
As discussed above, activation of central ~-adrenoceptors produces peripheral 
hypotension in humans and rodents. However, clonidine has an initial transient 
hypertensive effect when given iv to humans, rats, and dogs (Hoefke and Kobinger 
1966; Shaw et al 1971 ), and this hypertensive response is effected by clonidine 
activation of postjunctional vascular smooth muscle ~-adrenoceptors (Timmermans 
and Van Zwieten 1980). Thus, the hemodynamic effects of clonidine depend on the 
balance between activation of peripheral post-junctional and cental pre-synaptic ~­
adrenoceptors (Timmermans and Zwieten 1980). 
Mechanisms responsible for obesity-associated hypertension in humans and 
animals are unknown but likely include dysfunctions in the neural and humoral control 
of cardiovascular function (Krieger and Landsberg 1988; Ferrari and Weidmann 1990; 
Rocchini 1990). The role of ~-adrenoceptors in obesity-associated hypertension is not 
clear but available evidence suggests that down-regulation of central ~-adrenoceptors 
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may play a role in obesity-associated hypertension (Pettinger 1980; Levin 1990; 
Gulati 1991 ). The objectives of this experiment were to determine if cardiovascular ~­
adrenoceptor-dependent responses differed in lean normotensive sheep and obese 
hypertensive sheep. The hypertensive sheep model is a new and alternative animal 
model that displays hyperinsulinemia, hyperglycemia and insulin resistance (McCann 
and Bergman 1988; McCann et al 1991 ). 
Materials and Methods 
Animal Preparation 
Surgery was conducted with aseptic technique for survival surgery. Anesthesia 
was induced with 50 mg/kg pentobarbital sodium (Nembutal®, Abbott Lab., IL) and 
maintained with 1-2% halothane (Fiuthane®, Ayerst Lab, NY) in oxygen delivered to 
the sheep through an endotracheal tube by anesthesia machine (Ohio Chemical & 
Surgical Equipment, Madison, WI). 
Catheters with diameters of 12.7 mm (ID) were implanted in the abdominal 
aorta and the abdominal vena cava through the femoral artery and vein, respectively. 
The distal end of the catheters were exteriorized from the right hind leg and brought to 
mid back of the animal. The catheters were connected to Tuohy-Borst adapters, and 
wrapped in surgical adhesive tape which was glued to the animal. Sheep were treated 
with penicillin (300,000 U/kg) daily for 5 days after surgery. Catheters were flushed 
thrice weekly with sterile heparinized saline (1 0 U/ml) and filled with heparin ( 1 ,000 
U/ml). At least 2 wk elapsed between surgery and experiments in any sheep. 
Inspection at necropsy confirmed that both catheter tips were positioned about 3 to 4 
em cranial to the ileac bifurcations. 
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Experimental Protocol 
All experiments were done between 0900 and 1200 h in 16-h fasted lean (n=5) 
and obese (n=5) Rambouillet ewes that were, loosely held by halter in their own pen. 
The aortic catheter was connected to a calibrated blood pressure transducer (Narco 
Bio-System, Int. Biomedics, Houston, TX) located at the level of heart. Changes in 
blood pressure were recorded with a 4-channel Narcotrace model 40 MKIV physic-
graph (Narco Bio-System). Heart rates were determined using Narco biotachometer 
model 7302 (Narco Bio-System) linked to the blood pressure transducer, and 
occasionally from direct counting of the systolic waves for 1 min at slow (0.5 em/sec) 
chart speed. Before each clonidine injection, blood pressure and heart rate were 
recorded for 45 min (stabilization period), during which time three measurements were 
made at 15 min intervals to establish base line values of blood pressure and heart 
rate. After the stabilization period, 5 or 10 !lglkg clonidine (1 0 to 15 ml volume) were 
infused in 2 min via the venous catheter which was immediately flushed with 5 to 1 0 ml 
of saline. Clonidine hydrochloride (Sigma, St. Louis, MO) solutions were freshly 
prepared for each experiment in saline, filtered through a 0.2 llm filter, and kept on ice 
until injected. Blood pressure and heart rate were recorded throughout each 
experiment, but blood pressure and heart rate measurements were done at 2, 5, 10, 
15, 20, 30, 45, 60, 75, 90, 105 and 120 min post injection. Experiments were done 
simultaneously in a lean and obese sheep pair, with sequence of clonidine dose 
randomized among pairs; at least 5 days elapsed between successive doses of 
clonidine in each pair of sheep. 
Calculations and Statistical Analysis 
The mean arterial pressure (MAP) was determined as 2/3 of diastolic blood 
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pressure plus 1/3 of systolic blood pressure (West 1985). Differences between lean 
and obese sheep in blood pressure and heart rate after clonidine injections were 
compared using univariate correlated t test for repeated measurements (Gill 1979). The 
interactive effects of body condition and clonidine dose on blood pressure and heart 
rate variables were tested by 2 x 2 split-plot analysis of variance and Duncan's new 
multiple range test if a significant F-value (P<0.1) was found (Steel and Terrie 1980); 
for these analyses, clonidine-induced change in blood pressure for each sheep was 
quantified by area-under-the-curve (AUC) and peak heart rate and peak MAP also 
were used. AUC in each sheep was calculated by trapezoid method. Level of 
significance was 0.05. Values are mean ± SE. 
Results 
Basal MAP (91.5 ± 3.8 vs 73.8 ± 2.2 mmHg) and HR (72.7 ± 5.3 vs 50.6 ± 2.5 
beats/min) were greater (P< 0.01) in obese than lean sheep. Values of blood pressure 
variables and heart rates for each clonidine dose are summarized for lean and obese 
sheep in Table 1 and 2. Clonidine produced a dose-dependent increase in MAP in 
both lean and obese sheep (Fig. 1 ). MAP was greater (P< 0.05) after 10 ~g/kg than 
after 5 ~g/kg clonidine in lean sheep and in obese sheep. Maximum increment in MAP 
developed in response to clonidine was unaffected by body condition but was affected 
significantly by clonidine dose (Table 3). However, the overall MAP response to 5 
~g/kg clonidine was less (P< 0.05) in obese than lean sheep (Fig. 2). The response to 
low dose clonidine in obese sheep was only 46 % of that of lean sheep. Lesser MAP 
response to low dose clonidine together with similar MAP response to high dose 
clonidine are results suggesting fewer vasoactive ~-adrenoceptors in obese compared 
with lean sheep. 
TABLE 1 
BLOOD PRESSURE VARIABLES AND HEART RATE IN SHEEP AFTER ADMINISTRATION OF 5 ~g/kg CLONIDINE 
Lean (n=5) Obese (n=5) 
Time SBP DBP MAP HR SBP DBP MAP HR 
{min} {mmHg} {mmHg} {mmHg} {beat/min} {mmHg) {mmHg} {mmHg) {beat/min} 
-30 94.7 ± 2.4 64.1 ± 2.1 73.3 ± 2.0 52.0 ± 2.6 119.2 ± 3.2 81.2 ± 3.2 93.9 ± 3.1 71.6 ± 3.8 
-15 93.7 ± 2.9 62.6 ± 2.4 73.1 ±2.4 51.2 ± 2.9 118.7 ± 4.2 79.3 ± 3.4 92.4 ± 3.7 70.8 ± 3.3 
0 94.2 ± 3.4 63.1 ± 2.4 73.5 ± 2.5 51.6±2.4 120.1 ± 3.0 79.5 ± 2.9 93.1 ± 2.9 67.2 ± 2.9 
2 119.6 ± 8.9 86.7 ± 6.8 97.7 ± 7.5 40.0 ± 2.2 135.5 ± 2.2 93.7 ± 1.4 107.3±1.5 44.4 ± 2.6 
5 124.4 ± 7.0 83.8 ± 3.6 97.4 ± 4.7 52.6 ± 5.3 145.6 ± 2.5 95.1 ± 2.9 112.5 ± 2.5 65.6 ± 7.5 
10 121.6 ± 7.3 82.8 ± 4.2 95.8 ± 5.2 55.2 ± 6.5 134.1 ± 2.8 90.8 ± 3.3 105.2±3.1 65.8 ± 5.5 
15 118.7 ± 6.8 79.5 ± 3.8 92.6 ± 4.5 54.0 ± 3.6 127.8 ± 3.2 85.0 ± 2.1 99.3 ± 2.2 68.0 ± 4.0 
20 111.9 ± 7.3 76.1 ± 4.4 88.1 ± 5.1 60.4 ± 6.0 121.1 ± 3.9 78.8 ± 3.5 92.9 ± 3.6 74.8 ± 6.8 
30 107.1 ±5.5 70.8 ± 3.1 83.0 ± 3.5 55.2 ± 1.0 121.1 ± 3.7 77.3 ± 3.0 91.9 ± 3.2 72.4 ± 4.9 
45 101.4 ± 5.6 67.5 ± 3.4 78.8 ± 4.0 56.4 ± 2.4 124.5 ± 7.5 80.7 ± 5.3 95.3 ± 6.0 70.0 ± 2.4 
60 98.0 ± 5.0 65.5 ± 3.0 76.4 ± 3.4 54.4 ± 1.7 124.5 ± 11.2 83.6 ± 8.3 97.2 ± 9.3 67.2 ± 3.3 
75 96.6 ± 3.8 65.1 ±3.1 75.6 ± 2.9 52.8 ± 1.9 125.9 ± 10.1 84.1 ± 7.6 98.0 ± 8.6 66.4 ± 3.8 
90 96.1 ± 3.5 64.1 ± 2.8 74.8 ± 2.7 52.2 ± 2.4 125.9 ± 9.5 85.0 ± 7.4 98.7 ± 8.1 66.4 ± 2.9 
105 94.2 ± 3.5 63.1 ± 3.1 73.5 ± 3.0 52.4 ± 1.7 122.5 ± 9.9 82.6 ± 7.8 95.9 ± 8.5 68.4 ± 2.5 
120 93.7 ± 2.6 62.6 ± 2.5 73.1 ± 2.2 52.8 ± 1.7 121.1 ± 9.9 81.2 ± 6.0 94.5 ± 7.5 67.6 ± 2.9 
....... 
SBP= Systolic Blood Pressure; DBP= Diastolic Blood Pressure; MAP= Mean Arteial Pressur; HR= Heart Rate 1\.) 
(j) 
TABLE 2 
BLOOD PRESSURE VARIABLES AND HEART RATE IN SHEEP AFTER ADMINISTRATION OF 10 J.LQ/kg CLONIDINE 
Lean (n=5) Obese (n=5) 
Time SBP DBP MAP HR SBP DBP MAP HR 
{min} {mmHg} {mmHg} {mmHg} (beat/min} {mmHg} {mmHg} {mmHg) (beat/min} 
-30 92.5 ± 1.9 64.1 ± 2.2 73.6 ± 1.9 49.6 ± 2.4 115.3 ± 4.4 76.4 ± 4.2 89.4 ± 4.2 76.4 ± 7.0 
-15 93.9 ± 1.9 64.6 ± 2.1 74.4 ± 1.9 49.6 ± 2.2 116.8 ± 4.1 76.4 ± 4.6 89.9 ± 4.4 75.2 ± 7.3 
0 92.7 ± 2.3 64.6 ± 2.9 74.0 ± 2.6 49.6 ± 2.4 115.8 ± 4.3 77.4 ± 5.1 90.2 ± 4.8 75.2 ± 7.4 
2 118.4 ± 8.9 84.8 ± 6.6 96.0 ± 7.3 35.6 ± 0.7 133.1 ± 4.4 91.8 ± 3.5 105.6 ± 3.7 44.0 ± 2.8 
5 137.2 ± 4.7 93.9 ± 2.8 108.3 ± 2.9 37.6 ± 1.6 174.0 ± 16.3 110.0±7.1 131.4 ± 10.1 57.4 ± 7.9 
10 136.2 ± 3.8 95.9 ± 2.9 109.3 ± 1.9 43.6 ± 4.1 167.7 ± 15.3 106.2 ± 4.7 126.7 ± 8.1 63.2 ± 8.5 
15 131.4 ± 4.0 90.1 ± 3.2 103.8 ± 3.0 44.8 ± 3.8 161.0 ± 12.5 104.8 ± 4.3 123.5 ± 6.6 67.6 ± 9.3 
20 127.1 ± 4.6 84.8 ± 4.4 98.9 ± 4.3 47.8 ± 3.3 141.3 ± 4.3 95.7 ± 3.0 110.8 ± 3.3 74.4 ± 12.0 
30 118.4 ± 6.0 78.1 ± 5.1 91.5 ± 5.3 52.0 ± 2.6 126.4 ± 6.9 85.6 ± 4.5 99.2 ± 5.2 74.8 ± 9.2 
45 104.0 ± 6.4 74.2 ± 4.4 84.2 ± 4.9 56.0 ± 5.0 120.6 ± 5.1 81.2 ± 3.5 94.4 ± 4.0 75.0 ± 9.0 
60 98.8 ± 8.1 69.9 ± 4.4 79.5 ± 5.5 63.6 ± 9.6 116.8 ± 4.5 79.3 ± 3.8 91.8 ± 3.9 75.2 ± 7.0 
75 98.3 ± 6.6 67.0 ± 4.2 77.4 ± 4.9 54.4 ± 2.4 114.8 ± 4.0 77.9 ± 4.4 90.2 ± 4.1 74.0 ± 5.4 
90 96.8 ± 5.7 65.6 ± 4.3 76.0 ± 4.6 52.4 ± 1.6 115.8 ± 4.0 80.3 ± 4.2 92.1 ± 4.0 43.2 ± 4.7 
105 94.9 ± 5.3 66.1 ± 3.7 75.7 ± 4.2 54.2 ± 1.0 112.4 ± 3.2 76.0 ± 4.2 88.1 ± 3.8 72.0 ± 4.6 
120 95.9 ± 5.7 66.1 ± 3.8 76.0 ± 4.2 52.8 ± 2.0 113.9 ± 4.5 76.9 ± 4.6 89.2 ± 4.6 71.2 ± 4.4 
..... 
SBP= Systolic Blood Pressure; DBP= Diastolic Blood Pressure; MAP= Mean Arteial Pressur; HR= Heart Rate 1\) --.1 
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Figure 1. Hemodynamic effects of 5 and 10 JlQ/kg clonidine in lean (n=5) and 
obese (n=5) sheep. Arrows indicate iv injection of clonidine. 
TABLE 3 
MAXIMUM CHANGE IN MAP AND HR AFTER CLONIDINE INJECTION 
IN LEAN AND OBESE SHEEP1 
Clonidine Dose Probabilit~ Value 
Item Body Condition 5 Jlg/kg 10 Jlg/kg BC Dose lA 
MAP, mmHg Lean 24.0 ± 5.38b 35.4 ± 1.6° NS 0.025 NS 
Obese 18.8 ± 3.7" 41.6 ± 12.0bc 
HR, beats/min Lean 11.1 ± 1.o• 13.0 ± 3.o• 0.01 NS NS 
Obese 25.3 ± 3.0b 31.0 ± 5.0b 
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1 Values are mean ± SE and represent the difference between the peak MAP and nadir HR 
developed and corresponding basal values in each sheep. Peak MAP and nadir HR values were recorded 
1 to 5 min after clonidine injection. Probability values for significance of treatment effects from split-plot 
analysis of variance; means within each item with similar superscript letter are not different (P>0.05) as 
determined by Duncan's new multiple range test. (BC=body condition, lA= interaction). 
CD CJ LEAN > 1500 
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Figure 2. MAP response to 5 and 10 J.lg/kg clonidine in lean 
and obese sheep. Response calculated as area (AUC) 
above basal MAP plus one standard deviation of basal. 
Probability values from split-plot analysis of variance for 
treatment effects were body condition 0.1; clonidine dose 
0.005; interaction 0.1. Means with similar superscript letters 
are not different (P>0.05) as determined by Duncan's new 
multiple range test. 
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After clonidine injection, HR decreased acutely in lean and obese sheep before 
returning to basal levels immediately, except in lean sheep injected with 1 0 J.I.Q/kg 
clonidine (Fig. 1 ). The maximum decrements in HR after clonidine in each group of 
sheep were unaffected by dose , but the decrement was 2 to 3 times greater (P<0.05) 
in obese than lean sheep (Table 3). The bradycardiac response to clonidine appeared 
unrelated to the dose-dependent hypertensive effects of clonidine. Results in Table 3 
show that for the same time interval (+2 to + 10 min) after each dose of clonidine, the 
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decrement in HR was considerably greater in obese than lean sheep despite less or 
similar increment in peak MAP being developed in obese than lean sheep. 
Additional qualitative observations on behavior of sheep injected with clonidine 
are noteworthy. Salivation was noticeably increased in all sheep by either dose of 
clonidine. However, distinct respiratory distress was evident in obese but not lean 
sheep and this response was exacerbated by increasing dose of clonidine. Respiration 
rate increased along with marked reduction in volume of air breathed in the first +5 to 
+ 15 min after clonidine injection. 
Discussion 
In this experiment 5 and 10 ~J,g/kg clonidine produced marked hypertension in 
lean and obese sheep. Blood pressure did not decrease significantly below basal 
values in these clonidine-injected sheep when observations were made up to 4 h after 
clonidine treatment. The blood pressure response to clonidine is biphasic in many 
species including man (Kobinger 1978; Pettinger 1980). After iv injection, clonidine 
activation of vascular smooth muscle <X:2-adrenoceptors produces an initial short-lived 
hypertension response which precedes a chronic hypotensive response mediated by 
clonidine activation of central a2-adrenoceptors (Timmermans and Van Zwieten 1980, 
Jie et al 1987). The hypertensive response in man is evident after high but not low 
doses of clonidine (Pettinger 1980). Neither acute nor chronic hypotensive responses 
were observed in our sheep injected with doses of clonidine which were comparable to 
those used in studies reporting biphasic pressure responses to iv clonidine. 
Hypertension without any hypotensive response was reported previously for 
normal sheep injected iv with clonidine (Eisenach 1988; Castro and Eisenach 1989), 
but the degree of hypertension noted by these workers was less than that in our sheep 
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despite employment of similar doses of clonidine. Blood pressure response to iv 
injection of clonidine in sheep apparently differs from the biphasic hyper-hypotensive 
response observed in dogs (Schmitt and Schmitt 1969), goats (Eriksson and Tuomisto 
1982) and rats (Grichois et al 1990) treated with clonidine doses similar to those used 
in this study. The biphasic blood pressure response to iv clonidine has been explained 
by clonidine activation of a2-adrenoceptors in the peripheral vasculature and in the 
CNS that mediate clonidine's hypertensive and hypotensive responses, respectively 
(Kobinger and Walland 1967; Pettinger 1980; Head and DeJong 1986). Intravenously 
injected clonidine can interact with both central and peripheral adrenoceptors. Thus the 
blood pressure change after iv clonidine reflects the balance between the central 
hypotensive and peripheral vasoconstrictive effects of clonidine. 
Because ruminants are more sensitive to a-agonists than nonruminants 
(Hopkins 1972), it would be difficult to inject a dose of clonidine iv that would, on basis 
of dose, preferentially affect central but not peripheral adrenoceptors. Accordingly, the 
typical blood pressure response to iv clonidine in sheep is singularly hypertensive 
reflecting the dominant role of adrenoceptors in the peripheral vasculature, relative to 
those in the CNS, when both are exposed to iv clonidine. This is substantiated by the 
results of Eisenach (1988) and Eisenach and Tong (1991) in sheep where clonidine 
produced hypertension when administered iv but produced hypotension when similar 
dosage was administered intrathecally into spinal fluid. A few reports in ruminants, 
however, have noted mild hypotension after iv injection of 7 J.lg/kg clonidine in goats 
(Eriksson and Tuomisto 1982) and after epidural injection of approximately 2-5 11g/kg 
clonidine (Eisenach and Tong 1991 ). Reasons for the discrepancy in results between 
sheep and goats are not clear, but it is reasonable to assume that clonidine-induced 
hypotension in sheep could be masked by clonidine's dominant effect of peripheral 
vasoconstriction. Although central and peripheral adrenoceptors likely were stimulated 
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by iv clonidine, hypertension without development of hypotension occurred in the lean 
and obese sheep injected with clonidine in this experiment. 
The maximum increment in MAP after each dose of clonidine and the overall 
hypertensive response to high dose clonidine were comparable in lean and obese 
sheep. However, the hypertensive response to low dose clonidine was significantly 
less in obese than lean sheep. That the difference in response to clonidine between 
lean and obese sheep was observed in the presence of submaximal concentrations of 
clonidine, but not in the presence of saturating concentrations of clonidine, suggests 
that obese sheep had fewer <X.:!-adrenoceptors than lean sheep. Relative to control 
conditions, fewer cell-surface receptors are associated with a rightward shift in the 
dose-response curve for agonist action (Kahn 1985). This would be applicable if our 
results could be explained entirely by the peripheral vasoconstrictive actions of 
clonidine in vascular smooth muscle. If clonidine indeed has central and peripheral 
effects in sheep that are concurrent but antagonistic, then the lesser hypertensive 
response to low dose clonidine in obese than lean sheep could be explained by a 
greater central vasodilatory effect of clonidine in obese sheep than lean sheep without 
difference in response to the peripheral vasoconstrictive effects of clonidine. 
Reflex bradycardia was two to three times more prominent in obese than lean 
sheep a despite similar, or lesser, hypertensive response in obese than lean sheep. 
These results suggest that clonidine affected baroreceptor function by affecting 
baroreceptor sensing of increased MAP, central cardiovascular processing of 
baroreceptor information, and( or) efferent signalling to cardiac muscle in obese 
compared with lean sheep. Centrally acting clonidine inhibits sympathetic and 
enhances parasympathetic nervous activity (Pettinger 1980). The greater bradycardia 
in obese than lean sheep might indicate greater parasympathetic vagal response to 
clonidine in the obese sheep. Others have suggested that clonidine increases the 
sensitivity of the baroreflex response in normal rats (Grichois et al 1990). 
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The observed bradycardia in sheep in this study dissipated within 1 0 min even though 
MAP was increased for up to 30 to 60 min after clonidine injection. In contrast, 
bradycardia persisted throughout the hypertensive response in sheep injected with 
phenylephrine, an a1-agonist (see Chapter V). 
Clonidine can affect respiration in sheep by central and peripheral mechanism 
(Eisenach 1988; Eisenach et al 1988; Bolme and Fuxe 1973). Bolme and Fuxe (1973) 
hypothesized that clonidine interacts with a central inhibitory noradrenergic mechanism 
to control respiration. Clonidine had slight inhibitory effect on respiration in goats 
(Eriksson and Tuomisto 1982) but significantly reduced incidence and duration of 
breathing in foetal lambs (Bamford et al 1990; Bamford and Hawkins 1990). In this 
experiment, respiratory effects of clonidine were distinct in obese sheep but barely 
detectable in lean sheep. However, lean and obese sheep exhibited similar parietal 
gland response as illustrated by noticeable salivation in each sheep in the first 10 min 
approximately after each dose of clonidine. Furthermore, preliminary experiments to 
determine appropriate dose of clonidine revealed that 20 !J.g/kg clonidine produced 
severe dyspnea in obese (n=2) but not lean (n=2) sheep, and consequently only doses 
of 5 and 1 0 11g/kg clonidine were used in the experiment. The marked difference in 
respiratory response to clonidine in obese compared with lean sheep suggests that 
central ~-adrenoceptor activity was greater in obese hypertensive than in lean 
normotensive sheep. It would appear that obesity in sheep affects central and 
peripheral a2-adrenoceptor regulation of vasoconstriction and central a2-adrenoceptor 
regulation of respiration. Levin (1990) reported that density of binding sites for <X2-
agonists was greater in brain membranes of obese than lean rats. Putative differences 
in ~-adrenoceptor activity in obese compared with lean sheep may be the 
consequence of hypertension and not the obese state per se because the central 
response to a 2-agonist also was greater in spontaneously hypertensive rats than in 
their normotensive littermates (Yarbrough et al 1983; Tibirica et al 1988). 
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In summary, the cardiovascular response to low and high doses of iv clonidine 
differed in lean and dietary-obese sheep. Hypertensive response to low dose clonidine 
was greater in lean than obese sheep, whilst bradycardic response to clonidine was 
greater in obese than lean sheep regardless of clonidine dose. Hypertension without 
hypotension suggested that iv clonidine predominantly affected peripheral 
vasoconstrictive ~-adrenoceptors in sheep. However, clonidine-induced apnea and 
dyspnea were markedly more noticeable in obese compared with lean sheep. Dietary 
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CHAPTER VII 
HEMODYNAMIC EFFECTS OF CLONIDINE AND 
NALOXONE IN NORMOTENSIVE LEAN AND 
HYPERTENSIVE OBESE EWES 
Introduction 
Clonidine a is potent antihypertensive drug in humans and animals (Kobinger 
1978; Pettinger 1980; Isaac 1980; Jarratt et al 1987). The hypotensive action of 
clonidine is due both to a centrally-mediated decrease in sympathetic tone to the heart 
and vascular together with an enhanced vagal baroreceptor reflex (Kobinger 1978; 
Isaac 1980; Jarrot et al 1987; Maze and Tranquilli 1991 ). Despite the well documented 
hypotensive effect of clonidine in various species, the blood pressure response to iv 
clonidine is biphasic in humans, dogs, cats and certain strains of rats (Boissier et al 
1968; Kobinger 1978; Frisk-Holmberg et al 1984). Clonidine causes an initial short-
lived hypertension that precedes chronic hypotension and both responses are attended 
by bradycardia (Rhee and De Lapp 1988; Grichois et al 1990). 
The blood pressure response to clonidine reflects the balance of clonidine 's 
activation of centrally located a 2-adrenoceptors, which mediate hypotension, and 
peripheral a2-adrenoceptors in vascular smooth muscle which mediate hypertension 
(Schmitt et al 1969; Kobinger 1978; Isaac 1980; Langer 1985). The biphasic blood 
pressure response to clonidine depends on the dose of clonidine and accessibility of 
clonidine into brain tissue after its systemic administration by intravenous or oral routes 
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(Frisk-Holmberg et al 1984; Rhee and De Lapp 1988). Low levels of clonidine are 
associated with a hypotensive response, where increasing concentrations of plasma 
clonidine are associated with hypertensive response (Wing et al 1977; Pettinger 1980). 
The central effects of clonidine on blood pressure seem to involve opioid 
receptors active within the hypothalamus, nucleus tractus solitarius and (or) nucleus 
reticularis lateralis (Schmitt 1967; Jarrot et al 1987; Tibirica et al 1989; Bousquet et al 
1989). Concomitant administration of the opioid antagonist, naloxone, has inhibited or 
abolished the hypotensive response to iv clonidine in anaesthetized normotensive and 
hypertensive rats (Farsang and Kunes 1979; Shropshire and Wendt 1983; Mastrianni 
and Ingenito 1987; Mosquede-Garcia and Kunes 1988; Chang et al 1989) and in 
normotensive dogs (Pinto et al 1989). However, naloxone co-treatment had no effect 
on the hypotensive response to clonidine in normotensive and hypertensive humans 
(Watkins et al 1980; Bramnert and Hokfelt 1983) and normotensive Wistar-Kyoto 
rats(Mastrianni and Ingenito 1987). The ability of naloxone to affect the blood pressure 
response to clonidine may be species specific. 
Obese humans are frequently hypertensive (Stamler 1978; Van ltallie 1985 ). It 
has been suggested that dysfunction in central ~-adrenoceptors could lead to 
enhanced sympathetic outflow and development of hypertension in obese subjects 
(Bramnert and Hokfelt 1983; Veith et al 1984 ). We reported that the blood pressure 
response to iv clonidine differed between normotensive lean and dietary obese 
hypertensive sheep (Chapter VI). The pressor response was less and the bradycardic 
response was greater in obese than lean sheep injected iv with 5 j.lg/kg clonidine, 
whereas the hypertensive and bradycardic responses were comparable in both group 
after 10 11g/kg clonidine. The objectives of this experiment were to determine if 
naloxone affected the hypertensive and bradycardiac response to high dose clonidine 
(1 0 j.lg/kg) in sheep and whether these responses differed in normotensive lean sheep 
and hypertensive obese sheep. The dietary obese sheep is hyperinsulinemic, 
hyperglycemic, insulin resistant, and hypertensive (see Chapter V). 
Materials and Methods 
Animal Preparation 
Five normotensive lean (46 ± 2 kg) and 5 hypertensive obese (79 ± 3 kg) 
Rambouillet ewes were housed individually in a room with constant light and 
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temperature (20-21 C). Procedures for induction of dietary obesity in sheep were 
described in full in Chapter II. Briefly, lean adult Rambouillet ewes weighing 47 ± 3 kg 
were fed a pelleted hay-grain diet at maintenance (lean; control) or fed the same diet 
ad libitum (obese) until the maximum voluntary capacity for adipose accretion was 
attained at which point animals were in static-phase obesity characterized by steady-
state body weights and steady-state levels of maintenance intake. Consequently, all 
sheep were fed a specified maintenance intake of approximately 38 Kcal DE/kg in two 
equal amounts at 0900 and 1700 h such that each was in zero-energy balance before 
and during the experiments. 
Surgery was conducted with aseptic technique for survival surgery. Anesthesia 
was induced with 50 mg/kg pentobarbital sodium (Nembutal®, Abbott Lab., IL) and 
maintained with 1-2% halothane (Fiuthane®, Ayerst Lab. NY). The gas mixture was 
delivered from a surgical anesthesia machine (Ohio Chemical & Surgical Equipment, 
Madison, WS, USA) to the sheep through an endotracheal tube. 
Catheters with diameters of 12.7 mm (ID) were implanted in the abdominal 
aorta and the abdominal vena cava through the femoral artery and vein, respectively. 
The distal end of the catheters were exteriorized from the right hind leg and brought to 
mid back of the animal. The catheters were connected to Tuohy-Borst adapters, and 
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wrapped in surgical adhesive tape which was glued to the animal. Sheep were treated 
with penicillin (300,000 U/kg) daily for 5 days after surgery. Catheters were flushed 
thrice weekly with sterile heparinized saline (1 0 U/ml) and filled with heparin (1 ,000 
U/ml). At least 2 wk elapsed between surgery and experiments in any sheep. 
Inspection at necropsy confirmed that both catheter tips were positioned about 3 to 4 
em cranial to the ileac bifurcations. 
Experimental Protocol 
One lean and one obese sheep constituted a replicate and replicates were 
assigned randomly to one of the six sequences possible for treatment of clonidine (1 0 
!!g/kg), naloxone (3 mg/kg) and combined clonidine and naloxone (see below). On 
each experimental day, clonidine hydrochloride (Sigma, St. Louis, MO) and naloxone 
(Sigma) were prepared fresh in saline, filtered through a 0.2 11m filter and kept on ice 
until injected in via the venous catheter. At least 5 d separated successive treatments. 
Experiments were done between 0900 and 1200 h in conscious 16-h fasted 
sheep that were free-standing in their own pen. The aortic catheter was connected to a 
calibrated blood pressure transducer (Narco Bio-System, Int. Biomedics Houston TX 
USA) located at the level of heart. Changes in blood pressure were recorded with a 4-
channel Narcotrace model 40 MKIV physiograph (Narco Bio-System). Heart rates were 
determined using Narco biotachometer model 7302 (Narco Bio-System) linked to the 
blood pressure transducer. On each experimental day, recordings of blood pressure 
and heart rate were made for 45 min before iv injection of drugs. Three observations 
on blood pressure and heart rate were done during this stabilization period at 
approximately 15 min interval for each sheep. After the stabilization period, drugs in 5 
to 10 ml of saline were infused in 2 min and the venous infusion catheter flushed with 
similar volume of saline. Blood pressure and heart rate measurements were done at 2, 
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5, 10, 15, 20, 30, 45, 60, 75, 90, 105, and 120 min after injection of naloxone or 
clonidine. In the combined treatment, naloxone was injected iv 5 min before clonidine 
and blood pressure and heart rate measurements done at times indicated relative to 
clonidine injection and also at 2 min after naloxone. 
Statistical analysis 
The mean arterial pressure (MAP) was calculated as 2/3 of diastolic plus 1/3 
systolic blood pressure (West 1985). Effects of drug treatment on absolute values of 
MAP and heart rate within each body condition level were tested by repeated 
measures method of Gill (1979). Interactive effects of body condition and drug 
treatment on blood pressure and heart rate variables were determined using 2 x 3 
split-plot analysis of variance with separation of means by Duncans' new multiple 
range test if a significant F-value (P<0.1) was found (Steel and Torrie 1980). For this 
analysis the maximum change in MAP and heart rate measured after drug injection 
were used; additionally, the net effect of drug-induced change in MAP was quantified 
by area-under-the-curve (AUC) measured from time 0 until MAP returned to the mean 
plus one SD of that mean for basal MAP values in each sheep. Level of significance 
was 0.05 and reported values are means ± SE. 
Results 
Blood pressure variables and heart rates in lean and obese sheep before and 
after injection of drug are summarized in Table 1, 2 and 3. Overall basal MAP 
(92.6 ± 3.7 vs 74.6 ± 2.4 mmHg) and basal HR (69.8 ± 3.3 vs 51.6 ± 2.6 bpm) were 
greater (P<0.01) in obese than lean sheep (Table 1, 2, 3). Clonidine injection caused 
pronounced hypertension in lean and obese sheep (Fig. 1 ). The hypertensive response 
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to clonidine was equivalent in lean and obese sheep whether measured as maximum 
change in MAP (Fig. 3) or net change in MAP response (Fig. 4). Clonidine-induced 
bradycardia was greater in obese than lean sheep (Fig. 2; 5). 
Naloxone by itself induced noticeable hypertension in all sheep. In contrast to 
clonidine, hypertensive response to naloxone was greater in obese than lean sheep 
(Fig. 1, 3, 4). Interestingly, the hypertensive response to naloxone was accompanied 
by tachycardia, not bradycardia as was observed after clonidine injection (Fig. 1, 2). 
The degree of tachycardia in naloxone-treated sheep was two-to-three times greater in 
obese than lean sheep (Fig. 5). The clonidine-induced hypertension and bradycardia in 
both group of sheep were completely unaffected by antecedent treatment with 
naloxone (Fig. 4, 5). 
Other gross behavioral effects of clonidine were observed but not quantified. 
Clonidine induced noticible salivation in both group of sheep, but clonidine caused 
distinct respiratory stress (apnea) in obese but not lean sheep. Naloxone by itself had 
no observable effect on respiration or salivation, but naloxone appeared to attenuate 
the respiratory-inhibiting effects of clonidine in the obese sheep without affecting in a 
major way the salivation response to clonidine. 
TABLE 1 
BLOOD PRESSURE VARIABLES AND HEART RATE IN SHEEP AFTER IV ADMINISTRATION OF 10 JlQ/kg CLONIDINE 
Lean (n=5) Obese (n=5) 
Time SBP DBP MAP HR SBP DBP MAP HR 
{min} {mmHg} {mmHg} {mmHg} {beat/min} {mmHg} {mmHg} {mmHg} {beat/min} 
-30 92.5 ± 1.9 64.1 ± 2.2 73.6 ± 1.9 49.6 ± 2.4 115.3 ± 4.4 76.4 ± 4.2 89.4 ± 4.2 76.4 ± 7.0 
-15 93.9 ± 1.9 64.6 ± 2.1 74.4 ± 1.9 49.6 ± 2.2 116.8 ± 4.1 76.4 ± 4.6 89.9 ± 4.4 75.2 ± 7.3 
0 92.7 ± 2.3 64.6 ± 2.9 74.0 ± 2.6 49.6 ± 2.4 115.8 ± 4.3 77.4±5.1 90.2 ± 4.8 75.2 ± 7.4 
2 118.4 ± 8.9 84.8 ± 6.6 96.0 ± 7.3 35.6 ± 0.7 133.1 ± 4.4 91.8 ± 3.5 105.6 ± 3.7 44.0 ± 2.8 
5 137.2 ± 4.7 93.9 ± 2.8 108.3 ± 2.9 37.6 ± 1.6 174.0±16.3 110.0 ± 7.1 131.4 ± 10.1 57.4 ± 7.9 
10 136.2 ± 3.8 95.9 ± 2.9 109.3 ± 1.9 43.6 ± 4.1 167.7±15.3 106.2 ± 4.7 126.7 ± 8.1 63.2 ± 8.5 
15 131.4±4.0 90.1 ± 3.2 103.8 ± 3.0 44.8 ± 3.8 161.0 ± 12.5 104.8 ± 4.3 123.5 ± 6.6 67.6 ± 9.3 
20 127.1 ± 4.6 84.8 ± 4.4 98.9 ± 4.3 47.8 ± 3.3 141.3 ± 4.3 95.7 ± 3.0 110.8 ± 3.3 74.4 ± 12.0 
30 118.4 ± 6.0 78.1 ± 5.1 91.5 ± 5.3 52.0 ± 2.6 126.4 ± 6.9 85.6 ± 4.5 99.2 ± 5.2 74.8 ± 9.2 
45 104.0 ± 6.4 74.2 ± 4.4 84.2 ± 4.9 56.0 ± 5.0 120.6 ± 5.1 81.2 ± 3.5 94.4 ± 4.0 75.0 ± 9.0 
60 98.8 ± 8.1 69.9 ± 4.4 79.5 ± 5.5 63.6 ± 9.6 116.8 ± 4.5 79.3 ± 3.8 91.8 ± 3.9 . 75.2 ± 7.0 
75 98.3 ± 6.6 67.0 ± 4.2 77.4 ± 4.9 54.4 ± 2.4 114.8 ± 4.0 77.9 ± 4.4 90.2 ± 4.1 74.0 ± 5.4 
90 96.8 ± 5.7 65.6 ± 4.3 76.0 ± 4.6 52.4 ± 1.6 115.8 ± 4.0 80.3 ± 4.2 92.1 ± 4.0 43.2 ± 4.7 
105 94.9 ± 5.3 66.1 ± 3.7 75.7 ± 4.2 54.2 ± 1.0 112.4 ± 3.2 76.0 ± 4.2 88.1 ± 3.8 72.0 ± 4.6 
120 95.9 ± 5.7 66.1 ± 3.8 76.0 ± 4.2 52.8 ± 2.0 113.9 ± 4.5 76.9 ± 4.6 89.2 ± 4.6 71.2 ± 4.4 
__. 
SBP= Systolic Blood Pressure; DBP= Diastolic Blood Pressure; MAP= Mean Arterial Pressur; HR= Heart Rate -I» 0'1 
TABLE 2 
BLOOD PRESSURE VARIABLES AND HEART RATE IN SHEEP AFTER IV ADMINISTRATION OF 3 mg/kg NALOXONE 
Lean (n=5) Obese (n=5) 
Time SSP DBP MAP HR SSP DBP MAP HR 
(min) (mmHg) (mmHg) (mmHg) (beat/min) (mmHg) (mmHg) (mmHg) (beat/min) 
-30 96.8 ± 4.5 65.1 ± 1.8 75.7 ± 2.5 54.0 ± 2.5 120.1 ± 4.4 81.7 ± 3.3 94.5 ± 3.6 71.0 ± 5.2 
-15 96.4 ± 3.1 64.1 ± 2.0 74.9 ± 2.1 54.8 ± 3.4 119.7 ± 4.2 80.2 ± 3.4 93.4 ± 3.7 70.6 ± 4.9 
0 96.8 ± 3.0 65.1 ± 1.4 75.7 ± 1.7 54.8 ± 3.8 120.6 ± 4.8 81.2 ± 4.3 94.4 ± 4.4 71.6 ± 5.1 
2 119.9 ± 7.7 80.4 ± 4.5 93.6 ± 5.6 62.8 ± 2.9 161.5 ± 6.3 112.2 ± 6.2 129.1 ± 6.3 105.4±10.4 
5 115.1 ± 4.8 74.7 ± 2.9 88.2 ± 3.4 61.6 ± 4.3 151.4±6.1 101.1 ± 7.0 118.1 ± 6.6 104.2 ± 12.2 
10 110.2 ± 3.8 69.4 ± 2.5 83.0 ± 2.8 58.4 ± 3.5 143.2 ± 5.2 92.7 ± 6.2 109.6 ± 5.9 95.4 ± 9.4 
15 107.8±3.4 68.4 ± 2.1 81.6 ± 2.2 58.0 ± 3.3 138.4 ± 4.6 91.8 ± 5.9 107.3 ± 5.4 93.6±10.1 
20 105.4 ± 3.0 67.9 ± 2.0 80.5 ± 2.1 58.4 ± 3.5 134.6 ± 5.3 91.3 ± 6.3 105.7±6.1 96.2 ± 9.5 
30 103.0 ± 3.2 67.0 ± 1.9 79.0 ± 2.1 57.8 ± 3.4 132.2 ± 4.8 88.9 ± 5.9 103.3 ± 5.6 93.6 ± 9.4 
45 103.0 ± 4.1 66.5 ± 2.2 78.7 ± 2.7 59.8 ± 2.9 126.4 ± 3.5 86.0 ± 5.0 99.5 ± 4.6 87.6 ± 6.7 
60 100.6 ± 4.0 66.5 ± 2.0 77.9 ± 2.6 60.0 ± 3.0 122.5 ± 4.3 82.2 ± 4.6 95.7 ± 4.6 88.0 ± 7.0 
75 98.3 ± 4.4 65.1 ± 2.5 76.2 ± 3.0 58.8 ± 4.1 121.1 ± 4.4 83.1 ± 4.8 95.8 ± 4.7 87.2 ± 6.5 
90 96.8 ± 4.3 63.1 ± 2.9 74.4 ± 3.2 56.4 ± 4.0 119.7 ± 4.2 82.6 ± 4.7 95.0 ± 4.6 88.0 ± 5.2 
105 95.4 ± 4.5 62.6 ± 2.8 73.6 ± 3.2 56.6 ± 4.3 120.1 ± 4.5 83.1 ± 4.2 95.5 ± 4.4 85.2 ± 6.2 
120 93.5 ± 4.1 62.2 ± 2.9 72.6 ± 3.2 56.0 ± 4.2 122.1 ± 4.0 83.6 ± 3.8 96.5 ± 3.8 86.0 ± 5.4 
..... 
SBP= Systolic Blood Pressure; DBP= Diastolic Blood Pressure; MAP= Mean Arterial Pressur; HR= Heart Rate .f:>. 0"> 
TABLE 3 
BLOOD PRESSURE VARIABLES AND HEART RATE IN SHEEP INJECTED IV WITH NALOXONE (3 mg/kg) 5 MIN BEFORE 
CLONIDNE (1 0 mg/kg) 
Lean (n=5) Obese (n=5) 
Time SBP DBP MAP HR SBP DBP MAP HR 
(min) (mmHg) (mmHg) (mmHg) (beat/min) (mmHg) (mmHg) (mmHg) (beat/min) 
-30 93.9 ± 4.0 64.6 ± 3.1 74.4 ± 3.2 49.2 ± 2.3 118.7 ± 3.6 79.3 ± 4.0 92.5 ± 3.9 70.8 ± 3.7 
-15 93.9 ± 3.5 64.6 ± 3.3 74.4 ± 3.2 47.6 ± 2.1 121.1 ±3.9 82.2 ± 3.4 95.2 ± 3.5 70.0 ± 3.3 
-5 93.5 ± 3.4 64.6 ± 2.6 74.2 ± 2.6 48.6 ± 2.0 121.1 ± 3.9 81.2 ± 3.2 94.5 ± 3.4 69.6 ± 4.4 
-3 119.9 ± 7.4 80.9 ± 3.0 93.9 ± 4.1 58.8 ± 4.5 166.3 ± 5.9 111.6 ± 6.1 129.8 ± 6.0 95.6 ± 4.8 
0 114.1 ±5.1 74.7 ± 2.8 87.8 ± 3.1 59.2 ± 4.5 151.9 ± 5.6 99.5 ± 5.6 116.9 ± 5.5 96.0 ± 7.6 
2 136.7 ± 4.0 97.7 ± 3.8 110.7 ± 3.5 39.4 ± 2.6 168.2 ± 5.2 109.2 ± 7.2 128.8 ± 6.0 49.2 ± 4.9 
5 141.0 ± 6.1 91.5 ± 5.7 108.0 ± 5.5 44.8 ± 5.2 169.7 ± 3.7 111.1 ±3.5 130.6 ± 3.4 55.2 ± 6.9 
10 141.5±5.7 92.9 ± 4.7 109.1 ± 4.8 42.8 ± 3.6 168.7 ± 5.8 111.6 ± 4.1 130.6 ± 4.6 56.0 ± 6.3 
15 134.3 ± 4.7 86.2 ± 3.7 102.2 ± 3.9 48.6 ± 3.0 158.6 ± 2.5 104.7 ± 2.1 122.7 ± 2.2 61.2 ± 6.1 
20 127.6 ± 4.5 82.8 ± 3.6 97.8 ± 3.8 51.6 ± 3.0 152.8 ± 4.0 102.5 ± 2.8 119.2±3.1 66.4 ± 7.4 
30 118.9 ± 4.9 77.6 ± 5.7 91.4 ± 5.4 55.4 ± 3.9 141.3 ± 4.8 93.2 ± 4.1 109.2 ± 4.3 68.4 ± 8.2 
45 107.8 ± 5.8 73.2 ± 4.8 84.8 ± 4.8 62.4±12 132.2 ± 2.8 85.5 ± 2.5 101.1 ±2.5 71.2 ± 5.7 
60 98.8 ± 5.5 67.9 ± 3.8 78.2 ± 3.9 67.4 ± 15 127.8 ± 3.2 85.0 ± 3.0 99.4±3.1 73.6 ± 4.1 
75 93.5 ± 5.5 67.0 ± 3.5 75.8 ± 3.4 62.8 ± 9.4 124.0 ± 4.9 82.6 ± 3.4 96.5 ± 3.8 73.6 ± 3.0 
90 95.4 ± 3.3 65.5 ± 3.1 75.5 ± 2.9 55.2 ± 3.7 122.5 ± 4.6 81.7 ± 3.5 95.3 ± 3.8 71.6 ± 3.3 
120 94.9 ± 3.4 64.6 ± 2.1 74.7 ± 2.6 64.0 ± 2.1 120.6 ± 6.8 79.8 ± 5.0 93.4 ± 5.6 71.2 ± 2.8 -+>-
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Figure 1. Changes in absolute mean arterial pressure (MAP) in lean 
(n=5) and obese (n=5) sheep injected with clonidine 
(1 OJ.Lg/kg) alone, naloxone (3 mg/kg) alone, or naloxone 
5 min before clonidine (bottom panel). Arrows indicate 
time of injections. Values are means ± SE. 
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Figure 2. Changes in absolute heart rate (HR) in lean (n=5) and 
obese (n=5) sheep injected with clonidine (1 Oj.lg/kg) 
alone, naloxone (3 mg/kg) alone, or naloxone 5 min 
before clonidine (bottom panel). Arrows indicate 
time of injections. Values are means ± SE. 
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Figure 3. Maximum changes in mean arterial pressure (MAP) in 
lean (n=5) and obese (n=5) sheep injected iv with 
clonidine ( 10 11g/kg) alone, naloxone (3 mg/kg) 
alone, or naloxone 5 min before clonidine. Values 
are means± SE and were calculated using the 
difference between the peak MAP developed and the 
corresponding basal values in each sheep. The 
greatest change in MAP from basal occurred in the 
first 5 min after time 0 (see Fig 2, 3). Probability 
values from split-plot analysis of variance for 
treatment on MAP response were body condition NS, 
treatment 0.005, and their interaction 0.1. Mean with 
similar lower case letter are not different (P>0.05) 



















Figure 4. Mean arterial pressure (MAP) response in lean (n=5) and 
obese (n=5) sheep injected iv with clonidine (1 OJ.Lg/kg) 
alone, naloxone (3mg/kg) alone, or naloxone 5 min 
before clonidine. Response calculated as area above 
basal MAP plus one standard deviation of basal. 
Probability values from split-plot analysis of variance 
for treatment effects were body condition NS, drug 
treatment 0.005, and their interaction 0.1. Mean with 
similar lower case letter are not different (P>0.05) 
as determined by Duncan's new multiple range test. 
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Figure 5. Maximum changes in heart rate (HR) in lean (n=5) and 
obese (n=5) sheep injected iv with clonidine (1 0 11g/kg) 
alone, naloxone (3 mg/kg) alone, or naloxone 5 min 
before clonidine. Values are means ± SE and were 
calculated using the difference between greatest or 
lowest HR developed and the corresponding basal values 
in each sheep. The greatest change in HR from basal 
occurred in the first 5 min after time 0 (see Fig 2). 
Probability values from split-plot analysis of variance 
for treatment on HR were body condition NS, drug 
treatment 0.001, and their interaction 0.05. Means 
with similar lower case letters in each panel are not 
different (P>0.05) as determined by Duncan's new 




The blood pressure response to iv clonidine in many species is biphasic in that 
a brief hypertensive response precedes the development of a chronic hypotensive 
response (Kobinger 1978; Isaac 1980). In humans, high doses of clonidine given per 
os or iv results in hypertensive then hypotensive relatively whereas relatively lower 
doses result in hypotension generally (Pettinger 1980). Clonidine induces hypotension 
and bradycardia via activation of central a 2-adrenoceptors that lead to suppressed 
sympathetic outflow to heart and vasculature and enhanced vagal drive to the heart 
(Kobinger 1978; Pettinger 1980). On the other hands, the hypertensive response to 
clonidine is elicited by clonidine activation of vasoconstrictive ~-adrenoceptors in 
vascular smooth muscle. The blood pressure response to clonidine activation has been 
explained on the basis of the balance between clonidine activation of central 
hypotensive-related a2-adrenoceptors vis-a-vis activation of peripheral 
vasoconstrictive-related ~-adrenoceptors (Pettinger 1980; Isaac 1980). 
In this study, clonidine had a singularly hypertensive response in both lean and 
obese sheep. Clonidine-induced hypertension without hypotension was reported 
previously in sheep by Eisenach and colleagues (1987). Explanation of divergence in 
blood pressure response to iv clonidine between humans and sheep is not clear. The 
same dose of clonidine that produced hypotension in humans may induce hypertension 
in sheep because ruminants in general are more responsive to a2-agonists than 
nonruminants (Hopkins 1978). Additionally, less than 2% of iv injected clonidine enters 
the brain in nonruminants (Jarrett et al 1987) and differences in brain uptake of 
clonidine between sheep and humans may explain the divergence in demonstration of 
clonidine-induced hypotension between these species. The initial, transient 
hypertension seen in other species injected iv with clonidine (Pettinger 1980; Isaac 
1980) was intensified in sheep possibly because of a greater reactivity of peripheral 
a 2-adrenoceptors and (or) reduced brain uptake of clonidine in sheep as compared 
with other species. The suggestion of lesser brain uptake of clonidine in sheep as 
compared with other species is tenuous because ~-agonists clearly have potent 
centrally-mediated analgesic effects in ruminants (Eisenach et al 1987) and other 
species (Maze and Tranquilli 1991 ). 
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The hemodynamic responses to iv naloxone in sheep were unusual in that 
many previous studies reported no cardiovascular effects of naloxone in normotensive 
or hypertensive rats (Mastrianni and Ingenito 1987; Mosqueda-Garcia and Kunes 1988; 
Lasky et al 1989), normotensive dogs (Pinto et al 1989), or hypertensive humans 
(Bramnert and Hokfelt 1983). Naloxone caused hypertension and tachycardia in sheep 
and these responses were greater in obese than lean sheep. Dunlap et al (1989) 
increased blood pressure without affecting heart rate in foetal sheep injected iv with 
very high doses of 10 to 40 mg/kg naloxone. The same authors (Dunlap et al 1989) 
obtained hypertension and tachycardia when foetal sheep were exposed to an 
extraordinarily high dose of 80 mg/kg naloxone. 
Sites and mechanisms of action for naloxone's effects on blood pressure and 
heart rate in sheep are not clear from this study. Ordinarily, increased blood pressure 
is associated with reflex bradycardia (West 1985), but naloxone-treated sheep 
displayed tachycardia in the face of increased blood pressure. This suggests that 
naloxone somehow masked the baroreceptor reflex in sheep. The hypertensive 
response to naloxone could be due to central and(or) peripheral effects of naloxone 
that resulted in vasoconstriction and increased blood pressure. Feria et al (1990) 
reported that naloxone potentiates cardiovascular responses to sympathetic amines 
possibly by enhancing catecholamine discharge in peripheral adrenergic nerve 
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endings. Central effects of naloxone on blood pressure and heart rate cannot be 
ignored. Petty and DeJong (1982) reported that direct injection of the opioid agonist, B-
endorphin, into the nucleus tractus solitarius (NTS) produced hypotension and 
bradycardia at low doses of B-endorphin but a rise in blood pressure and heart rate at 
high doses of B-endorphin. That direct injection of enkaphalins in the NTS of rats also 
caused an increase in blood pressure (Petty and DeJong 1983), suggests that different 
opioid receptors involved in cardiovascular regulation exist in the NTS. Naloxone 
blockade of one or more types of opioid receptors in the NTS of sheep might explain 
their naloxone-induced hypertension and tachycardia. 
Pretreatment with naloxone had no effect on clonidine's ability to increase blood 
' 
pressure and decrease heart rate in sheep in this study and naloxone pretreatment 
also did not reverse clonidine's antinocioceptive effect in sheep (Eisenach et al 1987). 
Pretreatment with naloxone by iv or intracerebroventricular routes also did not affect 
the hypotensive response to clonidine in normotensive cats (Shropshire and Wendt 
1983), normo-tensive and hypertensive humans (Watkins et al 1980; Bramnert and 
Hokfelt 1983) and normotensive, anaesthetized Wistar-Kyoto rats (Mastrianni and 
Ingenito 1987). On the other, naloxone pretreatment abolished or inhibited significantly 
the hypotensive response to clonidine in normotensive conscious dogs (Pinto et al 
1989), spontaneously hypertensive rats (SHR) that were anaesthetized (Farsang and 
Kunos 1979; Mastrianni and Ingenito 1987) and in normotensive rats that were 
. 
anaesthetized (Mosqueda-Garcia and Kunos 1988) or conscious and unrestrained 
(Chang et al 1989). The ability of naloxone to block the cardiovascular effects of 
clonidine appears to be readily demonstratable in normotensive and hypertensive 
rodents but not so in normotensive or hypertensive sheep or humans. 
Clonidine and naloxone injected alone had similar effects on blood pressure 
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increase but markedly divergent effect on heart rate in sheep. Response to combined 
clonidine and naloxone treatment in sheep equalled that of clonidine injected alone. 
Feria et al (1990) showed convincingly that naloxone enhances pressor response to 
epinephrine, norepinephrine and phenylephrine, all cx.-adrenoceptor agonist, mechanism 
might involve naloxone blockade of presynaptic delta-type opioid receptors in 
peripheral nerve endings. Naloxone pretreatment potentiated the initial pressor 
response to clonidine in conscious normotensive Sprague-Dawley rats (Dixon and 
Chandra 1985; Chang et al 1989), which are results somewhat consistent with the 
finding of Feria et al (1990). Lack of an antagonistic, additive or synergistic effect of 
naloxone on the pressor response to clonidine in sheep is not readily explainable. One 
might suggest that naloxone and clonidine affect blood pressure in sheep by different 
and independent routes, or that naloxone works upstream of and with diametrically 
opposite effects to that of clonidine in their regulation of the same central neural relay 
system that controls baroreceptor function, vasoconstriction, and heart rate. In species 
where naloxone blocks cardiovascular response to clonidine, the locus of naloxone 
effect is within the baroreceptor relay center of the medulla (Isaac 1980). 
Naloxone-induced tachycardia was strikingly much greater in obese than lean 
sheep both in terms duration and magnitude. Naloxone-induced tachycardia was still 
prominent in obese sheep through the full 180-min period after naloxone injection; the 
greater naloxone-induced rise in blood pressure in obese than lean sheep was 
dissipated by 60 min after naloxone injection. These results suggest differences in 
opioid receptors between lean and obese sheep, particularly opioid receptor 
mechanisms concerned with increasing heart rate. Previous work showed that 
naloxone had approximately 4-fold greater inhibitory effects on feed intake in obese 
than lean sheep (see Chapter IV). Collectively, results of these studies suggest 
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down-regulation of opioid receptors, or specific receptor types, in anatomical sites 
concerned with appetite and cardiovascular regulation. The greater responses to 
naloxone in obese than lean sheep are expected findings to antagonist stimulation of a 
system that has undergone receptor down-regulation or desensitization. 
In summary, the hypertensive and bradycardic responses to iv clonidine in lean 
and obese sheep were unaffected by prior exposure to naloxone. The naloxone-
induced hypertension and tachycardia were greater in obese than lean sheep, which 
are results considerably different from the absent cardiovascular effects of naloxone in 
dogs and rodents. 
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CHAPTER VIII 
INFLUENCE OF OBESITY ON PHARMACOKINETICS 
OF NALOXONE IN RAMBOUILLET SHEEP 
Introduction 
Drug distribution, biotransformation and excretion may be changed due to 
alteration in body composition in obese compared with normal body weight humans 
and animals. Increased proportion and absolute amount of adipose tissue and 
increased lean body mass occur in human obesity (Baecke et al 1982; Forbes and 
Wells 1983). Changes in the size of these compartments in obese compared with lean 
individuals may alter distribution of lipophilic and lipophobic drugs (Abernethy and 
Greenblatt 1982, 1984). Additionally, adiposity may lead to altered protein binding of 
drug as well as altered processes of hepatic and renal biotransformation and excretion 
(Benedek et al 1984; Abernethy and Greenblatt 1986). 
Volume of distribution of drugs and their distribution between intravascular and 
extravascular compartments may be affected by solubility properties of drug in fat, or 
by altered binding of drug to plasma proteins (Abernethy and Greenblatt 1986). Obesity 
had no effect on plasma protein binding of verapamil or cimetidine to albumin, whereas 
increased concentration of a,-acid glycoprotein concentration explained the greater 
protein-bound fraction of propranolol in plasma of obese compared with lean humans 
(Benedek et al 1983; 1984 ). Biotransformation of drugs in obesity may be influenced 
by pathophysiological processes associated with obesity, such as fatty infiltration and 
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fibrosis of the liver (Adler and Schaffner 1979) and cardiovascular dysfunction, which 
may alter hepatic blood flow and peripheral organ perfusion (Rodighiero 1989; Crandall 
and DiGirolamo 1990). Finally, increased renal glomerular filtration in some obese 
subjects might be predicted to increase clearance of drugs that can be filtered and 
excreted by the kidney (Stokholm and Brochner-Mortensen 1980). These data support 
the importance of understanding parameters of drug disposition in obese individuals 
because drug therapy is commonplace in combating the pathophysiological problems 
of dyslipidemia, hypertension and diabetes that are associated with obesity (Abernethy 
et al 1986; O'Connor and Feely 1987). 
Animal models can serve as valuable tools in studies to distinguish the potential 
differences in drug disposition between lean and obese individuals. Two animal 
models, the Zucker obese rat (fa/fa) and the cafeteria-fed male Sprague Dawley rat, 
have provided preliminary data on the effects of obesity on pharmacokinetics of 
prednisolone, phenobarbital, verapamil, and d-fenfluramine (Blouin et al 1987; 
Fracasso et al 1988; Nichols et al 1989; Rice et al 1989). However, the genetically 
obese Zucker rat may have limited application because of its impaired renal function 
and cytochrome P-450 activity that are unrelated to the obese state (Litterst 1979; 
Abernethy and Greenblatt 1986). Limitations of the cafeteria-fed Sprague Dawley rat 
model of obesity identified to date are that only male rats become obese and that the 
unusual cafeteria diet itself can affect drug pharmacokinetics; obese rats consume a 
cafeteria diet of chocolate chip cookies, orange juice, condensed milk and high fat 
while lean control rats are fed standard rat chow (Abernethy and Greenblatt 1986). 
Naloxone is generally recognized as a short acting pure opiate antagonist. It is 
rapidly metabolized by the liver and eliminated by the kidney (Weinstein et al 1971; 
1973). The primary metabolite of naloxone is naloxone-3-glucuronide, although the 
N-dealkylation and reduction of the 6-ketone group of naloxone also takes place to 
some extent (Fujimoto, 1969; Weinstein et al 1971; 1973). Although naloxone has 
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been used in numerous studies in sheep, the pharmacokinetics of naloxone in sheep 
and domestic ruminants is unknown. Where necessary, investigators have extrapolated 
available data on the pharmacokinetics of naloxone in rats to sheep. The objectives of 
this study were to determine the pharmacokinetics of naloxone in sheep and determine 
how dietary obesity affected naloxone kinetics in sheep. 
Materials and Methods 
Animals 
Five lean (46 ± 2 kg) and 5 obese (77 ± 3 kg) ewes used in this experiment 
were housed individually in a room with constant light and temperature (21 ± 1 °C). 
Conditions for induction of dietary obesity and maintenance of lean sheep are 
described in detail elsewhere (Chapter II). Briefly, lean adult Rambouillet ewes were 
fed a pelleted hay-grain diet at maintenance to keep them in lean body condition or 
were fed the same diet at ad libitum (obese) until a static body weight was achieved. 
During static phase obesity, lean and obese sheep were fed the same diet at 
maintenance such that all sheep were in zero-energy balance. Body fat estimated as 
percent of body weight was approximated 27% in lean sheep and 37% in obese sheep 
(McCann et al 1991 ). Percent lipid in the eviscerated carcass was 23 ± 2% in lean 
sheep and 46 ± 1 % in obese sheep. Chronic catheters were placed in the caudal 
vena cava as described in Chapter 4. 
Drug Administration and Sample Collection 
Naloxone (Sigma, St.Louis, MO, USA) solution was prepared in sterile saline 
and filtered through a 0.2 J..Lm cellulose acetate filter (Micro Filtration System, USA) 
immediately before each experiment. Catheters were placed in the jugular vein of 
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sheep at least 12 h before sample collection. Naloxone (3 mg/kg) in saline was 
injected (0900 h) in 16-h fasted sheep via the vena cava catheter which was flushed 
immediately with 10 ml of saline. Blood samples (5 ml) were collected via the jugular 
catheter at 30, 15, and 1 min before and 2, 5, 10, 20, 30, 45, 60, 90, 120, 240 and 480 
min after naloxone injection. Samples were dispensed immediately into chilled glass 
tubes containing 50 J..LI of mixture of benzamidine (200 mg/ml) and heparin (5000 U/ml). 
Plasma obtained by centrifugation (1000 x g, 4 C) was stored frozen (-30 C). 
Experiments were conducted in a one lean and one obese sheep at a time. 
Naloxone Assay 
Instruments and Chemicals. Plasma naloxone concentrations were determined 
by the HPLC and electrochemical detection using a modification of method described 
by O'Connor et al (1989). The HPLC system (Waters, Millipore Co, Milford, MA, USA) 
comprised of a pump (model 510), autosampler with refrigerator unit (WISP, model 
712), electrochemical detector (model 460), and chromatographic software (Maxima 
820). A C-18 reverse phase radial pack cartridge column (10 x 0.5 em) with 4 J..L 
particles (Waters, Millipore Co. Milford, MA, USA) were used to resolve naloxone and 
naltrexone (internal standard). The voltage of the glassy carbon electrode was 
maintained at +8.5 mV against the Ag/AgCI reference electrode. 
Chloroform, 2-propanol, ammonium dihydrogenphosphate, octanesulfonic acid 
and sodium bicarbonate were all analytical grade chemicals from Fisher Scientific 
Pittsburgh, PA. Disodium EDTA was obtained from Sigma, St. Louis, MO, and 1-pro-
panol was purchased from Curtis Matheson, Houston, TX. 
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Sample Extraction and HPLC Analysis. Plasma (0.5 ml) was placed in a 5 ml 
vial and alkalinized with 0.5 ml of a mixture (pH 8.6) of 0.1 M ammonium dihydrogen-
phosphate, 0.05 M sodium bicarbonate and 0.043 M sodium carbonate. Vials were 
capped and mixed for 10 sec before 3.0 ml chloroform-2-propanol (9:1, v/v) were 
added and mixed until the contents turned buttery. Vials were centrifuged at 3000 X g 
for 15 min at room temperature, vigorously tapped once and then centrifuged again. 
Approximately 2.7 ml of the lower organic phase containing naloxone and naltrexone 
were transferred into clean 12x75 mm borosilicate test tubes. Tubes were evaporated 
to dryness under nitrogen at room temperature (90-120 min) and their contents 
redissolved in 100 ~-tl of mobile phase. Tubes were vortexed, centrifuged at 1000 x g 
for 5 min at 22 C and their contents were transferred to autoinjector vials, which were 
then loaded into refrigerated (8 C) autosampler. Standards for naloxone ( 10, 50, 100, 
200, 400, 800 ng/ml) and naltrexone (400 ng/ml) were prepared in sheep plasma. 
Inter-assay precision was determined by analysis of pooled sheep plasma spiked with 
naloxone and naltrexone (400 ng/ml each). In a preliminary analysis, detector linearity 
was demonstrated for standards containing naloxone concentrations of 10 to 2400 
ng/ml. 
Mobile phase (pH 4.5) consisted of 0.1 M ammonium dihydrogenphosphate, 
0.54 M disodium EDTA, 0.9 11M octanesulfonic acid and 3 to 10% 1-propanol. All 
solvents were filtered (0.2 11m HA filter; Waters, Millipore Co. Milford, MA, USA) and 
degassed by helium sparging. An additional 0.2 11m filter (Puradisc 25 AS, Whatman 
Inc, Clifton, NJ) was connected to the pump inlet to filter and degas the mobile phase. 




Data were analyzed using a microcomputer program for pharmacokinetic 
modelling (Bourne 1986). Initial estimates of the first-order rate constants were 
obtained by subjecting mean data for each body condition to analysis using several 
different models. Choice of the appropriate pharmacokinetic model was based on 
lowest weighted sum of squares, F test, and Akaike's information criterion (AIC) value 
for individual data (Akaike 1974; Boxenbaum et al 1974; Yamaoka et al1978). Areas-
under-the-curve (AUC) were calculated by trapezoidal approximation between the first 
(0 h) and last sampling times. 
Pharmacokinetic values of lean and obese were compared using Students' 
unpaired t test and Mann-Whitney U test (t%~, t%a, Vc, Vd(area)• Vd(ss) and Cl9}. 
Significance was tested at P<0.05. 
Results 
Mobile phase containing 4.5 % 1-propanol provided adequate separation of 
naloxone, naltrexone (internal standard) and benzamidine (anticoagulant). At an 
electrode potential of +0.85 V , the lower limit of detection was 1 ng/ml. Intra- and 
inter-assay coefficients of variation were 4.1 and 4.3%, respectively. Recovery of 
naloxone and naltrexone averaged 78 ± 4 and 76 ± 4%, respectively. Deterioration of 
sensitivity after 50 to 60 injections was obviated by refurbishing the electrode (-0.6 V 
for 60 sec) after every 30 injections. After refurbishing, electrode was stabilized by 
pumping (0.1 ml/min) mobile phase for 12-16 h. 
Disposition of naloxone in plasma after intravenous administration was best 
described by a two-compartmental open model using the equation: 
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where CP is the concentration of naloxone in plasma at time t, A and B are the zero-
time blood concentration intercepts of the biphasic disposition curve, and a. and B are 
the hybrid rate constants related to slopes of the distribution (a.) and elimination (B) 
phases. Pharmacokinetic parameters were calculated from exponents of coefficients of 
disposition curves (Gibaldi and Perrier 1975; Baggot 1977). 
Pharmacokinetic variables of naloxone in lean and obese sheep are presented 
in Table 1. Naloxone was rapidly eliminated (t% B) after intravenous administration in 
both lean 43.08 (range= 29.3-53.7 min) and obese 37.7 min (range= 24.4-82.8 min) 
sheep. 
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Figure 1. Disposition of naloxone (3 mg/kg) in plasma after intravenous 
administration to lean (n= 5) and obese (n=5) ewes. Data are 
mean± SD. Components of equation describing curves are shown in Table 1. 
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Median volume of distribution (Vd(area)) of naloxone was large in lean (4.51 Ukg) and 
obese (3.5 L.kg) sheep, indicating extensive distribution and possibly accumulation 
within extravascular tissue. Median clearance of naloxone was higher in lean (88.18 
TABLE 1 
PHARMACOKINETIC PARAMETERS (mean± SD) OF INTRAVENOUSLY INJECTED 
NALOXONE (3 mg/kg) IN LEAN AND OBESE SHEEP. 
Parameters Lean (n=5) Obese (n=5) 
A, ng/ml 1814 ± 968 2282 ± 772 
B, ng/ml 413 ± 172 573 ± 301 
a, min_, 0.19048 ± 0.09222 0.28154 ± 0.23220 
~.min_, 0.01710 ± 0.00448 0.01851 ± 0.00743 
K, 0, min_, 0.06296 ± 0.01814 0.06690 ± 0.02796 
K, 2, min_, 0.08668 ± 0.04924 0.15643 ± 0.14971 
K2,, min_, 0.05794 ± 0.04577 0.07672 ± 0.06342 
t%a, min a 3.55 (2.07-7.06) 2.41 (1.12-15.26) 
t%~. min a 43.08 (29.3-53.7) 37.73 (24.36-82.83) 
Vc, L kg-1 a 1.35 (0.81-2.94) 1.08 (0.73-1.71) 
Vd(area)•L kg_, a 4.51 (4.03-8.63) 3.54 (2.89-5.95) 
V L k -1 ab d(ss)• g 3.62 (2.80-6.43) 2.92 (2.55-3.23) 
Cl8 , ml kg_, min"1 ab 88.18 (71.08-111.44) 77.11 (49.77-82.31) 
AUC, ng h mr1 b 35900 ± 6440 47972 ± 9336 
k10 = first-order elimination rate constant; k12 , k21 are the first-order rate constants describing 
distribution between central (plasma) and peripheral compartment (tissue); t% a =distribution half-life after 
intravenous administration; t% B = elimination half-life after intravenous administration; Vc = volume of the 
central compartment; Vd1area) = apparent volume distribution calculated using AUC; Vd1ssJ = apparent volume 
of distribution at steady state; Cl9 = body clearance of the drug. 
a presented as median and range 
b lean and obese differ (P<0.05) 
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Discussion 
The objectives of this experiment were to describe naloxone pharmacokinetics 
in sheep and assess the impact of obesity on such kinetics. The elimination half-life of 
naloxone in sheep("" 40 min) was similar to that in rats (40 min) (Tepperman 1983). 
Fishman et al (1973) and Berkowitz (1975) reported an elimination half-life of 57 to 90 
min for naloxone in man whereas Kleiman-Wexler et al ( 1989) reported a half-life of 16 
to 31 min in rats. The relatively rapid elimination of naloxone is consistent with its short 
duration of action. Rapid distribution of naloxone throughout the body is important for 
its antagonistic effect on opiatergic receptors in CNS and peripheral tissues. Naloxone 
rapidly accesses the brain tissue of rats(< 5 min; Weinstein et al 1973) and can attain 
a two fold greater concentration in brain than serum of rats (Tepperman et al 1983). 
The volume of distribution (Vd(area)) in lean (4.5 Ukg) sheep was similar to that 
in obese (3.5 L/kg) sheep. A larger Vd(ss) of naloxone in lean than obese sheep may 
represent the significantly greater percent water composition in the body of lean 
compared with obese sheep. Obese sheep have more fat per unit body weight than 
lean sheep. Fat tissue has a low blood perfusion rate (Rowland and Toze 1980). The 
greater percent fat in obese sheep is associated with reduced percent body water 
composition. Therefore, the larger Vd(ss) of naloxone in lean than obese sheep could 
be explained by their greater. In addition, because fat has a relatively low blood 
perfusion rate, the distribution of naloxone among the compartments of unit weight of 
volume of distribution would differ between lean and obese sheep with relatively 
greater perfusable nonfat tissue compartment in the lean than obese sheep. 
Vd of naloxone was similar to Vd (2.8 to 3.9 L/kg ) of naloxone in man 
(Fishman et al 1973). Although the Vd of naloxone was large in sheep, a greater Vd (8 
Ukg) was reported in rats (Tepperman et al 1983). Rapid metabolism of naloxone by 
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the liver in vitro (Fujimoto 1969; Weinstein et al 1971; Weinstein et al 1973) explains 
the very low bioavailability (5%) of oral naloxone in man (Kalant and Roschlau 1989). 
In fact, Weinstein and co-workers (1973) emphasized that the low potency of oral 
administration of naloxone in man is associated with a very effective first-pass hepatic 
extraction of naloxone. Cheymol et al (1987) point out that altered hepatic function and 
blood flow need to be considered when dealing with pharmacokinetic disposition of 
drugs in obese individuals. Rapid distribution and clearance of the drug into well 
perfused tissues such as liver and kidney, with an accompanying rapid elimination, 
may have reduced the impact of adiposity on the disposition of naloxone. 
Generally, lipophilic drugs have larger volume of distribution than nonlipophilic 
drugs (Galletti et al 1989). A larger Vd of naloxone in lean than obese sheep is 
contrary to the characteristics of lipophilic drugs in that the lipophylic nature of 
naloxone should have increased its distribution in fat tissue of obese sheep. It seems 
clear that differences in drug lipophilicity are insufficient to explain complications of 
drug pharmacokinetics in obese individuals (Bickel 1984; Cheymol et al 1987). A 
recent pharmacokinetic study of propranolol, a lipophilic antihypertensive drug, showed 
an equal half-life but reduced Vd and clearance in obese compared with lean humans 
(Cheymol et al 1987), which are results agreeing with those reported here for naloxone 
in lean and obese sheep. 
We conclude that obesity did not alter the elimination half life, but had reduced 
the clearance and volume of distribution of naloxone in sheep. 
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CHAPTER VIII 
SUMMARY 
Obesity is a pathophysiological condition in humans that is associated with 
hyperinsulinemia, hyperglycemia and hypertension. How obesity may lead to 
dysregulation of appetite and blood pressure has been the topic of many investigations 
in humans and rodents. The opiatergic system clearly plays an important role in the 
regulation of appetite and blood pressure. Therefore, the primary objectives of this 
thesis were to study whether a dietary obesity alters opiatergic regulation of appetite 
and blood pressure in sheep, a new animal model of obesity. 
Our experiments showed that dietary obesity altered appetite drive in sheep. 
Chronic obesity reduced appetite drive in sheep. The appetite-inhibitory effects of the 
opioid antagonist, naloxone, were 4 times greater in obese than lean sheep. This 
appetite effects of naloxone were considered to be central and independent of 
coincidental changes in plasma insulin, glucose and free fatty acids. 
Obesity in sheep was associated with a 25 % increase in mean arterial 
pressur~ (MAP) and 50% increase in heart rate (HR). The baroreflex sensitivity was 
found to be similar in lean normotensive and obese hypertensive sheep, but the 
baroreceptor system setting had shifted rightward in obese compared with lean sheep. 
The reflex bradycardiac response to a,-agonist (phenylephrine) was greater in obese 
than lean sheep. 
Greater hypertensive and tachycardiac responses to naloxone in obese than 
lean sheep indicated that obesity had altered opiatergic regulation of blood pressure. 
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The altered appetite and cardiovascular responses in obese sheep to naloxone cannot 
be attributed to differences in disposition of naloxone because the pharmacokinetic 
parameters of naloxone were similar in lean and obese sheep. 
Clonidine, a hypotensive drug produced hypertension rather than hypotension in 
normotensive lean and hypertensive obese sheep. The degree of clonidine-induced 
hypertension was less in obese than lean sheep at low dose clonidine (5 J.Lg/kg) but 
was similar in both groups at high dose clonidine (1 0 J.Lg/kg). The clonidine-induced 
rise in mean arterial pressure and reflex bradycardia in lean and obese sheep were 
unaffected by antecedent treatment with iv naloxone. 
We conclude that development of dietary obesity alters opiatergic regulation of 
appetite and blood pressure in sheep possibly by down regulation of opioid receptors, 
and that obesity alters adrenergic receptor control of blood pressure. 
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